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ABSTRACT 
Mumps virus is the causative agent of mumps disease, of which humans are the only natural 
host.  Mumps infection is vaccine-preventable.  Mumps vaccines are live viruses attenuated by 
serial passage on cell substrates or in embryonated eggs.  They are known to vary in their 
effectiveness, degree of attenuation and adverse event profile.  The Jeryl Lynn mumps virus is 
the most commonly used vaccine strain.  Two related commercial mumps vaccines, which 
originate from the same attenuated strain (Jeryl Lynn-5) but have different efficacies, were 
investigated.  Jeryl Lynn-Canine Kidney (JL-CK), produced on primary canine kidney cells is 
less effective than RIT 4385 which is produced on chicken embryo fibroblasts.  JL-CK and RIT 
4385 could be distinguished by a number of in vitro and in vivo properties.  JL-CK produced 
heterogeneous, generally smaller plaques than RIT 4385, but gave 100 fold higher viral titres 
when grown on Vero or MDCK cells and produced a higher degree of hydrocephalus in the 
neonatal rat brain.  Sequencing of the JL-CK virus identified 14 regions of heterogeneity 
throughout the genome.  Plaque isolation demonstrated the presence of five mumps virus 
variants encompassing these mutations in the JL-CK vaccine.  One mutation was associated with 
a small plaque phenotype, the effects of the others either in vitro or in vivo were less clear.  Only 
4 % of the JL-CK vaccine population corresponded with the parent Jeryl Lynn-5 strain.  Deep 
sequencing of JL-CK and virus replicating in cell lines and neonatal rat brains showed that 
propagation in vitro or in vivo altered the population dramatically.  The data presented in this 
study suggest that growth of JL-CK in primary canine kidney cells resulted in the selection of a 
mixture of mumps virus variants that have different biological properties compared to the parent 
Jeryl Lynn-5 virus. 
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CHAPTER 1 – INTRODUCTION 
 
1.1 A brief history of mumps virus  
Mumps is one of the earliest human diseases recorded.  In his Book of Epidemics, in the 5
th
 
century B.C., Hippocrates described an outbreak of mumps on the island of Thasos in the 
Aegean Sea during the autumn equinox.  At the time he described the characteristic swelling of 
the parotid glands either unilaterally or bilaterally accompanied with a slight fever.  He noted 
that males who presented with parotid swelling would commonly develop swelling of the testes 
and that mumps disease in females was less common.  The cause of mumps disease remained 
unknown until the 19
th
 century, when in 1908 Granata suggested a filterable pathogen was the 
etiological agent of mumps, referenced in (Wollstein, 1916).  In 1934, Johnson and Goodpasture 
demonstrated by inoculating filtered saliva from infected patients into the Stensen’s duct of  
rhesus macaques, that the disease was caused by a virus (Johnson and Goodpasture, 1934).   The 
virus could also be transferred between macaques by inoculation with homogenised parotid 
glands excised from infected animals.  Further studies revealed that inoculation with filter-
sterilised, bacteria-free homogenised parotid glands from infected macaques caused disease in 
volunteer children.  The saliva from the volunteers who displayed clinical symptoms of mumps 
was used to inoculate healthy macaques.  The animals developed symptoms of mumps.  This 
fulfilled Koch’s postulates and led to the conclusion that the virus was the causative agent of 
mumps disease in humans (Johnson and Goodpasture, 1935).  
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1.2 Mumps virus taxonomy 
Mumps virus (MuV) is an enveloped, non-segmented, single-stranded, negative-sense RNA 
virus belonging to the genus Rubulavirus in the family Paramyxoviridae of the order 
Mononegavirales. The Paramyxoviridae are further classified into the sub-families 
Paramyxovirinae and Pneumovirinae.  The Paramyxovirinae sub-family are grouped based on 
the size and shape of their nucleocapsid.  They include mumps virus (Rubulavirus) measles virus 
(genus Morbillivirus), Sendai virus (genus Respirovirus), Newcastle disease virus (genus 
Avulavirus) and Hendra virus (genus Henipavirus).  The Pneumovirinae sub-family contains 
human respiratory syncytial virus (genus Pneumovirus) and human metapneumovirus (genus 
Metapneumovirus).   
Members of the Rubulavirus genus all display antigenic cross-reactivity and the presence of 
neuraminidase activity (Lamb and Parks, 2007).  Other members of the Rubulavirus genus 
include; parainfluenza virus 5 which was originally called simian virus 5 after its initial isolation 
from monkey kidney cultures (Chatziandreou et al., 2004), human parainfluenza virus type 2, 
type 4a and type 4b.  Porcine rubulavirus (previously called La Piedad Michoacan Mexico virus), 
(Lamb and Parks, 2007; Wang et al., 2007) and Menangle virus (Bowden et al., 2001) which 
have been isolated from pigs, and Tioman virus (Chua et al., 2001) and Mapuera virus 
(Henderson et al., 1995; Wang et al., 2007), which have been isolated from fruit bats.  More 
recently both fruit- and insect-eating bats have been identified as a reservoir for a number of 
novel rubulaviruses, including a bat rubulavirus which showed ~ 90 % sequence similarity to 
mumps virus (Drexler et al., 2012).   
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1.3 Mumps virus structure and genome 
MuV particles take on many forms and range in size from 100 – 600 nm.  They consist of a 
helical ribonucleoprotein (RNP) core containing the RNA genome.  This is associated with the 
nucleoprotein, phosphoprotein and polymerase encoded for by the large protein.  The RNP 
complex is surrounded by the viral matrix protein and a lipid envelope which is derived from the 
host cell.  The small hydrophobic protein is membrane-associated and incorporated into the lipid 
envelope (Takeuchi et al., 1996), which is also studded with the fusion and haemagglutinin-
neuraminidase viral glycoproteins, projecting 12 – 15 nm from the surface of the virion (Carbone 
and Rubin, 2007; Lamb et al., 2006) as depicted in Figure 1. 
 
MuV has a non-segmented negative-sense RNA genome which consists of 15,384 nucleotides.  
It contains seven genes encoding for nine proteins; nucleoprotein (N), V, I, phosphoprotein (P), 
matrix (M), fusion (F), small hydrophobic (SH), haemagglutinin-neuraminidase (HN) and the 
large (L) polymerase proteins.  The genome is ordered 3’–N-V/P/I-M-F-SH-HN-L-5’ and each 
gene is separated by non-transcribed sequences as depicted in Figure 2.  
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Figure 1: Schematic representation of a mumps virion. 
The virion contains the helical ribonucleoprotein complex (green) of viral RNA, N, P and L 
proteins, surrounded by the structural M protein (blue), with the F (purple) and HN (yellow) 
glycoproteins protruding from the surface of the virion.  The SH protein is non-structural and is 
not depicted. 
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Figure 2: Schematic representation of the MuV genome organisation. 
The genome is ordered from 3’ to 5’, with genes encoding the nucleoprotein (N), 
V/phosphoprotein/I, matrix (M), fusion (F), small hydrophobic (SH), haemagglutinin-
neuraminidase (HN) and large (L) proteins. 
 
 
1.4 Mumps virus proteins 
Each of the nine MuV proteins play a vital role in the lifecycle of the virus. 
 
1.4.1 Nucleoprotein  
The nucleoprotein, has a molecular weight of approximately 62 kilo Daltons (kDa) and consists 
of 549 amino acids (Cox et al., 2009).  It is the first protein to be translated in the viral genome 
and it functions as a RNA-binding protein coating the viral RNA and protecting it from nuclease 
digestion (Lamb and Parks, 2007).  The amino-terminal domain of the nucleoprotein is highly 
conserved and it is this region which is responsible for RNA binding and the formation of the 
helical nucleocapsid (Kingston et al., 2004; Kingston et al., 2008).  The carboxy-terminal domain 
is more variable, this is common to other paramyxoviruses, such as measles virus (Jensen et al., 
N V/P/I M F SH HN L 3’ 5’ 
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2011) and Sendai virus (Jensen et al., 2008).  The carboxy-terminus of the measles nucleoprotein 
has been shown to alter the dynamics and structure of the nucleocapsid, with the full-length 
nucleocapsid appearing to be a flexible structure, which has been show to become more rigid 
when the carboxy-terminal domain of the nucleoprotein is removed (Jensen et al., 2011).  
The MuV nucleoprotein carboxy-terminus binds the RNA-dependent-RNA-polymerase, a 
complex of the P and L proteins, in a similar manner to other paramyxoviruses such as measles 
virus (Jensen et al., 2011), Hendra virus (Communie et al., 2013) and Sendai virus (Buchholz et 
al., 1994).  Recently, the structure of the MuV nucleocapsid has been solved, leading to the 
observation that the MuV nucleocapsid binds to both the amino- and carboxy-terminal domains 
of the phosphoprotein (P), which has not been reported for other paramyxoviruses (Cox et al., 
2014).  The binding of the nucleocapsid to the amino-terminal domain of P reportedly induces 
uncoiling of the helical nucleocapsid, and binding to the carboxy-terminal domain of P is thought 
to assist the viral RNA-dependent-RNA-polymerase in gaining access to the viral RNA within 
the nucleocapsid allowing initiation of viral RNA synthesis.  
 
 
1.4.2 V/P/I proteins  
RNA editing results in the transcription of three mRNAs from the V/P/I gene, each encoding for 
a different protein (Paterson and Lamb, 1990).  The three proteins contain the same amino-
termini but differ at the carboxy-termini.  The unedited transcript encodes the V protein, the 
addition of two guanine (g) residues produces the P protein (Elliott et al., 1990) and the addition 
of four g residues results in the I protein (Paterson and Lamb, 1990), as depicted in Figure 3.   
The P protein is the largest, comprising 391 amino acids with a molecular weight of 41 - 47 kDa 
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(Takeuchi et al., 1988).  The V protein is 224 amino acids in length with a molecular weight of 
25 - 28 kDa (Takeuchi et al., 1990) and the I protein consists of 161 amino acids  and weighs 
approximately 19 kDa (Carbone and Rubin, 2007).  
 
 
 
 
 
 
 
Figure 3: Schematic representation of the V/P/I gene as transcribed during RNA editing. 
The addition of two or four guanine residues in the g-rich region (nt 460) produces the P and I 
proteins, the V protein is produced from the unedited transcript.  Each protein has the same 
starting nucleotide (nt 1) but differing termini (nt 511 / I), (nt 674 / V) and (nt 1173 / P). 
 
 
The V protein plays an essential role in the avoidance of the host cell interferon response and has 
been demonstrated to disrupt the signal transducer and activator of transcription-1 (STAT-1) 
(Kubota et al., 2001, 2002) and also STAT-3 (Puri et al., 2009; Ulane et al., 2003).  It has been 
shown to inhibit interferon production through its interaction with melanoma differentiation-
+ gg = P protein (nt 1 - 1173) 
3’ 5’ 
+ gggg  = I protein (nt 1 - 511) 
V protein (nt 1 - 674) 
 
nt 1 nt 511 nt 674 nt 1173 nt 460 
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associated gene-5 (mda-5) (Andrejeva et al., 2004), RACK1 (Kubota et al., 2002) and also to 
inhibit interleukin-6 signalling as a result of STAT-3 degradation (Xu et al., 2012).   
The P protein is essential for viral RNA synthesis allowing interaction of the viral RNA-
dependent RNA polymerase with the viral nucleocapsid (Kingston et al., 2004).  The carboxy-
terminus contains the nucleocapsid-binding domain at amino acids 343 – 391 (Kingston et al., 
2008).  It has also been reported that the amino-terminus (residues 1 – 194) of the P protein can 
bind nucleocapsid-like particles (Cox et al., 2013).  These studies have indicated that the 
carboxy-terminus of the P protein interacts with the amino-terminus of the nucleocapsid and the 
amino-terminus of P interacts with other regions of the nucleocapsid.  Recent studies (Cox et al., 
2014) have suggested that the amino- and carboxy-termini of the P protein act together to allow 
viral RNA synthesis.  The carboxy-terminus interacts with the nucleocapsid to enable 
recognition by the RNA-dependent RNA polymerase and the amino-terminus uncoils the 
nucleocapsid to allow access to the viral RNA. 
The role of the I protein in Rubulaviruses has not been identified and studies investigating the 
function of the I protein are lacking. 
 
1.4.3 Matrix protein  
The matrix (M) gene encodes the structural matrix protein which is 375 amino acids in length 
with a molecular weight in the range of 41 – 47 kDa (Elliott et al., 1989).  The M protein links 
the MuV nucleocapsid to the membrane of the virus particle.  Studies on related 
paramyxoviruses such as Sendai virus (Stricker et al., 1994) and Newcastle disease virus (Pantua 
et al., 2006) infer that the MuV M protein interacts with the cytoplasmic tails of the fusion and 
haemagglutinin-neuraminidase glycoproteins, creating a bridge to the nucleocapsid at the host 
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cell plasma membrane (Pei et al., 2011).  The M protein plays a critical role in virus assembly, 
with efficient production of virus-like particle (VLP) formation occurring when the M protein is 
co-expressed together with other viral proteins, nucleoprotein, P protein, fusion (F) protein and 
large (L) protein (Li et al., 2009).  The assembly of the M protein at the plasma membrane of 
infected cells, signals for other viral components to gather at the same location to enable budding 
to occur (Li et al., 2009).   
The role of the MuV M protein in transcriptional regulation is currently unknown.  However, the 
M protein in other negative-strand RNA viruses; vesicular stomatitis virus (Clinton et al., 1978), 
influenza virus (Watanabe et al., 1996), rabies virus (Finke et al., 2003) and more recently 
measles virus (Iwasaki et al., 2009)  have been shown play a role in inhibiting transcription and 
inducing genome replication. 
 
1.4.4 Fusion protein 
The fusion (F) protein is one of the surface glycoproteins which protrude from the lipid 
envelope.  It is synthesised as an inactive precursor F0, which is 538 amino acids long with a 
molecular weight range of 64 – 74 kDa  (Elliott et al., 1989).  The F0 precursor is cleaved by the 
proteolytic enzyme furin, at the R-R-H-K-R motif (Hosaka et al., 1991) to produce two 
biologically active peptides which remain bonded together by disulphide bonds (Scheid and 
Choppin, 1977; Server et al., 1985).  The smaller amino-terminal peptide F2 is 102 amino acids 
long with a molecular weight range of 10 - 16 kDa and the larger carboxy-terminal peptide F1, is 
436 amino acids long with a molecular weight range of 56 – 61 kDa (Merz et al., 1983).  The F1 
peptide contains a highly conserved, hydrophobic domain designated the fusion peptide and is 
thought to participate in membrane fusion (Liu et al., 2006).  The cleavage of F0 into  F1 and F2 is 
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essential for virus-to-cell and cell-to-cell fusion, which is required for virus infectivity and 
spread (Morrison, 2003). 
MuVs vary in their ability to induce fusion in cell culture, which may be strain or cell line 
specific.  The Hoshino vaccine strain of mumps does not induce fusion in B95a cells.  It was 
shown by co-expression of the Hoshino MuV F and HN proteins that a leucine residue (L) at 
position 383 was required for fusion in B95a cells (Yoshida and Nakayama, 2010).  In other 
studies, expression of recombinant cDNA clones has been used to identify that increased 
fusogenicity in COS-7 cells requires a serine (S) at position 195 (Tanabayashi et al., 1993).  In 
addition, recombinant MuVs have shown that an alanine residue (A) at position 91 produces a 
greater fusogenicity effect in Vero cells (Malik et al., 2007a). 
It has however been identified that the F protein alone is not sufficient to induce fusion activity 
(Tsurudome et al., 1986).  There is also the requirement for the expression of the 
haemagglutinin-neuramindase (HN) protein in addition to the F protein before virus-to-cell 
fusion is observed (Tanabayashi et al., 1992). 
 
1.4.5 Small hydrophobic protein  
The small hydrophobic (SH) gene is the smallest of the MuV genes encoding a protein 57 amino 
acids long with a molecular weight of 6 kDa (Elliott et al., 1989).  The SH protein is 
hydrophobic, membrane-associated and its sequence is highly variable.  It has not been detected 
within MuV virions (Takeuchi et al., 1996) and it is not thought to be required for replication in 
embryonated eggs (Takeuchi et al., 1996) or in cell culture (Afzal et al., 1990).  More recently it 
has been reported that the SH protein targets the cellular protein ataxin-1 ubiquitin-like 
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interacting protein (A1Up) which suggests a role for the SH protein in the prevention of cell 
apoptosis (Woznik et al., 2010).   
Due to the high variability in the nucleotide sequence of the SH gene (Afzal et al., 1997), it is 
most commonly used for genotyping MuV strains for epidemiological purposes. 
 
1.4.6 Haemagglutinin-neuraminidase protein  
The second glycoprotein on the lipid envelope is the haemagglutinin-neuraminidase (HN) 
protein.  It is 582 amino acids long with a molecular weight of approximately 74 – 80 kDa 
(Waxham et al., 1988).  It is thought to be bound to the F protein (Connaris et al., 2002) until it 
finds and binds to its cellular receptor initiating a conformational change of the proteins and 
allowing the release of F (Lamb, 1993).  The HN protein is responsible first for the attachment of 
released virus to neighbouring cells by the cell-surface receptor sialic acid and secondly for the 
neuraminidase activity which promotes cleavage of the sialic acid from the viral and cell surface 
(Malik et al., 2007b).  The HN protein works together with the F protein to mediate virus-to-cell 
and cell-to-cell fusion enabling viral spread. 
The HN protein is the major antigenic protein and is the cell surface target for neutralising 
antibodies which are thought to be important for protective immune response (Cusi et al., 2001; 
Houard et al., 1995).  Therefore the HN protein has been used to determine antigenic differences 
between mumps strains (Yates et al., 1996).  Much of what is known about mumps HN structure 
is inferred from other paramyxoviruses, in particular Newcastle disease virus and parainfluenza 
virus (Kulkarni-Kale et al., 2007).  However, based on HN sequence alignments of various MuV 
strains and isolates, there have been nine potential N-linked glycosylation sites identified at 
positions; 12, 127, 284, 329, 400, 448, 464, 507 and 514, recognised by the marker sequences N-
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X-S or N-X-T (Apweiler et al., 1999).  These positions were found to be conserved in wild-type 
and vaccine MuV strains (Kulkarni-Kale et al., 2007).  The amino acid regions aa265-288, 
aa329-340 and aa352-360 have also been proposed to be antigenic (Cusi et al., 2001; Kovamees 
et al., 1990; Orvell et al., 1997), with region aa329-340 reported to have shown the ability to 
induce neutralising antibodies to attenuated MuV and wild-type strains (Cusi et al., 2001). 
 
1.4.7 Large protein 
As its name suggests the large (L) protein is the largest of the MuV proteins.  It is 2261 amino 
acids in length with a molecular weight of 180 – 200 kDa (Okazaki et al., 1992).  Through 
studies from related viruses, Sendai and Newcastle disease viruses, the L protein of MuV is 
understood to be required for transcription and replication (Hamaguchi et al., 1983; Horikami et 
al., 1992).  It contains the catalytic subunit conferring polymerase activity for the synthesis of 
viral mRNA (Kingston et al., 2004) and is the major component of the RNA-dependent RNA 
polymerase in complex with the P protein.  This complex associates with the nucleoprotein and 
viral RNA to form the MuV nucleocapsid.   
 
1.5 Pathogenesis and disease 
Humans are the only natural host of MuV.  Whilst there have been experimental infections of 
MuV in animals, the results have been inconclusive and an animal model which mimics human 
disease has yet to be identified (Houard et al., 1995; Johnson and Goodpasture, 1934; Parker et 
al., 2013; Tsurudome et al., 1987).   
Mumps is commonly a childhood disease and is characterised by fever with pain and swelling of 
the parotid gland(s) which can be unilateral or bilateral.  This is the hallmark symptom occurring 
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in 95 % of symptomatic patients, however one third of patients are asymptomatic (Philip et al., 
1959).  Whilst usually a self-limiting mild illness, some complications such as; orchitis, 
oophoritis, aseptic meningitis, pancreatitis and deafness can occur.  MuV infection in adults can 
be more severe, with a higher rate of complications observed, for example orchitis and oophoritis 
(Gupta et al., 2005).   
MuV is transmitted by aerosol droplet and direct contact with infected persons.  It has an 
incubation period of 15 – 24 days, with the patient contagious from one to two days before the 
onset of clinical symptoms until around nine days after (Hviid et al., 2008).  The cellular receptor 
for MuV is sialic acid.  Sialic acid is expressed on the surface of most cells, which therefore 
allows MuV to infect almost all cell types.  MuV replicates in the nasal and upper respiratory 
tract and is frequently accompanied by a transient primary viremia (Hviid et al., 2008).  It is 
thought that the viremia is cell-associated, likely through T lymphocytes although this has not 
been confirmed (Fleischer and Kreth, 1982; Wolinsky et al., 1976).  This may allow the virus to 
spread throughout other organs, in particular parotid glands but also pancreas, heart,  kidneys and 
testes (Gupta et al., 2005; Hviid et al., 2008).  In some instances infection can remain in the 
respiratory tract (Foy et al., 1971).  MuV can also enter the central nervous system (CNS), with 
MuV infection the leading cause of aseptic meningitis and deafness prior to widespread 
vaccination coverage (Hviid et al., 2008; Rubin et al., 1998).   
 
1.6 Diagnosis 
Mumps disease is diagnosed clinically by pain and swelling of the parotid gland(s) either 
unilaterally or bilaterally and lasting for two or more days.  As mentioned earlier, other 
symptoms can also present, such as orchitis, oophoritis, aseptic meningitis, pancreatitis and 
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deafness.  Parotid gland pain and swelling can progress for around three days and lasts around 
one week (Hviid et al., 2008). Mumps is a notifiable disease in the United Kingdom under the 
Public Health (Control of Disease) Act 1984 and Health Protection (Notification) Regulations 
2010.  Health professionals are required to collect samples from patients presenting with 
suspected mumps infection, for confirmatory testing at diagnostic laboratories. 
Routine laboratory diagnosis is based on the isolation of MuV, detection of viral nucleic acid or 
detection of mumps IgM antibody by serological methods.  There is a short timeframe in which 
to isolate virus successfully, usually within the first week of displaying symptoms.  MuV is 
present in saliva for up to five days after the onset of clinical symptoms (Chiba et al., 1976).  
Isolation of MuV from clinical samples is performed on Vero (African Green monkey kidney) 
cells.  These are an interferon-deficient cell line, sensitive to MuV infection and are the most 
routinely used cell line for MuV isolation and propagation (Knowles and Cohen, 2001).  Mumps-
specific IgM or IgG antibodies are measured from saliva or sera, using the enzyme-linked 
immunosorbant assay (ELISA) method (Nicolai-Scholten et al., 1980; Ramsay et al., 1991; 
Ukkonen et al., 1981).  In the event of an inconclusive or negative result, reverse-transcriptase 
polymerase chain reaction (RT-PCR) is carried out on clinical samples to identify the presence or 
absence of MuV nucleic acid.  The SH gene is routinely amplified, which is the most variable 
MuV gene (Afzal et al., 1997) and also enables the clinical sample to be genotyped for 
epidemiological surveillance (Royuela et al., 2011). 
 
1.7 Epidemiology 
MuV is endemic throughout the world.  In the absence of vaccination, mumps cases peak every 
two to five years, usually in the winter and spring months.  Annual incidences of mumps 
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infections range from 100 to 1000 per 100 000 population (WHO, 2007).  There are 12 
recognised mumps genotypes which are designated A – N, with the exception of E and M which 
are now classified as genotypes C and K respectively (WHO, 2012).  MuV genotype is assigned 
based on the sequence diversity of the small hydrophobic (SH) gene and haemagglutinin-
neuraminidase (HN) gene.  MuV is known to be serologically monotypic (Plotkin, 2008) and 
cross-neutralisation between genetically distinct mumps strains is observed.  Circulating wild 
type MuVs are commonly genotypes C, G, H, J and K in the western hemisphere and genotypes 
B, F, I and L in Asia (Jin et al., 2014; Muhlemann, 2004).   
Mumps is historically considered to be a childhood disease affecting children between the ages 
of 5 and 9 years old.  However, over the past 20 years there has been a shift with the infection 
now typically observed in young adults aged 15 – 24 who are in university (Aasheim et al., 2014; 
Brockhoff et al., 2010; Centers for Disease and Prevention, 2012) or military settings (Arday et 
al., 1989; Eick et al., 2008), residing in close proximity and are likely to be the cohort who did 
not receive one or two doses of mumps-containing vaccine.   
Since the introduction of mumps vaccination in the 1960s there has been a dramatic reduction in 
the number of cases of mumps disease to < 1 case per 100 000 population (WHO, 2007).  
However, in more recent years there have been large outbreaks occurring within highly 
vaccinated populations.  The majority of these cases occur in 18 – 24 year old individuals, in the 
United States (Centers for Disease and Prevention, 2006) and similar trends were also observed 
in the United Kingdom in 2004 – 2005 (Savage, 2006), the Netherlands in 2004 (Brockhoff et 
al., 2010), Czech Republic 2005 – 2006 (Boxall et al., 2008) and Germany in 2010 (Otto et al., 
2010) amongst others.  In these outbreaks, where isolates were obtained and analysed, genotype 
G was common to all, which is phylogenetically distinct to genotype A (Jeryl Lynn) or genotype 
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B (Urabe) MuVs, which were the vaccine strains used in these countries.  This highlights the 
possibility of waning immunity as a cause for the increase in susceptibility to mumps infection, 
or that some circulating wild type MuV contain antigenic differences to vaccine strains which 
may result in the immune escape of MuVs (Crowley and Afzal, 2002; Nojd et al., 2001).  
 
1.8 Mumps vaccines  
The first mumps vaccine was developed by Karl Habel in 1946 (Habel, 1946).  It was based on a 
formalin-inactivated virus and was used between 1950 and 1978 in the United States.  Immunity 
was shown to be short-lived and the vaccine was discontinued (Habel, 1951; Ukkonen and 
Penttinen, 1981).  The advent of live attenuated mumps vaccines that were produced in 
embryonated hens eggs (Enders et al., 1946; Habel, 1945) and cell culture systems (Henle and 
Deinhardt, 1955) showed that MuV was capable of adapting to various cell substrates, including 
chicken embryo fibroblasts (CEFs) (Beck et al., 1989), canine kidney cells (Fedova et al., 1987), 
guinea-pig kidney primary cells (Odisseev and Gacheva, 1994) and human diploid cells (Gluck 
et al., 1986; Sassani et al., 1991).  It is this adaptation to cell substrates which forms the basis of 
MuV attenuation for vaccine production, although a universal genetic marker for attenuation of 
MuV has not been determined to date (Santak et al., 2014).    
 
The first live attenuated mumps vaccine originated from a throat culture isolate taken from the 
daughter of Maurice Hilleman, a scientist at Merck & Co who was responsible for vaccine 
development.  The isolate was serially passaged though embryonated hens’ eggs and chicken 
embryo cell culture to achieve attenuation (Buynak and Hilleman, 1966), producing the Jeryl 
Lynn mumps vaccine virus.  This Jeryl Lynn vaccine was manufactured by Merck & Co in the 
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1960s and gave approximately 95 % seroconversion in recipients (Dayan and Rubin, 2008).  It 
was later shown to be a mixture of two distinct but highly related MuV strains, Jeryl Lynn-2 (JL-
2) and Jeryl Lynn-5 (JL-5) (Afzal et al., 1993; Chambers et al., 2009).  The Merck & Co Jeryl 
Lynn MuV vaccine strain has been marketed as MumpsVax; single mumps vaccine, M-M-Vax; 
Measles, Mumps bivalent vaccine, MMR-II/MMRVaxPro; Measles, Mumps, Rubella (MMR) 
trivalent vaccine or ProQuad; MMR+Varicella (MMRV) tetravalent vaccine.  The single and 
bivalent vaccines were discontinued in 2009 (Plotkin, 2008). 
The JL-5 strain was isolated from the Merck & Co vaccine in 1998 by GlaxoSmithKline (GSK), 
and further passaged in chicken embryo fibroblasts (Tillieux et al., 2009).  This Jeryl Lynn strain 
was named RIT 4385 and was shown to have a similar safety profile and efficacy as the Merck & 
Co Jeryl Lynn vaccine (Tillieux et al., 2009; Usonis et al., 1998).  The RIT 4385 vaccine strain is 
marketed as Priorix; MMR trivalent vaccine or Priorix-Tetra; MMRV tetravalent vaccine.  
The Merck and GSK Jeryl Lynn strains are the most widely used MuV vaccine strain (Betakova 
et al., 2013; Carbone and Rubin, 2007). However, there have been many other live attenuated 
MuV vaccines produced using different MuV strains and used worldwide, some of the more 
recent MuV strains used in vaccines are shown in Table 1.    
Sevapharma in the Czech Republic, also manufactured a Jeryl Lynn strain mumps vaccine 
(Plesnik et al., 1984).  For the purposes of this thesis, this Jeryl Lynn strain will be referred to as 
Jeryl Lynn Canine Kidney (JL-CK).  The JL-CK vaccine virus was produced by passage in 
primary canine kidney cells (Fedova et al., 1987).  The exact history of the production of the JL-
CK vaccine virus is not known, however it is thought that it was produced by limiting dilution of 
the Merck & Co Jeryl Lynn vaccine, followed by passage in primary canine kidney cells. The 
JL-CK vaccine is marketed as Pavivac; monovalent mumps vaccine, Mopavac; Measles, Mumps 
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bivalent vaccine or Trivivac; MMR trivalent vaccine (Kubinyiova et al., 2008; Stepanova et al., 
2006). 
 
1.9 Safety, adverse events and vaccine efficacy 
Immunogenicity studies on mumps vaccine strains used in clinical trials before licencing have 
provided estimates of efficacy based on seroconversion rates.  This data combined with safety 
data obtained during clinical trials are used by manufacturers to apply for a medicine licence, 
otherwise known as a marketing authorisation.  The licencing authority in the United Kingdom is 
the Medicines and Healthcare products Regulatory Agency (MHRA).  Medicines in the UK have 
been regulated since the 1960s under the terms of the Medicines Act of 1968 which provides a 
legal framework for the control of medicines and requires medicines to be licenced before being 
allowed onto the UK market.  More recently many of the conditions of the Act have been 
superseded by regulations covering the European legislation of medicines. The MHRA 
collaborates with the European Medicines Agency (EMA), the European regulator and the 
regulatory agency in the United States the Food and Drug Administration (FDA).   
Once licenced, medicines are monitored for up to two years to enable reporting of additional side 
effects and adverse events which may not have been observed in the pre-licencing clinical trials.    
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Table 1: Live attenuated mumps vaccines in recent use 
*
derived from original Jeryl Lynn vaccine strain, 
#
 withdrawn from Europe, USA and Canada 
Strain Genotype Manufacturer Substrate Distribution Reference 
Jeryl Lynn A Merck & Co CEF Worldwide (Buynak and Hilleman, 1966) 
RIT 4385
*
 A GlaxoSmithKline CEF Worldwide (Tillieux et al., 2009) 
JL-CK
*
 A Sevapharma Primary canine 
kidney 
Czech Republic (Plesnik et al., 1984) 
S79
*
 A Shanghai, Beijing, and 
Lanzhou Institute of 
Biological Products, China 
CEF China (Fu et al., 2008) 
Urabe AM9 B Sanofi Pasteur, 
GlaxoSmithKline, Biken 
CEF Worldwide
#
 (Yamanishi et al., 1970) 
Leningrad-
Zagreb 
N Institute of Immunology 
Zagreb, Serum Institute of 
India 
CEF Worldwide (Beck et al., 1989) 
Leningrad-3 N Bacterial Medicine Institute 
Moscow 
Primary guinea-pig 
& Japanese quail 
embryo fibroblasts 
Russia (Smorodintsev et al., 1965) 
Rubini A Swiss Serum Institute Human Diploid Europe
#
 (Gluck et al., 1986) 
Hoshino B Kitasato Institute CEF Japan (Makino et al., 1976) 
S-12 H Razi State Serum and 
Vaccine Institute 
Human Diploid Iran (Sassani et al., 1991) 
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An Adverse Event Following Vaccination (AEFI) is defined by the Council for International 
Organisations of Medical Science and by the World Health Organisation as “any untoward 
medical occurrence which follows immunisation and which does not necessarily have a causal 
relationship with the usage of the vaccine” 
(http://whqlibdoc.who.int/publications/2012/9789290360834_eng.pdf). 
 
Different vaccine strains vary in protective efficacy and degree of attenuation (Goh, 1999), 
ability to cause aseptic meningitis and adverse event profiles (Brown and Wright, 1998; da 
Cunha et al., 2002; Gilliland et al., 2013; Kaic et al., 2008). 
 
1.9.1 Urabe vaccine strain 
The Urabe Am9 strain was developed in Japan from an isolate obtained from a mumps patient 
(Yamanishi et al., 1970) and attenuated by serial passage in chicken embryo fibroblasts.  The 
Urabe-containing vaccine induced seroconversion in approximately 85 % - 94 % of recipients 
(Ehrengut et al., 1983; Pons et al., 2000; Schlegel et al., 1999) and has been marketed as 
Trimovac (Sanofi-Pasteur), Immravax (GlaxoSmithKline) and Pluserix (Biken).  However, the 
Urabe Am9 vaccine has been associated an increased incidence of vaccine-associated aseptic 
meningitis (Brown and Wright, 1998; Miller et al., 2007; Miller et al., 1993; Sugiura and 
Yamada, 1991; Ueda et al., 1995).  The vaccine was found to contain a mixture of two MuVs 
(Brown et al., 1996).  The two MuV strains identified within the Urabe vaccine differed at amino 
acid 335 of the HN protein, with one variant associated with the development of aseptic 
meningitis in vaccinees (Brown et al., 1996).  This led to the withdrawal of Urabe-containing 
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vaccines from use in the United Kingdom, Canada and United States amongst others (Schmitt et 
al., 1993; WHO, 2001).  
 
1.9.2 Leningrad-3 and Leningrad-Zagreb vaccine strains 
The Leningrad-3 (L-3) strain was developed in Russia by serial passage in guinea pig kidney cell 
culture and Japanese quail embryo culture.  The L-3 strain is the parent virus for the Leningrad-
Zagreb (L-Zagreb) strain which was developed in Croatia in 1972 by passage in chicken embryo 
fibroblasts (Beck et al., 1989).   The L-Zagreb strain was given to the Serum Institute of India 
(SII), where it has been used for the manufacture of MuV vaccines (Ivancic et al., 2005) and is 
marketed as Tresivac (Serum Institute of India).  The L-3 and L-Zagreb containing vaccines have 
been shown to have similar seroconversion rates compared to Urabe, approximately 90 % (Beck 
et al., 1989; Bhargava et al., 1995; Smorodintsev, 1960; Smorodintsev et al., 1965).  However, 
both L-3 and L-Zagreb vaccines have been linked with vaccine-associated aseptic meningitis and 
mumps disease (Bakker and Mathias, 2001; Cizman et al., 1989; da Cunha et al., 2002; Gilliland 
et al., 2013) as well as horizontal transmission of the vaccine virus (Atrasheuskaya et al., 2006; 
Kaic et al., 2008; Tesovic et al., 2008).  Vaccines containing the L-Zagreb strain are still in use 
and manufactured by the Serum Institute of India.  
 
1.9.3 Rubini vaccine strain 
The Rubini strain was developed in Switzerland by serial passage of a clinical isolate in human 
diploid cell culture (Gluck et al., 1986).  Vaccines containing the Rubini strain were considered 
to have a good safety profile with lower incidences of post-vaccination fever or pain and 
swelling at injection site, compared to a Jeryl Lynn vaccine strain (Schwarzer et al., 1998).  The 
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Rubini strain has not been specifically linked with AEFI.  However, it has been associated with 
mumps outbreaks in previously vaccinated populations (Goh, 1999; Pons et al., 2000; Strohle et 
al., 1997).  Post-vaccination studies have revealed that the Rubini vaccine gave substantially 
lower rates of seroconversion and effectiveness compared to individuals vaccinated with Jeryl 
Lynn strains (Goh, 1999; Schlegel et al., 1999) with seroconversion reported to be as low as 38 
% in vaccine recipients (Schwarzer et al., 1998).  The World Health Organisation recommended 
that vaccines containing the Rubini strain should therefore not be used in national immunisation 
schedules (WHO, 2007).  The Rubini vaccine was marketed as Triviraten (Swiss Serum 
Institute) before its use was discontinued.  
 
1.9.4 Jeryl Lynn and RIT 4385 vaccine strains 
Vaccines containing the Jeryl Lynn strain of mumps are considered to have a good safety profile 
in comparison to many of the other vaccine strains and have not been associated with AEFI 
(Czajka et al., 2009; Hviid et al., 2008; Lim et al., 2007; Nokes and Anderson, 1991).  Jeryl Lynn 
mumps vaccines have also been shown to have similar seroconversion rates to Urabe-containing 
vaccines.  The Merck & Co Jeryl Lynn and RIT 4385 strains, which are both licenced for use in 
the UK, were  shown to induce seroconversion in approximately 95 % and 94 % of vaccine 
recipients respectively (Dayan and Rubin, 2008; Usonis et al., 1998).  However, these 
seroconversion rates were determined during clinical trials before licencing and have been shown 
to be higher than the seroconversion rates observed once the vaccines were in routine use.  The 
average effectiveness of Jeryl Lynn and Urabe-containing vaccines post-licensing, has been 
reported to be 77 %, with the Urabe vaccine strain seeming to offer greater protection (Hviid et 
al., 2008). 
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1.9.5 JL-CK vaccine strain 
The JL-CK vaccine, which is not licenced for use in the United Kingdom, has been associated 
with vaccine failure (Mrazova et al., 2003; Stepanova et al., 2006).  Clinical trials showed 
seroconversion rates in recipients to be approximately 75 %, six to eight weeks post-vaccination 
(Plesnik et al., 1984), increasing to 82 % after 35 months (Fedova et al., 1987; Mrazova et al., 
2003).  Despite high vaccination coverage with the JL-CK containing vaccine, a large mumps 
outbreak occurred in the Czech Republic between January 2005 and June 2006, with 5998 
notified cases; 70 % of these had received two doses of Trivivac, the JL-CK-containing MMR 
vaccine (Boxall et al., 2008).  This suggested the possibility of waning immunity (Limberkova 
and Lexova, 2014) or that that the vaccine may be over-attenuated (Goh, 1999).  The JL-CK 
monovalent mumps vaccine Pavivac was also used briefly in the United Kingdom in some 
private clinics, where unlicensed medicines can be administered by private prescription.  This 
was during the period when there was demand for a single mumps vaccine, until questions were 
raised about its manufacture, testing and storage 
(http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/home/gro
ups/pl-p/documents/websiteresources/con2031109.pdf).  
 
1.10 Aims and objectives 
Since the 1960’s, live attenuated mumps vaccines have been produced in cell culture systems 
worldwide, yet the effects of the cell substrates on the genetics and biology of the resulting virus 
populations are poorly understood.  The difference in seroconversion rates between the JL-CK 
vaccine virus and the RIT 4385 virus is interesting as they are descended from the same parental 
Jeryl Lynn vaccine strain, albeit with different production methods.  The lack of stability of MuV 
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during growth in cell cultures is well known.  Therefore adaptation of the JL-CK virus to 
primary canine kidney cells may have resulted in changes to the MuV, which may affect its 
ability to induce the same level of immunogenicity as RIT 4385.   
 
This project was designed to test the hypothesis that the JL-CK and RIT 4385 viruses differ 
despite their shared origin.  Using classical virology, molecular biology, in vitro and in vivo 
methods, the aims were to identify genotypic and phenotypic differences between the two 
viruses.  This study will provide novel insights and contribute to our knowledge of MuV 
adaptation and biology. 
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CHAPTER 2 - MATERIALS AND METHODS 
 
The viruses used in the study are detailed in Table 2.  The details of media components, 
chemicals and reagents which were prepared in-house are detailed in Table 3. 
 
Table 2:  Vaccine viruses and clinical isolates 
Virus Information Source/Reference 
JL-CK Live attenuated MuV component of 
Pavivac vaccine, Sevapharma, Czech 
Republic 
Eva Vitková, Official Medicines and 
Control Laboratory, Prague, Czech 
Republic 
(Fedova et al., 1987; Limberkova and 
Lexova, 2014; Stepanova et al., 2006) 
RIT 4385 Live attenuated MuV component of 
Priorix MMR vaccine, GSK, UK 
(Tillieux et al., 2009) 
Mu90 Clinical mumps isolate passaged four 
times on Vero cells.  Originally isolated 
in London in 1988, designated 
Lo1/UK/88  
(Afzal et al., 1997) 
Jeryl 
Lynn 
Live attenuated MuV component of 
MMR-II / MMRVaxPro MMR vaccine, 
Merck & Co, US. 
Contains two closely related mumps 
strains JL-5 and JL-2 (Afzal et al., 1993) 
(Tillieux et al., 2009) 
L3-SSW 
Pankow 
Leningrad-3 MuV strain, further 
passaged in primary canine kidney cells 
for vaccine production.  The vaccine did 
not pass clinical trials due to high 
incidence of aseptic meningitis (Tischer 
and Gerike, 2000) 
Dr Annette Marketz, Robert Koch 
Institute, Berlin, Germany 
(Starke and Hlinak, 1974) 
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Table 3:  Chemicals and reagents prepared in-house 
Reagent Components 
Bactoagar (2 %) Prepare 50 ml: 
1 g bactoagar (Sigma-Aldrich, UK) 
50 ml distilled H2O 
CMC (5 %) Prepare 50 ml: 
2.5 g (5% w/v) carboxymethylcellulose (Fisher Scientific, UK) 
50 ml PBS A (1x) 
Earles 20 x Prepare 500 ml: 
68 g NaCl (Fisher Scientific, UK)  
10 g D(+) glucose (Merck, UK) 
4 g KCl (Merck, UK)  
2.10 g MgSO4 7H2O (Merck, UK) 
1.90 g Na H2 PO4 2H2O (Merck, UK)   
1.80 g CaCl2 2H2O (Merck, UK) 
Adjust to final volume of 500 ml with distilled H2O 
Add 1 ml chloroform (Fisher Scientific, UK) 
Lactalbumin hydrolysate 
(4 %) 
Prepare 1 litre: 
40 g lactalbumin enzymatic hydrolysate (Sigma-Aldrich, UK) 
50 ml Earles 20 x 
Adjust to final volume of 1 litre with distilled H2O 
Methyl violet Prepare 1 litre: 
200 ml IMS (Tennant, UK) 
5 g (0.5 % w/v) methyl violet (Merck, UK) 
800 ml distilled H2O 
Neutral buffered 
formalin (10 %) 
Prepare 1 litre: 
100 ml formalin (Sigma-Aldrich, UK) 
4 g NaH2PO4 H2O (Merck, UK) 
6.5 g Na2HPO4 anhydrous (Merck, UK) 
Adjust to final volume of 1 litre with distilled H2O 
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Neutral red (0.17 %) Prepare 100 ml: 
0.17 g neutral red (Sigma-Aldrich, UK) 
100 ml distilled H2O 
PBS A Prepare 1 litre: 
1 g NaCl (Fisher Scientific, UK) 
0.25 g KCl (Merck, UK) 
1.44 g Na2HPO4 anhydrous (Merck, UK) 
0.25 g KH2PO4 (Merck, UK) 
Adjust to final volume of 1 litre with distilled H2O 
pH 7.5 (adjusted with NaOH or HCl) 
PBS 6-Salt Prepare 10 litres: 
80 g NaCl (Fisher Scientific, UK) 
2 g KCl (Merck, UK) 
1.3 g CaCl2 2H2O (Merck, UK) 
1 g MgCl2 6H2O (Merck, UK) 
29 g Na2HPO 12H2O (Merck, UK) 
2 g KH2PO4 (Merck, UK) 
Adjust to final volume of 10 litres with distilled H2O 
Sample buffer (4 x) Prepare 50 ml: 
250 mM tris HCl (Fisher Scientific, UK) 
8 % SDS (Sigma-Aldrich, UK) 
10 % glycerol (Sigma-Aldrich, UK) 
0.04 % bromophenol blue (Sigma-Aldrich, UK) 
Adjust to 50 ml with distilled H2O 
TBE 10 x Prepare 1 litre: 
109.03 g tris base (Fisher Scientific, UK) 
55.65 g boric acid (Sigma-Aldrich, UK) 
9.31 g EDTA (Merck, UK) 
Adjust to final volume of 1 litre with distilled H2O 
pH 7.5 (adjusted with NaOH or HCl) 
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TBS 10 x Prepare 500 ml: 
43.83 g NaCl (Fisher Scientific, UK) 
6.06 g tris (Fisher Scientific, UK) 
2 ml HCl (Merck, UK) 
pH 8.0 (adjusted with HCl) 
Transfer buffer 10 x Prepare 1 litre: 
30 g tris base (Fisher Scientific, UK) 
144.2 g glycine (Sigma-Aldrich, UK) 
Tris/HEPES/SDS 
running buffer 10 x 
Prepare 1 litre: 
121 g tris base (Fisher Scientific, UK) 
238 g HEPES (Sigma-Aldrich, UK) 
10 g SDS (Sigma-Aldrich, UK) 
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2.1  Viruses 
2.1.1  Preparation of virus aliquots 
JL-CK vaccine virus was supplied lyophilised in two-dose aliquots.  The vaccine was 
resuspended in 1400 µl Minimal Essential Medium (MEM) (Sigma-Aldrich, UK) and split into 
100 µl aliquots before storage at -80 
°
C. 
RIT 4385 virus was archived in 30 ml bulk liquid formulation.  The bottle was defrosted with 
100 µl aliquots prepared and stored at -80 
°
C. 
Jeryl Lynn was archived in 150 ml bulk liquid formulation. The bottle was defrosted with 1 ml 
aliquots prepared and stored at -80 
°
C. 
Mu90 was pre-aliquoted and archived at -80 
°
C.  
L3-SSW Pankow was supplied lyophilised in a five-dose aliquot.  The vaccine was resuspended 
in 500 µl sterile water and split into 50 µl aliquots before storage at -80 
°
C. 
 
Table 4:  Cell lines used in the study 
Cell line Origin Source References 
Vero African Green monkey 
kidney 
NIBSC, ref no 880101
*
 (Yasumura and Kawakita, 
1963) 
MDCK Canine kidney  NIBSC, ref no 821104
*
 (Madin and Darby, 1958) 
SH-SY5Y Human neuroblastoma ECACC, cat no 94030304 
 
(Biedler et al., 1978; Ross 
et al., 1983) 
*
 NIBSC Ref No refers to in-house cell bank number 
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2.2  Routine cell culture 
2.2.1  Cell line maintenance 
Cell lines in Table 4 were routinely cultured in T75 flasks every 3 to 4 days after microscopic 
examination and when suitable confluence was obtained.  Cell maintenance media for each cell 
line are described in Table 5.  Confluent flasks of cells were sub-cultured by removing the 
maintenance medium and washing the cell sheet with PBS A.  The cell sheet was washed with 5 
ml 0.25 % trypsin-EDTA solution (Sigma-Aldrich, UK) then the trypsin solution was decanted 
and the flasks incubated at 37 
°
C until the cell sheet dislodged.  A suitable volume of 
maintenance medium was added to each flask dependant on the sub-culture ratio to be prepared 
and the cells were resuspended before transfer of an appropriate volume of the resuspended cells 
to new T75 flask(s), containing 40 – 50 ml of maintenance medium.  All cell culture procedures 
were carried out in a class II microbiological safety cabinet and cells were routinely incubated at 
37 
°
C. 
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Table 5:  Cell culture media used in the study 
Medium Components 
Cell maintenance 
medium (Vero) 
Minimum Essential Medium (MEM) (Sigma-Aldrich, UK) 
1.5 % HEPES buffer (Sigma-Aldrich, UK) 
5 % new-born calf serum (Sigma-Aldrich, UK) 
4 % lactalbumin hydrolysate (in house) 
2 % 200 mM L-glutamine (Sigma-Aldrich, UK) 
1 % glucose  (Sigma-Aldrich, UK) 
Cell maintenance 
medium (MDCK) 
MEM (Sigma-Aldrich, UK) 
1.5 % HEPES (Sigma-Aldrich, UK) 
5 % foetal calf serum (FCS) (Gibco, Life Technologies, UK) 
1 % 200mM L-glutamine (Sigma-Aldrich, UK) 
Cell maintenance 
medium (SH-SY5Y) 
1:1 MEM : Ham’s F12 (Sigma-Aldrich, UK) 
15 % FCS (Gibco, Life Technologies, UK) 
Infection medium MEM (Sigma-Aldrich, UK) 
4 % FCS (Gibco, Life Technologies, UK) 
2 % 200 mM L-glutamine (Sigma-Aldrich, UK) 
1 % 10,000 units/ml penicillin/streptomycin (Sigma-Aldrich, UK) 
1 % 250 mM amphotericin B (Sigma-Aldrich, UK) 
CMC overlay  MEM (Sigma-Aldrich, UK) 
4 % FCS (Gibco, Life Technologies, UK) 
2 % 200 mM L-glutamine (Sigma-Aldrich, UK) 
1 % 10,000 units/ml penicillin/streptomycin (Sigma-Aldrich, UK) 
1 % 250 mM amphotericin B (Sigma-Aldrich, UK) 
50 ml 5 % CMC (in house) 
Agar overlay 40 ml MEM (Sigma-Aldrich, UK) 
50 ml 2 % bactoagar 
10 ml 0.17 % neutral red 
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2.3  In vitro growth of mumps viruses 
2.3.1  Virus infection of Vero cells 
Vero cells were seeded into 24-well plates or T25 flask(s) (both Corning Inc., US) at a density of 
ca. 1 x 10
5
 cells per well in 1 ml infection medium per well, or 5 ml infection medium per flask.  
Virus stocks were removed from -80
 °
C and allowed to thaw on ice.  A dilution range of each 
virus was prepared so that the same plaque forming units (pfu) per ml were inoculated, at 
approximately a multiplicity of infection (MOI) of 0.0001 pfu per cell.  Wells were inoculated in 
triplicate with 50 µl per well or 250 µl per T25 flask of the appropriate virus dilution and 
incubated at 35
 °
C, 5 % CO2 for ca. 3 hr. After incubation the inoculate was removed and 
replaced with either 1 ml per well or 5 ml per flask of infection medium before incubating at 35
 
°
C, 5 % CO2 for the appropriate time period for each assay, between 1 and 10 days.  Plates or 
flasks were then removed and stored at -80
 °
C, before titration of the viruses on Vero cells. 
 
2.3.2  Infection of cells and measurement of cell lysis 
Vero cells were seeded into 96-well plates (Corning Inc., US) at a density of ca. 2 x 10
4
 cells per 
well in 200 µl of infection medium.  Virus stocks were removed from -80
 °
C and allowed to thaw 
on ice.  10 µl of each virus (MOI = 0.0001 pfu per cell) was added to three wells of a 96-well 
plate and eight replicate 96-well plates were prepared.  The plates were incubated at 35 
°
C, 5 % 
CO2, with one plate removed each day for 7 days.  Each plate was washed with medium before 
incubation with 100 µl infection medium containing 20 % CellTiter 96
®
 AQueous One Solution 
Cell Proliferation Assay (MTS) (Promega, UK) at 37 
°
C, 5 % CO2 for 1 hr before analysing on a 
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FLUOstar OPTIMA plate reader (BMG Labtech, Germany) set at 492 nm.  The 8
th
 plate was 
removed on day 7 and used to titrate the viruses. 
 
2.3.3  Growth in Vero cells 
Vero cells were added to three wells of seven 24-well plates.  Each well was inoculated with 50 
µl of 1120 pfu per ml inocula consisting of either JL-CK or RIT 4385 MuVs at a MOI of 0.0001 
pfu per cell, with one well containing cells only.  The plates were incubated at 35 
°
C, 5 % CO2, 
with one plate removed daily for 7 days.  After incubation the plates were stored at -80 
°
C.  After 
at least one day at -80 
°
C, the plates were thawed and serially diluted before titration on Vero 
cells. 
 
2.3.4  Growth in Vero and MDCK cells 
Vero or MDCK cells were added to T25 flasks.  Each flask was inoculated with 250 µl of 1120 
pfu per ml inocula consisting of either JL-CK or RIT 4385 MuV at a MOI of 0.0001 pfu per cell 
and incubated at 35 
°
C, 5 % CO2 for 7 days.  After incubation the flasks were stored at -80 
°
C.  
After at least one day at -80 
°
C, the flasks were thawed, contents centrifuged at 700 xg for 3 min 
and aliquoted before titration on Vero cells. 
 
2.3.5  Growth in Vero, MDCK and SH-SY5Y cells 
Vero, MDCK or SH-SY5Y cells were added to T25 flasks.  Each flask was inoculated with 250 
µl of either JL-CK or RIT 4385 MuVs at a MOI of 0.0001 pfu per cell and incubated at 35 
°
C, 5 
% CO2 for 72 hr.  After incubation the supernatant was removed and stored at -80 
°
C, fresh 
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infection medium was added to each flask and the flasks incubated at 35 
°
C, 5 % CO2.  At days 
1, 4 and 7 the supernatant was removed from each flask and stored at -80
 °
C.  Fresh media was 
added back to each flask before freezing at -80
 °
C. 
After at least one day at -80 
°
C, the flasks were thawed and contents centrifuged at 700 xg for 3 
min and aliquoted.  The frozen cell lysate supernatant was also defrosted and both were serially 
diluted before titration in Vero cells. 
 
2.3.6  Virus concentration by sucrose gradient 
Three T75 flasks of confluent Vero cells were inoculated with either JL-CK or RIT 4385 at a 
MOI of 0.0001 pfu per cell, with 3 ml of infection medium added and incubated at 35 
°
C, 5 % 
CO2 for 90 min.  After incubation an additional 15 ml of infection medium was added to each 
flask and the flasks were re-incubated at 35 
°
C, 5 % CO2 until cytopathic effects (CPE) were 
observed, after ca. 3 days incubation.  The flasks were then transferred to -80 
°
C.  After at least 
one day at -80 
°
C, the flasks were thawed and the contents clarified by centrifugation at 950 xg 
for 10 min at 4
 °
C. 
Sucrose gradients were prepared (one per flask) in Ultra-Clear Thin wall 38.5 ml tubes 
(Beckman Coulter, UK) by layering sucrose solutions and virus.  First, 8 ml of 60 % sucrose was 
added, followed by 12 ml of 25 % sucrose.  Then a layer of ca. 15 ml clarified virus supernatant 
was added and the tube(s) topped up with sterile PBS.  Tubes were centrifuged at 47700 xg for 2 
hr at 4 
°
C.  The virus concentrates were pooled by removing the virus layer at the interphase and 
transferring them to a clean Ultra-Clear Thin wall 38.5 ml tube.  Each tube was topped up with 
sterile PBS and subjected to centrifugation at 82500 xg for 90 min at 4 
°
C, before removing the 
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supernatant and allowing the pellets to air-dry.  Pellets were resuspended in 60 µl sterile PBS 
before storing at -20 
°
C. 
 
2.3.7  Titration of viruses 
MuV were titrated by plaque assay in Vero cells.  Confluent T75 flasks of Vero cells were 
trypsinised into 40 ml infection media with 1 ml of cells added per well, to a 24-well plate.  
Serial dilutions of each virus were prepared in infection medium and 50 µl of each dilution was 
added in triplicate to the 24-well plate containing Vero cells.  Negative control wells contained 
cells only.  The plates were incubated for ca. 3 hr at 35 
°
C, 5 % CO2 to allow the cells to adhere.  
After the incubation period, the infection media was removed from the wells and replaced with 
1.25 % carboxymethylcellulose (CMC) overlay.  The plates were re-incubated at the same 
conditions, for 10 days.  The cells were fixed and stained with methyl violet and the virus titres 
calculated as plaque forming units (pfu) per ml.  Plaque sizes were measured using ImageJ 
(Rubin et al., 2005; Schneider et al., 2012). 
For comparison of overlay media the methodology above was followed with a 1 % bactoagar 
overlay used as a substitute for 1.25 % CMC.  After 10 days incubation, 1 ml of 1 % bactoagar 
containing neutral red (0.17 %) was added to each well and incubated for 4 hr at 35 
°
C, 5 % CO2, 
followed by incubation in the dark at 4 
°
C overnight. 
To identify temperature-sensitive viruses, the above methodology, including CMC overlay was 
followed, however the incubation temperatures used were 32 
°
C, 35 
°
C, 37 
°
C and 40 
°
C. 
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2.3.8  Plaque isolation  
JL-CK was grown in Vero cells as in section 2.3.7 (with agar overlay).  Before the fixation step, 
plaques were picked to 24-well plates containing confluent monolayer(s) of Vero cells and 
incubated at 35 
°
C, 5 % CO2 until CPE was observed, before transferring the plates to -80 
°
C. 
 
2.3.9  Plaque reduction neutralisation (PRN) assays 
Serum samples and the anti-mumps IgG human serum reference 93/582 (NIBSC in-house 
standard), were removed from -80 
°
C and thawed at room temperature before heat-inactivation 
by incubation at 56 
°
C in a water bath for 30 min, to inactivate complement. 
Each serum sample and the mumps serum reference (93/582) were diluted using infection 
medium and serial dilutions (1:2, 1:4, 1:8, 1:16, 1:32 and 1:64) were prepared.  The challenge 
virus (RIT 4385, JL-CK or Mu90), was added to each of the dilutions.  Controls contained only 
the virus without serum.  The samples were incubated at 4 
°
C for 90 min.  Confluent T75 flasks 
of Vero cells were trypsinised into 45 ml of infection media per flask and pooled. 
Each of the samples was added into 24-well plates with 1 ml of trypsinised Vero cells and mixed.  
The plates were incubated at 35 
°
C, 5 % CO2 for 3 hr.  After the incubation period the medium 
was removed and replaced with 1 ml 1.25 % CMC overlay.  The plates were re-incubated at 35 
°
C, 5 % CO2 for 10 days and then stained with methyl violet.  Plaque counts were used to 
calculate the ND50 values of the sera using the Spearman-Kärber formula (Anellis and 
Werkowski, 1968). 
 
 
 
55 
 
2.4  Molecular biology 
2.4.1  RNA extraction 
RNA was extracted using Trizol
®
 LS Reagent (Life Technologies, UK) following the 
manufacturer’s recommended protocol.  Briefly, three volumes of Trizol® LS reagent were added 
to one volume of sample. Additionally 2 µl of glycogen (Life Technologies, UK) and an 
appropriate volume of chloroform (Sigma-Aldrich, UK) were added before mixing by vortex and 
incubating at room temperature for 5 min.  Samples were centrifuged at 18000 xg for 10 min at 4
 
°
C and the top aqueous phase containing the RNA was removed to a fresh 1.5 ml nuclease-free 
tube.  An appropriate volume of isopropanol (Sigma-Aldrich, UK) was added and samples were 
incubated at -20
 °
C for ca. 30 min before centrifugation at 18000 xg for 10 min at 4
 °
C to pellet 
the RNA.  The supernatant was removed and the RNA pellet washed with ice cold 70 % ethanol 
before a final centrifugation at 18000 xg for 10 min.  The supernatant was removed and the pellet 
allowed to air-dry, before resuspension in 10 – 30 µl diethyl pyrocarbonate (DEPC)-treated H2O 
(Sigma-Aldrich, UK) and stored at -20 
°
C. 
 
2.4.2  cDNA synthesis 
Random hexamer cDNA was prepared from RNA using Superscript III First-Strand Synthesis 
Supermix (Life Technologies, UK), following the manufacturer’s protocol.  Briefly, 1 – 2 µl 
total RNA, 1 µl random hexamer and 1 µl annealing buffer were added to a nuclease-free tube, 
made up to 10 µl with DEPC-treated water and incubated at 65 
°
C for 5 min.  This was 
transferred to ice for 5 min before the addition of 10 µl 2 x First-Strand reaction mix and 2 µl 
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Superscript III enzyme.  This was incubated at 25 
°
C for 10 min, followed by 50 
°
C for 50 min 
then 85 
°
C for 5 min.  The resulting cDNA was stored at -20 
°
C. 
 
2.4.3  Real-time quantitative polymerase chain reaction  
Real-time quantitative polymerase chain reaction (qPCR) was performed on RNA samples using 
the TaqMan
®
 EZ RT-PCR kit (Life Technologies, UK). Primers and probes, described in Tables 
6 and 7, were used at a working concentration of 10 µM (primers) and 5 µM (probes).  All real-
time qPCR reactions were performed on a 7900HT Real Time PCR System (Life Technologies, 
UK) with the protocol and thermal profile detailed in Table 8. 
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Table 6:  Primers used for real-time qPCR 
Primer name Sequence 5’ – 3’ Target Source 
T701 GGCAATCCAACCTCCCTTA SH gene of JL-5 and JL-2 
mumps strains 
L.C. Ozoemena, NIBSC 
T702 GTTCTAGCGTGACGGATCG 
JL2fw GCTAACCCTTCTCTATCTAATCATAACT SH gene of JL-2 This study 
JL2rev GGACTTGCCCTAACTGAGGA 
 
 
Table 7:  Probes used for real-time qPCR 
Probe name Sequence 5’ – 3’ Target Source 
TP703 FAM-TATTAACTATAAGACGGCGGTGCGAT-TAMRA SH gene JL-5 L.C. Ozoemena, NIBSC 
TP704 FAM-CATTAACCATAATACGGCGGTTCGGC-TAMRA SH gene JL-2 
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Table 8:  Real-time qPCR protocol and thermal cycling conditions 
 
 
 
 
 
 
 
                     
 
 
 
 
 
         *data collection 
 
2.4.4  Reverse-transcription polymerase chain reaction 
The JL-5 MuV sequence (accession AF201473) was used to design over-lapping primers (Table 
9) covering the whole mumps genome in ca. 1 kb fragments.  Primers were also designed against 
the Leningrad-3 MuV sequence (accession AY508995), detailed in Table 10.  One-Step reverse 
transcription (RT) PCR was performed using either the Qiagen
®
 One-Step RT-PCR kit or the 
MyTaq™ One-Step RT-PCR kit (Bioline, UK) following the manufacturer’s recommended 
protocols.  Primers were used at a working concentration of 10 µM for both protocols and 1 – 5 
µl of RNA was used as a template.  RT-PCR mixes and thermal cycling parameters for both RT-
PCR kits are described in Table 11.  All PCR reactions were performed on an Eppendorf 
MasterCycler. 
PCR Protocol Thermal Cycling Parameters 
TaqMan
®
 EZ RT PCR 
5x TaqMan
®
 EZ Buffer     10 µl 
dNTP                                   3 µl 
Mn
2+ 
                                 2.5 µl 
Primer fw (10 µM)              1 µl 
Primer rev (10 µM)             1 µl 
Probe (5 µM)                    0.5 µl 
RT                       1 µl 
AmpErase UNG             0.25 µl 
RNA                                 2 µl 
Water                             8.75 µl 
50 
°
C 2 min 
 58 
°
C 30 min 
95 
°
C 5 min 
94 
°
C 20 sec 
                   55 
°
C   1 min*   40 cycles 
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Table 9:  PCR primers for amplification of Jeryl Lynn-5 MuV 
Primer Name Sequence 5’ – 3’ Target Primer Name Sequence 5’ – 3’ Target 
Pav1fw GGAAGTGGTGTTTTGCGATT N gene Pav9fw TGGCAGGATCACAGATCAAA M gene 
Pav2rev CCATTTGGTCCCTAGTGCAT Pav10rev GGTTTTGCAGTTGTCGGAAT 
Pav3fw TATGCAATGGTGGGTGACAT Pav11fw AGATATGTGGGGACCAACCA 
Pav4rev ACTTGCAACTGTGCGTTTTG Pav12rev ACGTGCATTTGTCTGTGCTT 
Pav5fw GGGCGAACACGTAAACACTT Pav61fw GCGCAAAGGCAGAAATAAAC 
Pav6rev GCACCTTGTCCACCTTTTGT Pav62rev CCGGTCAAATTTGCTTGATT 
Pav35fw CTTTTGTTCCTCCGGTTCAA Pav69fw GAGCCAGGTACACCTTCCAA 
Pav36rev ATCTTCGCCAATTCCACACT Pav70rev TGTCATCAGTCTTTGCAAGTGAT 
Pav73fw ACCAAGGGGAGAATGAATATG Pav77fw TTTTGCTTCGGGTAACTTGC 
Pav74rev GTCATCTGCAAGCAAAGCAT Pav78rev CTTCGAAGACTGCCCGATTA 
Pav75rev CCCGGAAAGAAACACGATAA Pav47fw AAGCAACAGGTCAGGCAACT F gene 
Pav7fw AGAGGTCCGGGTCTTTGAGT P gene Pav48rev TGCCTCATTGTATTGGCAGA 
Pav37fw GGACCAGGAGATGTGTCGTT Pav49fw ATGGCGCTATCCAGCTAAGA 
Pav38rev TGCGGTTGATCTCGAATAAG Pav50rev AAGGATCGCTGGTACAGTGC 
Pav57fw TCCTCAAGTCAGCAACATGC Pav63fw CGGTCTAATGGAGGGTCAGA 
Pav58rev AATTCCCACATTTGCAGGAG Pav64rev TGACTGCATGATGGTCAGGT 
Pav59fw CAGTGCGAACGAGATTATGG Pav79fw CGGTCTAATGGAGGGTCAGA 
Pav60rev ATGCACGCTGTCACTACAGG Pav51fw GGCAATCCAACCTCCCTTAT SH gene 
  Pav76fw CAGGATGAGACCGGTGATTT 
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Primer Name Sequence 5’ – 3’ Target Primer Name Sequence 5’ – 3’ Target 
Pav17fw ACTAGCTGGTGGCCGTATGA HN gene Pav52rev GAGCAGCTTTTCCGATTCAG L gene 
Pav18rev TGCCGAAGATCATATGCTTG Pav31fw ATCTGACGGTGCCCATCTAT 
Pav53fw CGTCAGGGTATCCCATGTTC Pav32rev GCTTGGCCCTTTAGGATTTC 
Pav54rev GATTCACCCTGGTTGTGCTT Pav33fw CCGAGCACAAGAAAATGGTT 
Pav55fw TGATCCCTGGCCATTAACTC Pav34rev CCAAGGGGAGAAAGTAAAATCA 
Pav65fw TTTATCCCCACTGCAACCTC Pav39fw GCCCCATATGGTACTCAAGG 
Pav66rev TATTCCACTCCCCACTCCTG Pav40rev CCCACTCCACTCATTGTTGA 
Pav19fw GTGGACCCGATCTCAAAGAG Pav41fw CGCCCAATTACAGTATGGTG 
Pav20rev GATGGCCCCAAAGTCTCATA L gene Pav42rev TCCATTCAAACAAGTGGGGTA 
Pav21fw TATGAGACTTTGGGGCCATC Pav43fw GGGGGCTTAAACTTTCTTTCA 
Pav22rev GCAGGCTGCTATCTCAAACC Pav44rev TGAGATTAACACGAGTGGAAGC 
Pav23fw CATGAGATGCCTGATGATGG Pav45fw CGCCAAGCAGATGGTAAATA 
Pav24rev AGCCCGCTTTAATTAATCGTT Pav46rev TGCAATCAGGAATTGTCCTTC 
Pav25fw GCAATTGCTGATGTGAAACG Pav67fw ATTTCCTCAACCCCCACTTC 
Pav26rev CATCCTGCCATGATTCCTCT Pav68rev GAGCCAGGTACACCTTCCAA 
Pav27fw GAACGAAGGGTTGCATCAAT Pav71fw ATCAGAGCACAGCCGAAGAT 
Pav28rev TGGGGCTATGACATCCAAAT Pav72rev GTGGTGATTGCAATTGCTTG 
Pav29fw ATGGCCATAACAGGCATCTC Pav80rev TGGTAACTGGCCATGCAATA 
Pav30rev CCACTTCCCTCTGCCAAGTA Pav81fw TAGAGGGACGGCTGAATGTT 
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Table 10:  PCR primers for amplification of Leningrad-3 MuV 
 
  
Primer Name Sequence 5’ – 3’ Mutation Targeted 
L3 1f ACCAAGGGGAAAATGAAGATG Non-coding leader, K36R, E108D 
L3 2r GTCATCTGCAAGCAAGGCAT 
L3 3f CTTTTGTTCCTCCCGTTCA V529A, L542L, Ter550Q, L557P, N56T 
L3 4r ATCTTAGCCAATTCCACACTT 
Pav77fw TTTTGCTTCGGGTAACTTGC C244R 
L3 5r GTTTTGCAGTTGTTGGAATG 
L3 6f AAGCAACAAGTCAGGCAACT P93S, F295S 
Pav48rev TGCCTCATTGTATTGGCAGA 
Pav55fw TGATCCCTGGCCATTAACTC E569K 
L3 7r TGGTAATTGGCCATGCAATA 
L3 8f TAGAGGGACGACTGAATGTT D311G 
Pav20rev GATGGCCCCAAAGTCTCATA 
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Table 11:  PCR protocols and thermal cycling parameters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR Protocol Thermal Cycling Parameters 
Qiagen
®
 One-Step RT-PCR 
5x One-Step RT mix          10 µl 
dNTP                                    2 µl 
Primer fw (10 µM)            1.5 µl 
Primer rev (10 µM)           1.5 µl 
RT                      2 µl 
RNA                            1 - 5 µl 
Water                        28 - 32 µl 
50 
°
C 30 min 
95 
°
C 15 min 
94 
°
C 1 min 
50 
°
C 30 sec         35 cycles 
72 
°
C 1 min 
72 
°
C 10 min 
  4 
°
C HOLD 
Bioline MyTaq
™
 RT-PCR 
2x One-step mix                  25µl 
Primer fw (10 µM)            1.5 µl 
Primer rev (10 µM)           1.5 µl 
RT                    0.5 µl 
RiboSafe RNase Inhibitor    1 µl 
RNA                             1 - 5 µl 
Water                   19.5 - 23.5 µl 
48 
°
C 20 min 
95 
°
C 1 min 
95 
°
C 15 sec 
50 
°
C 15 sec         35 cycles 
72 
°
C 30 sec 
72 
°
C 10 min 
  4 
°
C HOLD 
Qiagen
®
 HotStarTaq 
2x HotStarTaq mix            25 µl 
Primer fw (10 µM)          1 µl 
Primer rev (10 µM)             1 µl 
Water                    18 µl 
cDNA           5 µl 
95 
°
C 15 min 
94 
°
C 30 sec 
50 
°
C 30 sec         35 cycles 
72 
°
C 1 min 
72 
°
C 10 min 
Phusion
®
 High Fidelity mastermix 
2x Phusion mix                   25 µl 
Primer fw (10 µM)        2.5 µl 
Primer rev (10 µM)           2.5 µl 
Water                     18 µl 
cDNA            2 µl 
98 
°
C 1 min 
98 
°
C 10 sec 
65 
°
C 30 sec         28 cycles 
72 
°
C 1 min 
72 
°
C 10 min 
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2.4.5  Polymerase chain reaction (PCR) 
PCR reactions were prepared with cDNA as the template, using the Qiagen
®
 HotStarTaq 
mastermix.  The reaction mix and cycling conditions are described in Table 11, all PCR reactions 
were performed on an Eppendorf MasterCycler. 
 
2.4.6  DNA gel electrophoresis 
All PCR products were visualised on 1 % Tris-Borate-EDTA (TBE) agarose gels containing a 
ethidium bromide (Promega, UK) at a final concentration of 1 µg/ml, or SYBR
®
 Safe (Life 
Technologies, UK), using a UV transilluminator (UVP Bio-Imaging Systems). 
 
2.4.7  PCR purification 
All PCR products were gel-purified before further downstream applications, using either the 
Qiagen
®
 QIAquick Gel Extraction or the Bioline ISOLATE PCR and Gel kits following the 
manufacturer’s recommended protocols.  PCR products were briefly visualised using a UV 
transilluminator as above before excision from the agarose gel(s) using a sterile scalpel and 
transferred to a nuclease-free microfuge tube before weighing.  
For the Qiagen
®
 QIAquick Gel Extraction kit, all centrifugation steps were performed at 18000 
xg for 1 min at room temperature.  Briefly, three volumes of Buffer QG were added to one 
volume of gel slice and incubated in a water bath at 50 
°
C for 10 min or until the gel slice 
dissolved.  One volume of isopropanol was added and mixed by vortex before transferring to a 
QIAquick column in a collection tube and centrifuged.  The flow-through was discarded and 500 
µl Buffer QG was added to the column(s), centrifuged, flow-through discarded and 750 µl Buffer 
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PE added to the column to wash.  The flow-through was discarded and a final centrifugation step 
performed to ensure all Buffer PE was removed. Each column was transferred to a clean 
nuclease-free tube and 30 µl Buffer EB was added to the column(s) which were allowed to stand 
at room temperature for 1 min before centrifugation. The eluted purified PCR product(s) were 
stored at -20 
°
C. 
For the Bioline ISOLATE Gel and PCR kit all centrifugation steps were performed at 10000 xg 
for 1 min at room temperature.  Briefly 650 µl Gel Solubilizer was added to the gel slice and 
incubated in a water bath at 50 
°
C for 10 min or until the gel slice dissolved, 50 µl Binding 
Optimizer was added and mixed by vortex before transferring to a spin column in a collection 
tube and centrifuged.   The flow-through was discarded and 750 µl Wash Buffer A added to the 
column(s) and centrifuged, the flow-through was discarded and the wash step repeated.  The 
flow-through was again discarded and the spin column(s) centrifuged for 2 min to ensure 
complete removal of the wash buffer. Each column was transferred to a clean nuclease-free tube 
and 30 µl Elution Buffer was added to the column(s) which were allowed to stand at room 
temperature for 1 min before centrifugation at 6000 xg. The eluted purified PCR product(s) were 
stored at -20 
°
C. 
 
2.4.8  Mutant analysis by PCR and restriction enzyme cleavage (MAPREC) 
Mutagenic primers, described in Table 12, were designed to cover each specific mutation 
allowing a single unique restriction enzyme site to be introduced into only one of the PCR 
products (either JL-CK or RIT 4385).  PCR reactions were prepared with cDNA, mutagenic 
primers and Qiagen
®
 HotStarTaq mastermix, as described in section 2.4.5.  PCR products were 
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visualised as described in section 2.4.6 and purified using QIAquick
®
 PCR Purification Kit 
(Qiagen, UK) following the manufacturers protocol, eluting the DNA in 30 µl water. 
In nuclease-free tubes, 15 µl of purified PCR product, 2 µl 10 x restriction buffer, 1 µl restriction 
enzyme and 2 µl water or BSA (if required) were added.  The tubes were incubated in a water 
bath at 37 
°
C for 1 hr.  Undigested PCR product and the digested PCR product were run on a 10 
% TBE acrylamide gel for 1.5 hr at 100 V, before staining with ethidium bromide and visualised 
using a UV transilluminator. 
 
2.4.9  Sanger sequencing 
Samples were prepared by mixing 7.5 µl of purified PCR product, 7.5 µl dH2O and 2.25 µl, 10 
mM of either forward or reverse primer used in the RT-PCR, in a nuclease-free tube.  The PCR 
product/primer mix was sent to Eurofins MWG Operon for the Value Read Tube Sequencing 
Service.  Sequencing was performed by chain-terminating Sanger sequencing and the sequence 
trace files were analysed using Lasergene 8.0 – SeqMan software (DNASTAR) and aligned 
using ClustalW (EMBL-EBI). 
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Table 12:  Primer sequences for MAPREC analysis 
Forward 
primer 
Sequence 5’ – 3’ Reverse 
primer 
Sequence 5’ – 3’ Restriction 
site 
Restriction 
Enzyme 
E108Dfw CTGTGAGATTGATGGTTTGGA E108Drev CGATCCAGGAACTGCTCAAT GGATCC  BamHI 
V529Afw ATGCAAGGGGCGAACCC V529Arev ATTTGGGCAGTTAGCTGTGG CCGC  AciI 
L542Lfw CACGCAAACACTTTCCCAAAC L542Lrev CCCGGAAAGAAACACGATAA CAGCTG*  PvuII 
Ter550Qfw GTGGGAGACTGGGATGCG Ter550Qrev CACCGGTCTCATCCTGTTTT GCGC  HhaI 
L557Pfw GGGGCTGGAACACCAAGATT L557Prev ATTGTTGCGATTGGGGCT CTAG  BfaI 
N56Tfw ATTGGCAATCCAGAGCAGAAG N56Trev GATCTTCGCCAATTCCACAC GAAGAC  BbsI 
*Restriction site found within fragment, not introduced with primer 
Restriction site bases integrated within primer are identified by bold font and the mutagenic bases are identified by underlining. 
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2.5  Deep sequencing 
2.5.1  Generation of long range amplicons for shotgun sequencing 
Oligo dT cDNA and gene-specific primer cDNA was synthesised as in section 2.4.2.  
Combinations of primers Pav1fw, Pav2rev, Pav8rev, Pav20rev, Pav25fw, Pav34rev, Pav36rev 
Pav47fw, Pav48rev, Pav55fw, Pav73fw and Pav80rev, detailed in Table 9 were used to amplify 
1 - 5 kb fragments of the MuV genome using Phusion
®
 High-Fidelity PCR mastermix (New 
England Biolabs, UK), following the protocol and thermal cycling profile in Table 11, adjusting 
the annealing temperature to 53 
°
C and the volumes of cDNA to 1 µl, 2.5 µl, 3 µl or 5 µl. 
 
2.5.2  Amplicon-based deep sequencing 
Random hexamer cDNA was synthesised as in section 2.4.2.  Fusion primers were designed to 
amplify ca. 400 bp fragments covering the regions of interest of the MuV genome, all primers 
contained universal tails as detailed in Table 13.  The fusion primers were originally designed for 
use in 454 sequencing, therefore incorporate “adaptor” and “key” sequences which did not 
interfere with the Illumina sequencing method.  The “adaptor” and “key” sequences were 
removed during downstream processing of the sequence reads.  Amplicons were generated using 
Phusion
®
 High-Fidelity PCR mastermix (New England Biolabs, UK) following the protocol and 
thermal cycling profile detailed in Table 11.  The amplicons were purified to remove short 
fragments and primer dimers using Agencourt AMPure XP Beads (Beckman-Coulter, UK). 
Briefly, in nuclease-free tubes an appropriate volume of PCR amplicon(s) was added to 72 µl 
AMPure beads and incubated at room temperature for ca. 10 min. The tube(s) were placed on a 
Magnetic Particle Concentrator (MPC) (Life Technologies, UK) for ca. 5 min, then the 
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supernatant was removed, 200 µl 70 % ethanol was added before mixing by vortex and placing 
back in the MPC.  The supernatant was again removed and replaced with 200 µl 70 % ethanol 
before mixing and replacing on the MPC. The supernatant was removed and the pellet dried at 
37 
°
C before resuspending in 10 µl TE buffer (Sigma-Aldrich, UK).  The tubes were placed in 
the MPC and the supernatant containing the purified amplicons was transferred to a clean 
nuclease-free tube and stored at -20 
°
C.  Purified amplicons were quantified using the Agilent 
high sensitivity DNA kit (Agilent Technologies, US) following the manufacturer’s protocol and 
analysing on the Agilent 2100 Bioanalyser (Agilent Technologies, US).  The concentration of 
amplicons was determined using Qubit™ dsDNA HS Assay kit (Life Technologies, UK) 
following the manufacturer’s protocol, with samples analysed on the Qubit® 2.0 Fluorometer 
(Life Technologies).  Purified amplicons were pooled in equimolar concentration (2 ng/µl) and 
libraries prepared by Nextera
® 
XT DNA sample preparation kit (Illumina, UK) following the 
manufacturer’s protocol, before running on an Illumina MiSeq Sequencer. 
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Table 13:  Fusion primers for deep sequencing 
Primer 
Name 
Sequence 5’ – 3’ 
ADAPTOR – KEY – Mumps-specific sequence 
Mutation targeted 
FP1fw CGTATCGCCTCCCTCGCGCCATCAGACCAAGGGGAGAATGAATATG Non-coding leader 
FP1rev CTATGCGCCTTGCCAGCCCGCTCAGGCTTCGGGTGATCTATCTGC 
FP2fw CGTATCGCCTCCCTCGCGCCATCAGTCACAGGGTAGGTGCATTGA E108D 
FP2rev CTATGCGCCTTGCCAGCCCGCTCAGGCAGCATGTATCTTGCCTCA 
FP3fw CGTATCGCCTCCCTCGCGCCATCAGTCCTCAAGTCAGCAACATGC V529A, L542L, 
Ter550Q, L557P FP3rev CTATGCGCCTTGCCAGCCCGCTCAGCACCGGTCTCATCCTGTTTT 
FP4fw CGTATCGCCTCCCTCGCGCCATCAGTCATTTCCTATCCACCCCAAT N56T 
FP4rev CTATGCGCCTTGCCAGCCCGCTCAGCCCCCTCTTAAATTCTGTCACC 
FP5fw CGTATCGCCTCCCTCGCGCCATCAGCTGATGGAGAAGGGTGCATT C244R 
FP5rev CTATGCGCCTTGCCAGCCCGCTCAGGAGGCAGACTTCCTGAATGG 
FP6fw CGTATCGCCTCCCTCGCGCCATCAGACCGAATATCCAACCCACTG P93S 
FP6rev CTATGCGCCTTGCCAGCCCGCTCAGTAATCGGTGACAATGCTGGA 
FP7fw CGTATCGCCTCCCTCGCGCCATCAGCGGTCTAATGGAGGGTCAGA F295S 
FP7rev CTATGCGCCTTGCCAGCCCGCTCAGTGACTGCATGATGGTCAGGT 
FP8fw CGTATCGCCTCCCTCGCGCCATCAGACACCACAACCACCTGCTTT E569K 
FP8rev CTATGCGCCTTGCCAGCCCGCTCAGCTCTTTGAGATCGGGTCCAC 
FP9fw CGTATCGCCTCCCTCGCGCCATCAGTGCACTACTCATGGGGGATA D311G 
FP9rev CTATGCGCCTTGCCAGCCCGCTCAGCGCATCTCAATGAGGCTTTT 
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2.5.3  Deep sequencing data analysis 
Sequencing data in the form of FASTQ files were exported into Geneious software version 6.1.3 
(Biomatters Ltd). The reads were paired and the ends trimmed using the fusion primer sequences 
(Table 13), the Nextera transposase sequences and the Nextera index primer sequences 
(http://supportres.illumina.com/documents/documentation/chemistry_documentation/experiment
-design/illumina-customer-sequence-letter.pdf), allowing for an 8 base-pair (bp) overlap and 0.01 
error probability.  Once the sequences were trimmed, the long fragments were extracted, in the 
range of 50 bp to 251 bp and these were mapped to the JL-5 database reference sequence 
(AF201473).  Single nucleotide polymorphisms (SNPs) were identified by way of a nucleotide 
variation to the reference sequence at a minimum frequency of 0.01 % on regions where 
coverage was greater than 2000 reads. 
 
2.6  Mumps protein analysis 
2.6.1 Polyacrylamide gel electrophoresis 
Concentrated and purified JL-CK and RIT 4385 viruses were prepared in triplicate for 
electrophoresis as follows; 20 µl virus concentrate, 10 µl 4 x sample buffer and 2 µl β-
mercaptoethanol, were added to 1.5 ml tubes and denatured at 95 
°
C for 5 min.  The samples 
were loaded on to 12 % Precise
™
 Tris-HEPES polyacrylamide gel(s) (Life Technologies, UK), 
with one lane containing 5 µl full-range Amersham Rainbow Marker (GE Healthcare, UK).  
Gel(s) were electrophoresed at 100 V constant for 2 hr.  To visualise the protein bands, gel(s) 
were stained using the Novex Colloidal Blue staining kit (Life Technologies, UK).  First, the 
gel(s) were fixed for 10 min in a solution of 50 % methanol and 10 % acetic acid. The fixative 
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was removed and the gel(s) were stained in a solution consisting of 55 ml water, 20 ml methanol 
and 20 ml stain A for 10 min at room temperature before 5 ml of stain B was added and 
incubated overnight at room temperature on a rocking platform. Finally the stain was removed 
and the gel(s) were placed in water until ready for analysis. 
 
2.6.2  Western Blotting 
Unstained polyacrylamide gel(s) containing JL-CK or RIT 4385 as in section 2.6.1 were wet 
blotted at room temperature, overnight with 40 mA onto PVDF membrane.  The membrane was 
subjected to blocking for 1 hr at room temperature with TBS containing 0.1 % Tween 20 and 5 
% (w/v) milk powder.  A 1:10000 dilution of rabbit α-mumps nucleoprotein (a kind gift from Dr 
Steven Rubin, F.D.A., US) was prepared in TBS containing 0.1 % Tween 20 and 5 % (w/v) milk 
powder and incubated for 1 hr at room temperature on a rocking platform. The membrane was 
subjected to three, 10 min room temperature washes with TBS containing 0.1 % Tween 20. A 
1:2000 dilution of goat α-rabbit HRP (Dako, UK) was prepared in TBS containing 0.1 % Tween 
20 and 5 % (w/v) milk powder and incubated for 1 hr at room temperature on a rocking platform.  
The membrane was washed three times, 10 min each wash, at room temperature with TBS 
containing 0.1 % Tween 20.  Mumps nucleoprotein was visualised using the Immobilon Western 
Chemiluminescent Kit (Merck Millipore, UK).  Briefly, a working HRP substrate was prepared 
by adding 3 ml luminol reagent to 3 ml peroxide allowing the solution to incubate at room 
temperature for 10 min. After placing the membrane protein side up on cling film, the membrane 
was covered in HRP substrate and allowed to incubate at room temperature for 5 min, before 
draining off excess substrate. The membrane was covered in cling film and air bubbles removed 
before exposing the membrane to x-ray film for an appropriate exposure time. 
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2.6.3  Mass spectrometry 
Gel bands within the molecular mass region of 52 – 76 kDa, identified by Western blot and 
described in section 2.6.2, were excised, washed and trypsin digested.  Tryptic peptides were 
extracted and subjected to online nanoscale liquid chromatography coupled to tandem mass 
spectrometry (nano-LC/MS/MS) analysis using a LTQ-Orbitrap mass spectrometer system 
(Thermo Scientific, UK) (Chen et al., 2011).  Mass spectra were processed and the database 
searched using Proteome Discoverer v.1.2 with built-in Sequest (Thermo Scientific, UK) and 
UniProt FASTA database release 56.4 (www.uniprot.org).   A FASTA sequence file of the JL-
CK nucleoprotein containing the additional amino acids at the C-termini 
(HANTFPNNPNQNAQLQVGDWDEQITDMIKP/KLTPIATIPGQSSHS) was also created. 
Mass spectrometry was performed by Dr Jun X. Wheeler, Laboratory for Molecular Structure, 
NIBSC. 
 
2.7  In vivo studies 
2.7.1  Ferret studies 
Groups of three male ferrets aged between 6 – 12 months were inoculated intra-nasally with ca. 
2 x 10
4
 pfu in 400 µl (200 µl per nostril) of either, JL-CK, RIT 4385, JL-CK1, JL-CK2, JL-CK3, 
JL-CK4, JL-CK5 or the “Parental” virus isolated from the JL-CK vaccine.  The titres of the 
remainder of the inocula were checked after inoculation by titration on Vero cells. 
Each study ran for 28 days, with pre-bleed samples collected 7 days before inoculation.  Blood 
samples were collected on days 7, 14, 21 post-infection, with a terminal bleed taken on day 28.  
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Clinical signs including temperature, weight, parotid gland(s) and testicle swelling were 
measured throughout the studies. 
All animal procedures were performed by fully trained and licensed NIBSC Biological Services 
Division staff. 
 
2.7.2  Blood sample processing 
Blood samples were collected in serum-gel clotting activator tubes (Sarstedt Ltd, UK) and 
allowed to clot at room temperature for 25 min.  The tubes were centrifuged at 15000 xg for 5 
min at 4 
°
C to allow separation of the serum and red blood cells.  Serum was removed from the 
top layer of the separation gel and split into two aliquots and stored at -80 
°
C. 
 
2.7.3  Rat neurovirulence 
In each of the studies neonatal rat pups were inoculated intra-cerebrally within 12 – 24 hours of 
birth with 100 pfu in 20 µl, adapted from (Rubin et al., 2005).  The titre of each inoculum was 
confirmed by titration on Vero cells. 
In the initial study, groups of 22 neonatal rats were inoculated either with JL-CK, RIT 4385 or 
Mu90 MuV’s.  This study ran for 25 days with three rat pups in each group sacrificed at days 1, 
4, 7 and 25 with the brains harvested for virus titration. At day 25 the remaining rats were 
sacrificed with the brains removed and fixed in 10 % neutral-buffered formalin for determination 
of hydrocephalus severity. 
In the second study, groups of six neonatal rat pups were inoculated as in the initial study, with 
either JL-CK, RIT 4385, JL-CK1, JL-CK2, JL-CK3, JL-CK4, JL-CK5 or the “Parental” virus 
isolated from the JL-CK vaccine. 
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This study ran for 25 days, the rat pups in each group were sacrificed at day 25 with the brains 
removed and fixed in 10 % neutral-buffered formalin for determination of hydrocephalus 
severity. 
In the third study, groups of 16 neonatal rat pups were inoculated as in the initial study, with 
either JL-CK, RIT 4385, JL-CK1, JL-CK2, JL-CK3, JL-CK4, JL-CK5 or the “Parental” virus 
isolated from the JL-CK vaccine.  This study ran for 10 days with three rat pups in each group 
sacrificed at days 1, 4, 7 and 10 and the brains harvested for virus titration. 
 
2.7.4  Virus titration from rat brains 
Brain weights were recorded and the required volume of cold MEM (Sigma Aldrich, UK) was 
added to prepare a 20 % homogenate for each brain.  The brains were homogenised for 7 sec at 
5000 rpm in a Precellys 24
®
 cell lysis and tissue homogeniser (Bertin Technologies, France) 
using 2.8 mm ceramic beads (Bertin Technologies, France).  1 ml of homogenate was removed, 
centrifuged at 9300 xg for 5 min at 4 
°
C and the supernatant transferred into a clean tube.  The 
homogenate, supernatant and pellet were all stored at -80 
°
C.  The supernatant from each brain 
homogenate was serially diluted and titrated on Vero cells as described in section 2.3.7. 
 
2.7.5  Processing of fixed brains 
Fixed brains were sectioned and stained (Propath UK Limited).  Briefly, the brains were cut 
along the anatomical midline, processed and paraffin embedded before sectioning and staining 
with haematoxylin and eosin as described previously (Rubin et al., 2005).  Hydrocephalus 
severity was calculated as a percentage of the cross-sectional area of the ventricle from the area 
of the whole brain using ImageJ (Rubin et al., 2005; Schneider et al., 2012). 
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2.8  Designated accession numbers  
The sequences of the five JL-CK virus variants have been deposited in GenBank and designated 
accession numbers as follows; JL-CK1 JQ946550, JL-CK2 JQ946551, JL-CK3 JQ946552, JL-
CK4 JQ946553 and JL-CK5 JQ946554. 
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CHAPTER 3 – COMPARISON OF JL-CK AND RIT 4385 VACCINE VIRUSES 
 
Mumps vaccines are live viruses which have usually been attenuated by passage in embryonated 
hens’ eggs and/or in chicken embryo fibroblasts (CEFs).  The Jeryl Lynn strain of mumps is the 
most commonly used strain in mumps vaccine production worldwide (Carbone and Rubin, 
2007).  The RIT 4385 vaccine virus is the JL-5 mumps strain which originated from the Jeryl 
Lynn vaccine, containing the JL-2 and JL-5 strains, and has been further propagated on CEFs.  In 
contrast, the JL-CK vaccine virus which is also derived from the Jeryl Lynn vaccine has been 
further propagated on primary canine kidney cells, the use of which is atypical for mumps 
vaccine production.  The JL-CK vaccine has been associated with vaccine failure (Mrazova et 
al., 2003). This may in part be related to its production.  In order to identify any differences in 
the biological characteristics of the two viruses a number of in vitro and in vivo assays were 
performed. 
 
3.1  Plaque morphology and size 
Mumps virus (MuV) isolates are routinely cultured using the African Green monkey kidney 
(Vero) cell line.  This cell line is considered to be the “gold standard” and is used in clinical 
laboratories to isolate and propagate MuV from clinical specimens. 
Plaque assays on Vero cells were performed on both the JL-CK vaccine and RIT 4385 bulk 
material, in order to check viral titres and to confirm that the JL-CK vaccine contained live virus.  
The virus titre for JL-CK was in line with the titre given by the manufacturer.  A representative 
plaque assay showing the plaque morphologies of both viruses is shown in Figure 4. 
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Figure 4:  Plaque morphology after infection of Vero cells with either JL-CK or RIT 4385. 
Vero cells were inoculated a MOI of 0.0001 pfu per cell and incubated at 35 °C, 5 % CO2 for 10 
days before fixing and staining with methyl violet to visualise plaques. 
 
 
It was apparent from the plaque morphology that the JL-CK and RIT 4385 MuVs are different.  
JL-CK produced a mixture of small and large plaques whereas RIT 4385 formed a population of 
larger plaques.  The plaques produced from both JL-CK and RIT 4385 viruses were measured 
using ImageJ software and are compared in Figure 5.  A total of 25 JL-CK plaques and 33 RIT 
4385 plaques were measured.  The JL-CK MuV produced plaques that were at least three times 
smaller (by area) than those formed by RIT 4385; the analysis of the data by student’s t-test 
identified the difference in plaque size between the two groups to be significantly different where 
p < 0.0001. 
 
RIT 4385 JL-CK 
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Figure 5:  Plaque size produced by JL-CK and RIT 4385 in Vero cells. 
Plaque areas were measured using ImageJ software.  The bars represent the standard error of the 
mean for each group (n = 25, JL-CK; n = 33, RIT 4385).  A student’s t-test was applied to the 
data with a p value < 0.05 considered significant, * p < 0.0001. 
 
 
It has been reported (Omata et al., 1986; Wright et al., 2000) that plaque-forming viruses, such as 
MuV or poliovirus can display a small plaque phenotype that is linked to temperature sensitivity 
and differences in overlay media have been shown to affect plaque size and clarity in influenza 
virus (Matrosovich et al., 2006).  In order to determine whether either of these conditions might 
explain the small plaque phenotype observed with the JL-CK MuV, plaque assays were 
performed on Vero cells incubated at 32 
°
C, 35 
°
C, 37
 °
C or 40
 °
C.  In each case the plaque sizes 
remained consistent throughout.  Plaque assays were also performed comparing solid and semi-
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solid overlay media.  Vero cells were infected with JL-CK and RIT 4385 and overlain with either 
CMC (semi-solid) overlay or bactoagar (solid).  Again, there was no observed difference in 
plaque size.  
The distinct plaque size differences produced by the JL-CK vaccine were therefore not due to 
temperature sensitivity or overlay medium but more likely due to the presence of two or more 
populations of virus.  The smaller plaque size may also indicate a growth defect or an issue with 
budding and/or fusion of the virus particles from/to neighbouring cells.  
 
3.2  Real-time qPCR 
The original Jeryl Lynn vaccine manufactured by Merck & Co was shown to be a mixture of two 
distinct but highly related MuV strains, JL-2 and JL-5 (Afzal et al., 1993).  The major JL-5 
component was isolated from the Jeryl Lynn vaccine by GlaxoSmithKline, passaged in CEFs and 
named RIT 4385.  The JL-CK vaccine strain was also developed from the original Jeryl Lynn 
vaccine (Limberkova and Lexova, 2014), by passage in primary canine kidney cells, although the 
exact history of its production is not available.  To determine whether the JL-CK vaccine is 
composed of JL-2 and JL-5 MuVs, a strain-specific probe-based real-time qRT-PCR assay was 
performed on RNA from individual JL-CK plaques.  Primers and probes were designed against 
the highly variable SH gene.  Their sequences are detailed in Tables 6 and 7.  A graph showing 
the amplification of either JL-2 or JL-5 is depicted in Figure 6. 
All plaques analysed, except the positive control (plaque 2) which contained RNA extracted 
from the original Jeryl Lynn vaccine (Merck & Co), showed amplification of only the JL-5 MuV 
sequence, not the JL-2 MuV sequence.  Therefore the JL-CK vaccine contains only the JL-5 
MuV. 
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Figure 6:  Real-time qPCR of individual plaques purified from JL-CK vaccine to identify the MuV strain (JL-5 or JL-2). 
Each point represents one plaque, reactions were performed in duplicate. The average number of cycles of amplification detected 
above the Ct value is plotted. Plaque 1 is the negative control containing no RNA, plaque 2 is the positive control containing RNA 
from the Jeryl Lynn vaccine consisting of JL-5 and JL-2 viruses. 
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3.3  In vitro characteristics 
3.3.1  Growth of JL-CK and RIT 4385 in Vero cells  
In order to identify if there were differences in growth, Vero cells were infected with either JL-
CK or RIT 4385 MuVs at a MOI of 0.0001 and incubated.  At each daily timepoint the progeny 
viruses were titrated in Vero cells and the results calculated as the pfu per cell, Figure 7. 
 
The data in Figure 7 show that the JL-CK virus grows as well if not slightly better than the RIT 
4385 virus in Vero cells and therefore the small plaque phenotype is not due to a growth defect 
of the JL-CK virus.  
The ability of JL-CK and RIT 4385 to lyse Vero cells was also compared.  Vero cells were 
inoculated at the same MOI (0.0001 pfu/cell) with JL-CK or RIT 4385 MuVs and incubated.  
Lysis of cells was determined as a measure of cell viability using the Cell Titer 96
®
 Aqueous 
Non-Radioactive Cell Proliferation Assay (MTS) (Promega, UK).  Over the course of 7 days, 
cell viability was measured on JL-CK and RIT 4385 infected Vero cells and the results expressed 
as percentage (%) cell survival as shown in Figure 8.  Both JL-CK and RIT 4385 lyse Vero cells 
at comparable rates, 3.7 days for JL-CK and 4 days for RIT 4385.  
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Figure 7:  Progeny virus titres from JL-CK and RIT 4385 infected Vero cells. 
Cells were infected at a MOI of 0.0001 pfu per cell and samples were harvested daily by 
freeze-thawing of the cells, followed by plaque assay in Vero cells.  Each timepoint was titrated 
in triplicate, the error bars represent the standard error of the mean for each timepoint. 
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Figure 8:  Vero cell lysis after infection with JL-CK or RIT 4385 viruses. 
Cells were infected at a MOI of 0.0001 pfu per cell and cell viability determined daily by 
measuring the amount of MTS formazan produced by viable cells at 492 nm.  Each timepoint 
was measured in triplicate.  The error bars represent the standard error of the mean for each 
timepoint and the dotted line marks 50 % cell survival. 
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The 7 day timepoint progeny viruses were titrated in Vero cells to compare titres of both JL-CK 
and RIT 4385 with the results expressed as pfu per cell.  The data in Figure 9 show that whilst 
both viruses share a similar cell lysis profile, by day 7 JL-CK produced at least 100 times more 
progeny virus.  Analysis of the data by student’s t-test identified the difference in progeny virus 
titre between the two groups to be significantly different where p < 0.0002, indicating efficient 
release of the JL-CK virus. 
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Figure 9:  Progeny virus titres of JL-CK and RIT 4385 after 7 days incubation in Vero 
cells. 
Cells were inoculated at a MOI of 0.0001 pfu per cell, incubated for 7 days before titration in 
Vero cells, in triplicate.  The error bars represent the standard error of the mean for each group.  
A student’s t-test was applied to the data with a p value < 0.05 considered significant, ***p < 
0.0002. 
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3.3.2  Growth of JL-CK and RIT 4385 in MDCK cells  
The propagation of JL-CK MuV in primary canine kidney cells may have provided the virus 
with a preference for growth in canine kidney cells.  In order to determine if there was a 
difference in virus growth and yield, JL-CK and RIT 4385 were inoculated at a MOI of 0.0001 
pfu per cell on both Vero (simian kidney) and MDCK (canine kidney) cells and incubated for 3 
or 7 days at 35 
°
C, 5% CO2 (primary canine kidney cells were not available).  The progeny 
viruses were titrated in Vero cells and the resulting plaques counted.  Figure 10 shows the titres 
of progeny virus after 3 days growth in Vero and MDCK cells and Figure 11 shows the titres of 
progeny virus after 7 days growth. 
 
JL-CK produced at least 10 times more progeny virus than RIT 4385 in both Vero (*p = 0.0591) 
and MDCK cells (p = 0.1550) after 3 days growth (Figure 10) and at least 100 times more 
progeny virus in both Vero (***p = 0.0002) and MDCK cells (****p < 0.0001) after 7 days 
growth (Figure 11).  There was significant difference in JL-CK progeny virus titres between 
Vero and MDCK cells (****p < 0.0001) suggesting that passage of JL-CK in primary canine 
kidney cells led to adaptation of the virus to this cell type.  The difference in progeny virus titre 
between Vero and MDCK cells was also significant (*p = 0.0100) for the RIT 4385 virus, with a 
higher titre observed in Vero cells. 
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Figure 10:  Progeny virus titres of JL-CK and RIT 4385 after 3 days incubation in Vero 
and MDCK cells.  
Cells were inoculated at a MOI of 0.0001 pfu per cell and incubated for 3 days before titration in 
Vero cells, in triplicate. The error bars represent the standard error of the mean for each group. A 
student’s t-test was applied to compare the data for the two viruses in each group, with a p value 
< 0.05 considered significant, Vero *p = 0.0591, MDCK p = 0.1550. Note, the Y-axis is 
represented in a log scale for visualisation, however the data is not log transformed. 
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Figure 11:  Progeny virus titres of JL-CK and RIT 4385 after 7 days incubation in Vero 
and MDCK cells. 
Cells were inoculated at a MOI of 0.0001 pfu per cell and incubated for 7 days before titration in 
Vero cells, in triplicate. The error bars represent the standard error of the mean for each group.  
A student’s t-test was applied to compare the data for the two viruses in each group with a p 
value < 0.05 considered significant, ***p = 0.0002, ****p < 0.0001 and to compare the titre of 
each virus in the two cell lines ****p < 0.0001, *p = 0.0100.  Note, the Y-axis is represented in a 
log scale for visualisation, however the data is not log transformed. 
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3.3.3  Comparison of progeny virus titres in Vero, MDCK and SH-SY5Y cells and media  
To identify whether there was a difference in the titres of progeny virus budding from different 
cell types or species an assay was set up using Vero, MDCK and the human neuronal cell line, 
SH-SY5Y, which has been shown to enable MuV replication (Ninomiya et al., 2009; Rubin et 
al., 1998).  Cells were infected at a MOI of 0.0001 pfu per cell, with either JL-CK or RIT 4385 
MuVs and incubated.  Cell lysates and supernatant were collected and titrated separately for each 
timepoint, to compare progeny virus titres.  Figure 12 shows the virus titres at each timepoint for 
each cell type and corresponding supernatant.  
 
The JL-CK virus produced higher titres of progeny virus compared to RIT 4385, in all cell lines.  
However the titres in the supernatants were in each case higher than those that were cell-
associated, which was also seen with RIT 4385.  The result also shows that by day 7, JL-CK 
produced more progeny virus in MDCK cells and supernatant compared to SH-SY5Y, which had 
titres that remained similar to those at day 4. 
These results suggest that there is no preference for cell species i.e. simian, canine, and human, 
however JL-CK may display a preference for cell type (kidney).  This also confirms our 
hypothesis that JL-CK and RIT 4385 display different in vitro characteristics, despite their 
shared origin. 
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Figure 12:  Comparison of JL-CK and RIT 4385 progeny virus titres from cell lysates and 
cell supernatants after growth in Vero, MDCK or SH-SY5Y cells. 
Cells were inoculated at a MOI of 0.0001 pfu per cell, cell lysates and supernatants harvested at 
days 1, 4 and 7, followed by plaque assay in Vero cells.  Left-hand panels represent JL-CK and 
right-hand panels represent RIT 4385.  Cell lysates and supernatants from each timepoint were 
titrated in triplicate, the error bars represent the standard error of the mean. 
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3.4  In vivo characteristics 
There currently is no animal model which mimics mumps disease.  However there have been 
studies which showed that ferrets can generate a neutralising antibody response to MuV (Gordon 
et al., 1956; Parker et al., 2013).  The antibody response against the JL-CK and RIT 4385 viruses 
was assessed in ferrets. 
Two groups of male ferrets were pre-bled before being inoculated intra-nasally with either JL-
CK (Ferrets A, B and C) or RIT 4385 (Ferrets D, E and F) MuVs.  Over the course of the 28 day 
study, blood samples were collected at 7 day intervals before a terminal bleed at day 28.  Ferrets 
were monitored throughout the study with temperature, weight, parotid gland(s) and testicle 
swelling measured.  There were no clinical signs of disease in any of the ferrets.  Serum from 
each timepoint was separated from red blood cells and used to detect neutralising antibodies. 
 
 
3.4.1  Plaque reduction neutralisation assays 
Plaque reduction neutralisation (PRN) assays measure the dilution of serum required to reduce 
plaque formation of a challenge virus by 50 % (ND50) in cell culture.  PRN titres are a function 
of the challenge virus strain used (Pipkin et al., 1999; Yates et al., 1996).  Therefore, the serum 
from each ferret was challenged with the same virus that was inoculated into each ferret, i.e. sera 
from Ferrets A, B and C were challenged with the JL-CK virus and the sera from Ferrets D, E 
and F were challenged with the RIT 4385 virus.  Each PRN assay had a positive control, which 
was the challenge virus without serum; the average plaque count for the positive control was 50 
pfu.  Figure 13 shows the neutralising antibody response expressed as ND50 for each ferret over 
28 days. 
91 
 
 
Ferret A
Pr
e 
B
le
ed
D
ay
 7
D
ay
 1
4 
D
ay
 2
1
D
ay
 2
8
0
10
20
30
40
50
Serum Sample
5
0
 %
 E
n
d
 p
o
in
t 
ti
tr
e
(N
D
5
0
)
Ferret B
Pr
e 
B
le
ed
D
ay
 7
D
ay
 1
4 
D
ay
 2
1
D
ay
 2
8
0
10
20
30
40
50
Serum Sample
5
0
 %
 E
n
d
 p
o
in
t 
ti
tr
e
(N
D
5
0
)
Ferret C
Pr
e 
B
le
ed
D
ay
 7
D
ay
 1
4 
D
ay
 2
1
D
ay
 2
8
0
10
20
30
40
50
Serum Sample
5
0
 %
 E
n
d
 p
o
in
t 
ti
tr
e
 (
N
D
5
0
)
Ferret D
Pr
e 
B
le
ed
D
ay
 7
D
ay
 1
4 
D
ay
 2
1
D
ay
 2
8
0
10
20
30
40
50
Serum Sample
5
0
 %
 E
n
d
 p
o
in
t 
ti
tr
e
 (
N
D
5
0
)
Ferret E
Pr
e 
B
le
ed
D
ay
 7
D
ay
 1
4 
D
ay
 2
1
D
ay
 2
8
0
10
20
30
40
50
Serum Sample
5
0
 %
 E
n
d
 p
o
in
t 
ti
tr
e
 (
N
D
5
0
)
Ferret F
Pr
e 
B
le
ed
D
ay
 7
D
ay
 1
4 
D
ay
 2
1
D
ay
 2
8
0
10
20
30
40
50
Serum Sample
5
0
 %
 E
n
d
 p
o
in
t 
ti
tr
e
 (
N
D
5
0
)
93/582 Human Reference Serum
0
10
20
30
40
50
5
0
 %
 E
n
d
 p
o
in
t 
ti
tr
e
 (
N
D
5
0
)
 
Figure 13:  Neutralising antibody titres in ferret sera, produced in response to inoculation 
with JL-CK or RIT 4385 viruses. 
Sera from each ferret was challenged with either the JL-CK (ferret sera A, B, C) or RIT 4385 
viruses (ferret sera D, E, F), and the dilution required to reduce the number of plaques by 50 % 
(ND50) was calculated.  The human reference serum (93/582) was included as a control.  All 
PRN assays were performed in triplicate and the error bars represent the standard error of the 
mean. 
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Ferrets A, B and C, which had been inoculated with the JL-CK virus, failed to neutralise the 
challenge JL-CK virus as the ND50 values at each timepoint were similar to those for the pre-
bleed.  Ferrets D, E and F which had been inoculated with the RIT 4385 virus, showed an 
increase in ND50 by day 28.  The control human reference serum which was challenged with the 
RIT 4385 virus gave an average ND50 value of 12, which was lower than the day 28 ND50 values 
for the sera from the RIT 4385 inoculated ferrets.  
 
MuV is serologically monotypic and immunisation with one strain is known to provide cross 
protection to other MuV strains.  To identify if the neutralising antibodies produced by the ferrets 
could neutralise other MuVs, PRN assays were performed using different challenge MuVs and 
the day 28 sera, which contained the highest level of neutralising antibody.  The serum from each 
ferret was challenged with the JL-CK, RIT 4385 or Mu90 MuVs.  Figure 14 shows the ND50 
values for the serum from each ferret after challenge. 
Ferrets A, B and C that had been inoculated with JL-CK did not show any difference in ND50 
when challenged with a related (RIT 4385) or representative wild-type (Mu90) MuV.  The ND50 
values after challenge with JL-CK produced similar results to those in Figure 13.  Ferrets D, E 
and F, which had been inoculated with the RIT 4385 virus did show cross-protection, with higher 
ND50 values after challenge with the JL-CK virus, compared with the RIT 4385 virus.  There was 
also a high neutralising response from Ferret F to all three challenge viruses, this ferret produced 
the highest ND50 value at day 28 (Figure 13), which may explain why this serum produced a 
better response to the Mu90 virus compared to ferrets D and E. 
 
 
93 
 
 
 
 
Ferret D
Mu90 RIT 4385 JL-CK
0
20
40
60
Challenge virus
5
0
 %
 E
n
d
p
o
in
t 
ti
tr
e
 (
N
D
5
0
)
Ferret E
Mu90 RIT 4385 JL-CK
0
20
40
60
Challenge virus
5
0
 %
 E
n
d
p
o
in
t 
ti
tr
e
 (
N
D
5
0
)
Ferret F
Mu90 RIT 4385 JL-CK
0
20
40
60
Challenge virus
5
0
 %
 E
n
d
p
o
in
t 
ti
tr
e
 (
N
D
5
0
)
Ferret A
Mu90 RIT 4385 JL-CK
0
20
40
60
Challenge virus
5
0
 %
 E
n
d
p
o
in
t 
ti
tr
e
 (
N
D
5
0
)
Ferret B
Mu90 RIT 4385 JL-CK
0
20
40
60
Challenge virus
5
0
 %
 E
n
d
p
o
in
t 
ti
tr
e
 (
N
D
5
0
)
Ferret C
Mu90 RIT 4385 JL-CK
0
20
40
60
Challenge virus
5
0
 %
 E
n
d
p
o
in
t 
ti
tr
e
 (
N
D
5
0
)
 
Figure 14:  Neutralising antibody titres in day 28 ferret sera, produced in response to 
inoculation with JL-CK or RIT 4385 viruses. 
Sera from each ferret was challenged with either the JL-CK, RIT 4385 or Mu90 viruses and the 
dilution required to reduce the number of plaques by 50 % (ND50) was calculated.  PRN assays 
were performed in triplicate and the error bars represent the standard error of the mean. 
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3.4.2  Rat neurovirulence 
The neonatal rat model has been proposed for neurovirulence safety testing of MuV (Malik et al., 
2009; Rubin et al., 2005).  Groups of 22 neonatal rats were infected intra-cerebrally with JL-CK, 
RIT 4385 or Mu90 and monitored daily.  At days 1, 4, 7 and 25 the brains from three animals in 
the JL-CK and RIT 4385 groups were removed for titration of virus.  The remaining animals in 
each group were terminated at day 25.  The brains were removed, fixed, sectioned and stained 
with haematoxylin and eosin (H&E).  The cross-sectional areas of the whole brain (excluding 
cerebellum) and ventricles were measured using ImageJ (Schneider et al., 2012) and the results 
expressed as the percentage of the cross-sectional area of the whole brain (Rubin et al., 2005).  
Figure 15 shows a representative stained section from brains inoculated with either JL-CK or 
RIT 4385 MuVs. 
 
 
 
 
 
Figure 15:  Representative sections from rat brains inoculated with JL-CK or RIT 4385 
viruses. 
Brains were fixed, cut through the anatomical midline, processed and embedded in paraffin wax 
with 10 µm sections cut and stained with haematoxylin and eosin. 
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The brains from rats inoculated with the JL-CK virus showed larger ventricles compared to the 
brains from rats inoculated with the RIT 4385 virus.  Figure 16 shows the results from individual 
rat brains.  On average JL-CK displayed a higher neurovirulence potential compared to RIT 4385 
(p = 0.0035 unpaired two-tailed t-test) and the negative control (p < 0.0001 unpaired two-tailed t-
test), but when compared to Mu90, a neurovirulent, representative wild-type MuV (Rubin et al., 
2005), the hydrocephalus observed in JL-CK was less (p < 0.0001 unpaired two-tailed t-test).  
We also observed significant variation between individual animals. 
 
 
 
Figure 16:  Ventricle size measured from individual rat brains inoculated with JL-CK, RIT 
4385 or Mu90 viruses. 
Each bar represents one rat brain, four sections were measured per brain and the error bars 
represent the standard error of the mean. 
0
5
10
15
20
JL-CK
RIT 4385
Mu90
Uninfected Control
Brains analysed
V
e
n
tr
ic
le
 s
iz
e
 (
a
s 
p
e
rc
e
n
ta
g
e
 o
f 
to
ta
l 
b
ra
in
 a
re
a
)
Im
a
g
e
J
 u
n
it
s
96 
 
3.4.3  Virus titres in the rat brain 
To compare progeny virus titres in the brains for the JL-CK and RIT 4385 groups, 20 % 
homogenates of the brains removed at days 1, 4, 7 and 25 were prepared.  The brain 
homogenates were titrated in Vero cells.  The titre of progeny virus expressed as pfu per ml of 
brain homogenate over time for each group is shown in Figure 17.  The JL-CK virus yielded at 
least 10 fold more progeny virus by day 4 compared to RIT 4385.  By day 7, the JL-CK yield 
dropped almost 10 fold, and the RIT 4385 progeny virus was undetectable. This phenomenon of 
progeny virus in rat brains peaking by day 4 has been observed previously (Sauder et al., 2011). 
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Figure 17:  Progeny virus titres from rat brains inoculated with JL-CK or RIT 4385 
viruses. 
Brains were homogenised, clarified and serially diluted before titration in Vero cells, in 
triplicate.  The error bars represent the standard error of the mean. 
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Both in vitro and in vivo data show that there are differences between the JL-CK and RIT 4385 
viruses.  To identify if these phenotypic differences are due to changes at the genomic level, both 
viruses were subjected to Sanger sequencing. 
 
3.5  Genome analysis 
3.5.1  Sanger sequencing of JL-CK and RIT 4385 vaccine viruses 
Using the JL-5 MuV database sequence (accession AF201473) overlapping primers were 
designed to amplify both JL-CK and RIT 4385.  Primers and their sequences are detailed in 
Table 9.  RNA was extracted from both JL-CK and RIT 4385 and one-step RT-PCR was 
performed.  PCR products were purified and sequenced before aligning against the JL-5 database 
sequence.  The JL-CK virus genome contained 13 nucleotide positions, throughout the genome 
which showed variation to the database sequence.  These translated into 10 predicted amino acid 
substitutions, which are depicted in Figure 18.  The JL-CK amino acid sequences for each 
protein, highlighting the predicted substitutions aligned against the JL-5 sequences are detailed 
in Appendix 1. 
Every gene contained at least one position which displayed a mixture of nucleotides and there 
was a mutation in the non-coding leader sequence.  The N gene contained the most variation 
with four predicted amino acid substitutions plus one silent mutation.  The Ter550Q amino acid 
substitution extends the nucleoprotein by 21 amino acids, which encompasses the L557P 
mutation.  Interestingly the SH gene, which is known to be the most variable did not have any 
genetic variation to the database sequence.  An example of the sequence chromatograms showing 
the mixture of nucleotides corresponding to the predicted amino acid substitutions E108D, 
Ter550Q and N56T is shown in Figure 19.  
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Figure 18:  Schematic diagram of the JL-CK genome highlighting the predicted amino acid substitutions. 
Consensus sequence from Sanger sequencing of JL-CK was compared and aligned to the JL-5 database sequence (accession 
AF201473) using ClustalW (EMBL-EBI). 
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Figure 19: Example JL-CK sequence chromatograms identifying peaks which show a 
mixture of nucleotides. 
The positions showing variation are marked with an arrow and correspond to the predicted amino 
acid substitutions E108D, Ter550Q and N56T. 
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protein (L542L), and one in the 5’ non-coding region of the N gene, in this case.  Both were also 
found in JL-CK (L542L and L557P). 
The extent of variation in the JL-CK virus was unexpected, and is likely to be due to its 
propagation in primary canine kidney cells and the adaptation of the virus to the cell substrate. 
In order to see if any of the mutations were specific to MuVs which have been propagated on 
primary canine kidney cells, a different MuV which had been produced in a similar manner was 
sequenced.  The L3-SSW Pankow MuV is a Leningrad-3 strain which had been further passaged 
in primary canine kidney cells in the 1970’s for use in the German Democratic Republic (Starke 
and Hlinak, 1974).  However, it was withdrawn during clinical trials due to high incidence of 
aseptic meningitis (Tischer and Gerike, 2000).  RNA extraction and RT-PCR using primers 
designed using the Leningrad-3 database sequence (accession AY508995), detailed in Table 10 
produced PCR products covering the regions of interest.  Sequence analysis did not detect any of 
the mutations observed in the JL-CK virus. 
 
3.5.2  Comparison of JL-CK and RIT 4385 by MAPREC 
To confirm the sequence data, the N and P genes of both JL-CK and RIT 4385 were subjected to 
Mutant Analysis by PCR and Restriction Enzyme Cleavage (MAPREC).  The results of the 
MAPREC analysis are shown in Figure 20.  
 
All mutations produced cleavage products in JL-CK, and the two mutations (L542L and L557P) 
identified in RIT 4385 were also confirmed by the presence of cleavage products.  This 
confirmed that the sequence data was valid and not an artefact of the sequencing process. 
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Figure 20:  Analysis of the mutations in the N and P genes of JL-CK using MAPREC, 
compared to RIT 4385. 
Digested (+) PCR products were run alongside undigested (–) PCR products, to allow for 
comparison and the identification of cleavage products.  Mutations E108D, V529A, Ter550Q 
and N56T were confirmed in JL-CK (with L542L and L557P present in both viruses) by the 
identification of cleavage products after the addition of restriction enzyme. 
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3.5.3  Nucleoprotein analysis by mass spectrometry 
The gene encoding the nucleoprotein shows the most variation between JL-CK and RIT 4385. 
One mutation in particular, Ter550Q, was of interest as it extended the C-terminus of the 
nucleoprotein by 21 amino acids.  Purified JL-CK and RIT 4385 were subjected to 
polyacrylamide gel electrophoresis and Western blotting in order to identify the location of the 
nucleoprotein band(s) on a polyacrylamide gel and to confirm that the nucleoprotein is 
expressed.  The protein profile of JL-CK and RIT 4385 on a 12 % polyacrylamide gel stained 
with colloidal blue is shown in Figure 21. 
 
A replicate gel of Figure 21 was used to determine which bands corresponded to the 
nucleoprotein.  This was determined by Western blotting using a polyclonal α-mumps 
nucleoprotein antibody raised in rabbits.  Figure 22 shows the blot with chemiluminescent signal 
identifying the nucleoprotein at approximately 62 kDa. 
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Figure 21:  Polyacrylamide gel stained with colloidal blue showing the protein banding for 
JL-CK and RIT 4385. 
Lanes 1 and 2 contain replicate samples of JL-CK virus concentrate and lanes 3 and 4 contain 
replicate samples of RIT 4385 virus concentrate, with the full-range Amersham Rainbow marker 
for size determination. The bands excised for mass spectrometry analysis are identified with 
arrows (two bands for JL-CK and three bands for RIT 4385), with both bands in each replica 
lane excised. 
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Figure 22:  Detection of mumps nucleoprotein in JL-CK and RIT 4385 by Western 
blotting. 
Primary antibody rabbit α-mumps nucleoprotein (1:10000) was incubated with the membrane 
followed by the secondary antibody goat α-rabbit HRP (1:2000).  Mumps nucleoprotein was 
identified at approximately 62 kDa, using HRP chemiluminescence. 
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The purpose of the Western blot was to be as a guide to pinpoint the region of the colloidal blue-
stained gel that contained the nucleoprotein, with an expected size of approximately 62 kDa.  
Unfortunately the blot did not transfer thoroughly as shown by the incomplete labelling pattern 
of the band(s) in the JL-CK lane.  The multiple bands detected in the RIT 4385 sample were 
unexpected, most likely due to a combination of the polyclonal nature of the antibody and 
degradation of the nucleoprotein.  The incomplete transfer, whilst unattractive, did not affect the 
downstream analysis which was performed on the colloidal blue-stained gel shown in Figure 21.   
 
The preparation of samples and mass spectrometry was performed by Dr J. X. Wheeler, 
Laboratory for Molecular Structure, NIBSC.  All visible bands between 52 kDa and 76 kDa 
(Figure 21) were excised, two from JL-CK and three from RIT 4385 before undergoing trypsin 
digestion.  The tryptic peptides were extracted and subjected to online nano LC-MS/MS (Gaspari 
and Cuda, 2011) before identification by database searching. 
The mass spectra produced were used to search the whole UniProt FASTA database in order to 
identify the peptides.  All peptides identified were confirmed to be mumps nucleoprotein in both 
the JL-CK and RIT 4385 samples.  The mass spectra produced from the JL-CK sample matched 
9 peptides, with 190 residues identical to the 549 residues of the MuV (Jeryl Lynn) nucleoprotein 
(UniProt Q77158), corresponding to a sequence coverage of 34.6 %.  The mass spectra produced 
from the RIT 4385 sample matched 10 peptides, with 214 residues out of 549 residues identical 
to the MuV (Jeryl Lynn) nucleoprotein (UniProt Q77158), this corresponded to a sequence 
coverage of 39 %.  The additional peptide identified from the RIT 4385 sample was confirmed to 
be the nucleoprotein carboxy-terminal peptide (GEHVNTEPNNPNQNAQLQVGDWDE).  The 
sequence coverage map showing the matched peptides identified from the RIT 4385 sample and 
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compared to the UniProt database sequence (Q77158) of the MuV nucleoprotein is detailed in 
Appendix 2a.  The mass spectra from the JL-CK sample did not identify the carboxy-terminal 
peptide.  This suggested that the JL-CK nucleoprotein had a different carboxy-terminus to RIT 
4385 and any other MuV nucleoprotein within the database.  The sequence coverage map 
showing the matched peptides identified from the JL-CK sample compared to the UniProt 
database sequence (Q77158) of the MuV nucleoprotein is detailed in Appendix 2b.   
The UniProt database was manually updated to include the putative additional JL-CK protein 
sequences (QITDMIKLTPIATIPGQSSHS) and (QITDMIKPTPIATIPGQSSHS), which had 
been predicted from Sanger sequence analysis.  The mass spectra from both the JL-CK and RIT 
4385 samples were searched against the updated database.  This search identified 10 peptide 
matches from the JL-CK sample, corresponding to 203 residues out of 570 residues, (35.6 % 
sequence coverage).  The carboxy-terminal peptide (LTPIATIPGQSSHS) of the putative 
extended nucleoprotein was identified in the JL-CK sample but not in the RIT 4385 sample.  
The L557P mutation, which is located in the same peptide of the putative elongated 
nucleoprotein (PTPIATIPGQSSHS), was however not detected in the JL-CK sample.  This is 
most likely due to the proline (P) disrupting the trypsin digestion motif therefore making the 
peptide too long to be sequenced.  The identification of the carboxy-terminal peptide, 
LTPIATIPGQSSHS in the JL-CK sample but not in RIT 4385, confirmed that the elongated 
nucleoprotein, encoded by the Ter550Q mutation, is expressed at the protein level in the JL-CK 
MuV.  The peptides identified from the RIT 4385 and JL-CK samples, mapped to the modified 
database entries for the MuV nucleoprotein are detailed in Appendices 2a and 2b.   
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CHAPTER 4 – IDENTIFICATION OF JL-CK VIRUS VARIANTS 
 
The variation at the genomic level of the JL-CK vaccine virus was suggestive of multiple 
populations of MuV within the vaccine.  Sanger sequencing of the unpassaged JL-CK virus 
identified 13 nucleotide polymorphisms, corresponding to four amino acid substitutions in the 
nucleoprotein; E108D, V529A, Ter550Q and L557P (Ter550Q extended the nucleoprotein by 21 
amino acids, comprising the L557P mutation) plus one silent mutation (L542L).  The shared 
region encoding proteins V/P/I contains one mutation, N56T.  The matrix protein contains a 
C244R mutation, whilst the fusion protein contains two mutations P93S and F295S, which is 
based on two changes in adjacent nucleotides.  The haemagglutinin-neuraminidase and large 
proteins both contain one mutation, E569K and D311G, respectively.  Interestingly, no mutations 
were detected in the gene encoding the small hydrophobic (SH) protein, which is the most 
variable gene when comparing different mumps strains (Afzal et al., 1993) and used to classify 
MuV strains (Yeo et al., 1993).  This indicated that if there is a mixture of MuVs within JL-CK, 
any virus isolated would be classified as the JL-5 strain and not any other MuV strain. 
 
4.1  Isolation and sequence analysis of JL-CK variants 
In order to identify whether there were more than one JL-5 virus present within the JL-CK 
vaccine, the JL-CK virus was plaque purified and subjected to Sanger sequencing.  The resulting 
sequences from each plaque, covering the regions which displayed a mixture of nucleotides were 
aligned against the published sequence of JL-5.  Analysis of 81 individual plaques identified five 
JL-CK variants plus the parent virus, which was identical to the published sequence of JL-5.  The 
predicted amino acid changes, silent mutation and mutation in the non-coding leader sequence 
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that were identified in each variant, compared to the JL-5 sequence are depicted in Figure 23. 
The JL-CK variants contained a variety of the identified mutations, with JL-CK1 containing the 
least (n = 3) and JL-CK5 containing the most (n = 9).  All of the JL-CK variants contained the 
non-coding leader mutation g/a
nt92
 plus the C244R and E569K mutations in the M and HN 
proteins.  Each variant contained in addition at least one of the other mutations.  JL-CK1 also 
contained a previously unidentified mutation, K36R in the N gene.  Retrospective analysis of the 
plaque sequence data summarised in Table 14, revealed that 36 out of 79 plaques (45 %) 
contained this mutation, which had not been detected in the JL-CK vaccine vial by Sanger 
sequencing.  The JL-CK2 variant contained the E108D mutation, identified in 6 out of 81 
plaques (7 %), whilst JL-CK3 encompasses E108D plus Ter550Q, identified in 2 out of 81 
plaques (2 %).  The JL-CK4 variant contained E108D, Ter550Q, N56T, P93S and D311G, 
identified in 31 out of 81 plaques (38 %) whilst JL-CK5 included E108D, V529A, L542L, 
Ter550Q, L557P (in the extended nucleoprotein) and F295S identified in 3 out of 81 plaques (4 
%).  The virus with the identical sequence to JL-5 represented only 4 % of the population of 
plaques analysed.  Some mutations appeared to be associated with each other, with g/a
nt92
, 
C244R and E569K appearing together (* in Figure 23), as do N56T, P93S and D311G (# in 
Figure 23), and V529A, L542L, L557P and F295S (+
 
in Figure 23).   
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Figure 23:  Schematic diagram of the JL-CK variants identified after plaque isolation and Sanger sequencing. 
The specific mutations which appear to be associated with each other are depicted by
 *
(g/a
nt92
, C244R and E569K), 
# 
(N56T, P93S and 
D311G) or 
+ 
(V529A, L542L, L557P and F295S) 
JL-CK1  
JL-CK2 
JL-CK3 
JL-CK4 
JL-CK5 
N V/P/I M F SH HN L 3’ 5’ 
E569K* C244R* 
g/ant92* 
K36R 
N V/P/I M F SH HN L 3’ 5’ 
E569K* C244R* 
g/ant92* 
E108D 
N V/P/I M F SH HN L 3’ 5’ 
E569K* C244R* 
g/ant92* 
E108D Ter550Q 
N V/P/I M F SH HN L 3’ 5’ 
E569K* C244R* 
g/ant92* 
E108D Ter550Q N56T
#
 P93S
#
 D311G
#
 
N V/P/I M F SH HN L 3’ 5’ 
 
E569K* C244R* 
g/ant92* 
E108D Ter550Q 
L557P
+
 
F295S
+
 
L542L
+
 
V529A
+
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Table 14:  Mutations identified in each JL-CK variant and the frequency of each 
variant isolated from plaques. 
 
#
frequency of each variant from 81 plaques sequenced, n/a – not applicable 
 
 
4.2  Biological characteristics of each variant 
To identify if a phenotype could be attributed to a particular JL-CK variant, each variant was 
assayed for its growth and plaque-forming ability in vitro and the ability to produce 
neutralising antibodies and neurovirulence potential in vivo. 
 
4.2.1  In vitro growth of JL-CK variants 
To identify if each JL-CK variant could grow on their own, without the presence of the other 
variants, and to compare the titres of the progeny viruses, Vero cells were infected with each 
 Amino acid substitution  
Variant Leader N V/P/I M F HN L Frequency
# 
JL-CK1 g/a
nt92
 K36R  C244R  E569K  45 % 
JL-CK2 g/a
nt92
 E108D  C244R  E569K  7 % 
JL-CK3 g/a
nt92
 E108D 
Ter550Q 
 C244R  E569K  2 % 
JL-CK4 g/a
nt92
 E108D 
Ter550Q 
N56T C244R P93S E569K D311G 38 % 
JL-CK5 g/a
nt92
 E108D 
V529A 
L542L 
Ter550Q 
L557P 
 C244R F295S E569K  4 % 
“Parental” n/a n/a n/a n/a n/a n/a n/a 4 % 
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JL-CK variant and incubated.  As in earlier experiments, Vero cells were inoculated at a MOI 
of 0.0001 pfu per cell and incubated.  At each daily timepoint the progeny viruses were 
titrated in Vero cells and the results calculated as pfu per ml of cell lysate, Figure 24. 
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Figure 24: Progeny virus titres from individual variants incubated in Vero cells over 7 
days. 
Progeny viruses were titrated in Vero cells, in triplicate and plotted as pfu per ml of cell 
lysate.  Error bars represent the standard error of the mean. 
 
 
JL-CK1 produced the highest progeny virus titre (1.35 x 10
7 
pfu per ml) in the shortest time 
(3 days post-infection).  Compared to JL-CK and the other variants, JL-CK5 appeared to lag 
behind slightly at days 1 and 2 but did reach similar endpoint titres to JL-CK and the other 
variants by day 7, (JL-CK5 2.3 x 10
5 
pfu per ml and JL-CK 6.1 x 10
5 
pfu per ml).  All JL-CK 
variants were capable of independent growth and each variant plus the JL-CK virus produced 
higher titres of progeny virus compared to RIT 4385. 
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4.2.2  Plaque size comparison of JL-CK variants 
Each JL-CK variant was titrated in Vero cells to identify if the smaller plaque phenotype 
could be attributed to one particular variant or mutation.  Representative plaque assays for 
each JL-CK variant plus the JL-CK and RIT 4385 viruses are shown in Figure 25. 
 
 
 
 
 
 
 
Figure 25:  Representative images of plaques produced in Vero cells by JL-CK, RIT 
4385 and each JL-CK variant. 
The “Parental” panel is the parent-like JL-5 virus isolated from the JL-CK vaccine which did 
not contain any of the mutations identified in JL-CK. 
 
 
The plaques produced by JL-CK3, JL-CK4 and JL-CK5 variants all appeared to display the 
smaller plaque phenotype.  In order to quantify the plaque sizes, plaques from each variant 
plus the JL-CK and RIT 4385 viruses, were measured using ImageJ (Schneider et al., 2012).  
The results are shown in Figure 26.  The data plotted is the number of plaques with 
corresponding plaque size, measured in ImageJ units.  
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113 
 
RIT 4385
1-
5
5-
10
10
-1
5
15
-2
0
20
-2
5
25
-3
0
30
-3
5
35
-4
0
40
-4
5
45
-5
0
50
-5
5
0
5
10
15
20
Plaque size
N
u
m
b
e
r
 o
f 
p
la
q
u
e
s
JL-CK
1-
5
5-
10
10
-1
5
15
-2
0
20
-2
5
25
-3
0
30
-3
5
35
-4
0
40
-4
5
45
-5
0
50
-5
5
0
5
10
15
20
Plaque size
N
u
m
b
e
r
 o
f 
p
la
q
u
e
s
"Parental"
1-
5
5-
10
10
-1
5
15
-2
0
20
-2
5
25
-3
0
30
-3
5
35
-4
0
40
-4
5
45
-5
0
50
-5
5
0
5
10
15
20
Plaque size
N
u
m
b
e
r
 o
f 
p
la
q
u
e
s
JL-CK1
1-
5
5-
10
10
-1
5
15
-2
0
20
-2
5
25
-3
0
30
-3
5
35
-4
0
40
-4
5
45
-5
0
50
-5
5
0
5
10
15
20
Plaque size
N
u
m
b
e
r
 o
f 
p
la
q
u
e
s
JL-CK2
1-
5
5-
10
10
-1
5
15
-2
0
20
-2
5
25
-3
0
30
-3
5
35
-4
0
40
-4
5
45
-5
0
50
-5
5
0
5
10
15
20
Plaque size
N
u
m
b
e
r
 o
f 
p
la
q
u
e
s
JL-CK4
1-
5
5-
10
10
-1
5
15
-2
0
20
-2
5
25
-3
0
30
-3
5
35
-4
0
40
-4
5
45
-5
0
50
-5
5
0
5
10
15
20
Plaque size
N
u
m
b
e
r
 o
f 
p
la
q
u
e
s
JL-CK5
1-
5
5-
10
10
-1
5
15
-2
0
20
-2
5
25
-3
0
30
-3
5
35
-4
0
40
-4
5
45
-5
0
50
-5
5
0
5
10
15
20
Plaque size
N
u
m
b
e
r
 o
f 
p
la
q
u
e
s
JL-CK3
1-
5
5-
10
10
-1
5
15
-2
0
20
-2
5
25
-3
0
30
-3
5
35
-4
0
40
-4
5
45
-5
0
50
-5
5
0
5
10
15
20
Plaque size
N
u
m
b
e
r
 o
f 
p
la
q
u
e
s
 
Figure 26:  Comparison of plaque sizes produced by JL-CK, RIT 4385 and each JL-CK 
variant. 
Plaque size measured using ImageJ, in terms of ImageJ units.  The “Parental” panel is the 
parent-like virus isolated from the JL-CK vaccine which did not contain any of the mutations 
identified in JL-CK. 
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The smaller plaque phenotype was observed in the JL-CK3, JL-CK4 and JL-CK5 variants.  
The mutation that is unique to these variants is the Ter550Q mutation, which suggests that 
this mutation may play a role in this phenotype. 
 
4.3  In vivo characteristics 
Seven groups of male ferrets were pre-bled before being inoculated intra-nasally with either 
RIT 4385 (Ferrets 1, 2, 3), “Parental” virus (Ferrets 4, 5, 6), JL-CK1 (Ferrets 7, 8, 9), JL-CK2 
(Ferrets 10, 11, 12), JL-CK3 (Ferrets 13, 14, 15), JL-CK4 (Ferrets 16, 17, 18) or JL-CK5 
(Ferrets 19, 20, 21) MuVs.  Over the course of the 28 day study, blood samples were 
collected at 7 day intervals before a terminal bleed at day 28.  Ferrets were monitored 
throughout the study with temperature, weight, parotid gland(s) and testicle swelling 
measured.  There were no clinical signs of disease in any of the ferrets.  Serum from each 
timepoint was separated from the red blood cells, for use in the detection of neutralising 
antibodies by PRN assay. 
 
4.3.1  Plaque reduction neutralisation assays 
The serum from each ferret was challenged with the RIT 4385 virus.  Each PRN assay had a 
positive control which was the challenge virus without serum added.  The average plaque 
count for the positive control was 50 pfu.  Figure 27 shows the neutralising antibody response 
expressed as ND50 for the ferrets inoculated with either the RIT 4385 virus or the “Parental” 
virus over 28 days. 
 
115 
 
RIT 4385
Ferret 1 Ferret 2 Ferret 3
0
10
20
30
40
50
Pre Bleed
Day 7
Day 14
Day 21
Day 28
5
0
 %
 E
n
d
p
o
in
t 
ti
tr
e
 (
N
D
5
0
)
"Parental"
Ferret 4 Ferret 5 Ferret 6
0
10
20
30
40
50
5
0
 %
 E
n
d
p
o
in
t 
ti
tr
e
 (
N
D
5
0
)
RIT 4385*
Ferret D Ferret E Ferret F
0
10
20
30
40
50
5
0
 %
 E
n
d
p
o
in
t 
ti
tr
e
(N
D
5
0
)
 
Figure 27:  Neutralising antibody titres in ferret sera, produced in response to 
inoculation with RIT 4385 or the “Parental” virus isolated from the JL-CK vaccine.  
Sera from each ferret were challenged with the RIT 4385 MuV and the dilution required to 
reduce the number of plaques by 50 % (ND50) was calculated.  PRN assays were performed 
in triplicate and the error bars represent the standard error of the mean.  For comparison, RIT 
4385* shows the ND50 values from the RIT 4385 inoculated ferrets described in Figure 13. 
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The ND50 values for Ferrets 1, 2 and 3 inoculated with RIT 4385 were low compared to the 
earlier PRN assays (Figure 13).  This is most likely due to an error in the inocula which was 
found to be lower than that used in the earlier in vivo study.  Therefore, for comparison the 
results from the previous PRN assay (RIT 4385*) described in Chapter 3 are included in 
Figure 27.   Nevertheless a similar trend was observed; ferrets 1, 2 and 3 again showed an 
increase in ND50 by day 28.   In contrast, the “Parental” virus (Ferrets 4, 5 and 6) did not 
behave like RIT 4385.  The ND50 values reached their maximum titre at day 7 which reduced 
at day 14 to the levels of the pre-bleed samples by days 21 and 28.  This could be a response 
to cellular debris left over from the “Parental” virus isolation and growth in Vero cells, rather 
than the virus.  Despite variability between different animals, the results were comparable 
within each experimental group. 
The ND50 values from the sera obtained from ferrets inoculated with the remaining JL-CK 
variants are shown in Figure 28. 
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Figure 28:  Neutralising antibody titres in ferret sera, produced in response to 
inoculation with JL-CK1, JL-CK2, JL-CK3, JL-CK4 or JL-CK5 variants. 
Sera from each ferret were challenged with the RIT 4385 MuV and the dilution required to 
reduce the number of plaques by 50 % (ND50) calculated.  PRN assays were performed in 
triplicate and the error bars represent the standard error of the mean. 
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The ND50 values from ferrets 7, 8 and 9, inoculated with the JL-CK1 variant showed a similar 
trend to those of RIT 4385, increasing by day 28.  Ferrets 13, 14 and 15, inoculated with the 
JL-CK3 variant also showed an increase in neutralising antibody.  Ferret 14 in particular 
produced the highest ND50 value (ND50 = 54), whilst ferret 15 was inconsistent, with a high 
pre-bleed (ND50 = 21) making the data not comparable.  The sera from ferrets 19, 20 and 21 
inoculated with JL-CK5, behaved similarly to the sera from the ferrets inoculated with the 
“Parental” virus i.e. the maximum ND50 value was obtained by day 7 then reduced at day 14, 
with days 21 and 28 showing similar ND50 values to the pre-bleed sample.  The sera from JL-
CK4 inoculated ferrets were more variable.  All three ferrets showed a slight increase in ND50 
values, similar to the “Parental” virus and JL-CK5 variant with the highest ND50 observed at 
day 7.  The serum from ferret 17 remained at a similar level throughout the study with a 
slight drop observed at day 14, regaining a similar value to day 7 by day 21.  The pre-bleed 
from ferret 16 produced a raised ND50 value, which was similar to those observed at days 14, 
21 and 28.  Ferret 18 produced a ND50 of similar value at each timepoint so could not be 
compared.  The sera from ferrets inoculated with JL-CK2 did not produce neutralising 
antibodies within the 28 day study with the ND50 values lower than the pre-bleed values for 
each ferret. 
There is considerable variation between each JL-CK variant and also between each ferret in 
some cases, but overall the sera from ferrets inoculated with RIT 4385, JL-CK1 and JL-CK3 
appeared to neutralise the RIT 4385 virus with an increase in neutralising antibody titre by 
day 28.  The sera from ferrets inoculated with JL-CK5 and two of the ferrets inoculated with 
JL-CK4 neutralised the RIT 4385 virus in a similar manner to the “Parental” virus (isolated 
from the JL-CK vaccine).  This again could be a response to cellular debris in the inoculum, 
left over from the isolation and growth in Vero cells of the variants.  There was no obvious 
association between individual mutations and ND50 value. 
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4.3.2  Rat neurovirulence 
Groups of six neonatal rats were infected intra-cerebrally with JL-CK, RIT 4385, JL-CK1, 
JL-CK2, JL-CK3, JL-CK4, JL-CK5 or the “Parental” virus isolated from the JL-CK vaccine, 
and monitored daily.  At day 25, the rats were terminated and the brains were removed, fixed, 
sectioned and stained with H&E.  The cross-sectional areas of the whole brain (excluding 
cerebellum) and ventricles were measured using ImageJ (Schneider et al., 2012) and the 
results were expressed as the percentage of the cross-sectional area of the whole brain.  
Figure 29 shows the results from individual rat brains. 
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Figure 29:  Ventricle sizes from individual rats inoculated with JL-CK, RIT 4385 or 
each individual JL-CK variant. 
Each bar represents one rat with four brain sections measured for each.  The error bars 
represent the standard error of the mean.  Uninfected rat brains were used as a control. 
120 
 
There was considerable variation between animals in each group.  Each bar represents the 
average measurement from four sections from one rat brain.  At least 50 % of rats in the 
groups inoculated with JL-CK1, JL-CK4 and JL-CK5 variants showed an increase in 
ventricle size, suggesting an increase in neurovirulence potential, which was similar to the 
JL-CK inoculated rats.  The ventricle sizes of the brains from rats inoculated with the 
“Parental” virus isolated from JL-CK, appeared similar to the RIT 4385 inoculated rats. 
In order to compare each group, the ventricle sizes were plotted as one bar per group as 
shown in Figure 30. 
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Figure 30:  Ventricle sizes measured from rat groups inoculated with JL-CK, RIT 4385 
or each individual JL-CK variant. 
Each bar represents each group containing six rats.  Four brain sections were measured for 
each rat and the error bars represent the standard error of the mean. 
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Each bar represents the average measurement from four sections from each rat brain in a 
group.  The results for JL-CK and RIT 4385 were comparable to the data shown for a 
previous experiment (Figure 16).  JL-CK1 and JL-CK5 showed a similar increase in ventricle 
size as the JL-CK virus, suggesting an increase in neurovirulence potential.  When compared 
to RIT 4385, the p values obtained were; JL-CK, p = 0.0478 (*), JL-CK1, p = 0.0406 (*) and 
JL-CK5, p = 0.0100 (*).  Compared to JL-CK, the “Parental” virus did not show an increase 
in neurovirulence potential, behaving like RIT 4385, as did JL-CK3 and JL-CK4, with p 
values of p = 0.0440 (*), p = 0.1055 and p = 0.1627 respectively.  JL-CK2 showed 
significantly lower neurovirulence potential compared to both RIT 4385 (p = 0.0181) and JL-
CK (p = 0.0032). 
 
4.3.3  Titres of progeny virus in rat brains 
In order to assess the growth of the JL-CK variants in the brain, groups of 16 neonatal rats 
were infected intra-cerebrally with JL-CK, RIT 4385, JL-CK1, JL-CK2, JL-CK3, JL-CK4, 
JL-CK5 or the “Parental” virus, isolated from the JL-CK vaccine and monitored daily.  At 
days 1, 4, 7 and 10 the brains from three animals from each group were removed for titration 
of virus.  The titre of progeny virus expressed as pfu per ml of brain homogenate over time 
for each brain is shown in Figure 31.  
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Figure 31:  Progeny virus titres from rat brains inoculated with JL-CK, RIT 4385 or 
each individual JL-CK variant. 
Each dot represents the progeny virus titre from one brain titrated in Vero cells, in triplicate.  
The error bars represent the standard error of the mean.  Note, data for the JL-CK1 variant 
graph are shown using a different y-axis compared to the other variants. 
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Each dot represents the average progeny virus titre from one brain performed in triplicate 
plaque assays, with three animals per timepoint.  Again there was considerable variation 
between animals, shown by the range of the error bars.  All JL-CK variants grew in the rat 
brain, reaching their maximum yield at different timepoints.  JL-CK1 and JL-CK3 both 
reached their maximum progeny virus yield by day 4, producing average titres of 1.5 x 10
4
 
pfu per ml and 2.2 x10
3
 pfu per ml respectively, one rat in the JL-CK1 group produced the 
highest progeny virus titre of 3.5 x 10
4
 pfu per ml at day 4.  The RIT 4385, JL-CK2, JL-CK5 
and the “Parental” viruses all reached their maximum yield by day 7, with average titres of 
2.4 x 10
3
 pfu per ml, 4.6 x 10
3
 pfu per ml, 6.5 x 10
3
 pfu per ml and 3.7 x 10
3
 pfu per ml 
produced respectively.  The maximum yield for the JL-CK4 variant and JL-CK virus progeny 
were not observed until day 10 with titres of 4.3 x 10
3
 pfu per ml and 2.5 x 10
3
 pfu per ml 
respectively.  The yield of JL-CK and RIT 4385 progeny virus in this study is higher than in 
the previous in vivo study (Figure 17), although the maximum titre was reached at day 7 (RIT 
4385) and day 10 (JL-CK) and the titres of each were more similar.  Compared to the initial 
study, the average yield of JL-CK progeny virus at day 4 in this study was 847 pfu per ml 
compared with 1.4 x 10
3
 pfu per ml in the earlier study and the average yield of RIT 4385 
progeny virus at day 4 in this study was 600 pfu per ml compared with 31 pfu per ml at the 
same point in the earlier study. 
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CHAPTER 5 – COMPARISON OF JL-CK AND RIT 4385 BY DEEP SEQUENCING 
 
MuV has been shown to adapt to various cell lines and it is this adaptation to cell lines which 
forms the basis of MuV attenuation for vaccine production.  It has also been suggested that 
Vero cells may alter MuVs (Afzal et al., 2005; Parker, 2013).  To identify whether the virus 
populations identified in plaques formed in Vero cells after a 10 day incubation period are 
represented at similar ratios in the unpassaged JL-CK vaccine, deep sequencing of JL-CK and 
RIT 4385 was performed.   
 
5.1  Shotgun sequencing approach 
Oligo dT cDNA produced from RNA extracted from unpassaged JL-CK was used as a 
template to amplify 5 kb fragments using primers pairs Pav73fw:Pav48rev, 
Pav47fw:Pav80rev, Pav55fw:Pav20rev and Pav25fw:Pav34rev as detailed in Table 9.  
However, none of the primer combinations produced fragments of the correct size despite 
adjusting the PCR parameters.  To confirm that the template cDNA was suitable for 
amplification, primers Pav1fw and Pav2rev were used to successfully generate a 1 kb 
amplicon.  Using the same cDNA, primers Pav73fw and Pav36rev were used to attempt the 
amplification of a 3 kb fragment, however the same PCR conditions as the Pav1fw:Pav2rev 
reaction (increasing the extension time from 1 min to 3 min) failed to produce a 3 kb 
amplicon.  The fact that no amplification from the oligo dT cDNA was observed, was an 
obvious outcome in hindsight, as there are no poly A tails in the genomic RNA for the oligo 
dT to bind to in the cDNA synthesis step.  
To increase the chance of producing MuV cDNA from the JL-CK RNA, a gene-specific 
primer approach was used to generate cDNA.  The Pav34rev primer was used to produce 
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cDNA.  However amplification using primers Pav73fw and Pav48rev and the PCR conditions 
as before, failed to produce a 5 kb amplicon.   
Using shotgun sequencing for deep sequencing the JL-CK virus from the vaccine vial does 
not appear to be a feasible approach.  It is possible that whilst RNA was extracted from the 
vaccine virus it may not contain a high enough concentration of good quality genetic material 
to allow amplification of 5 kb fragments even when the MuV genome is targeted. 
 
5.2  Amplicon-based deep sequencing of unpassaged JL-CK and RIT 4385 
Random hexamer cDNA was produced from RNA extracted from unpassaged JL-CK and 
RIT 4385 viruses and used as a template.  Amplicons covering the regions containing the 
mutations, as shown in Figure 23 were generated using the fusion primers detailed in Table 
13, and libraries prepared for sequencing as detailed in 2.5.2.   The resulting sequences were 
aligned against the database sequence for JL-5 and the frequencies of each mutation 
established.  The frequencies of each mutation determined by plaque isolation of JL-CK 
compared to the frequencies obtained by deep sequencing of unpassaged JL-CK and RIT 
4385 are shown in Table 15. 
 
The rank order of the majority of mutations in JL-CK remained consistent between the two 
methods.  However, the data suggested that not all variants in the JL-CK vaccine behaved 
equally in Vero cell culture.  The frequencies of the four mutations V529A, L542L, L557P 
and F295S that are unique to the JL-CK5 variant were all reduced ~ 6.8 fold in Vero cells, 
compared with unpassaged JL-CK virus.  The E108D and Ter550Q mutations, which are 
present in variants JL-CK2, JL-CK3, JL-CK4 and JL-CK5, were also less prominent after 
growth in Vero cells, but only reduced ~ 2 fold.  The K36R mutation in the nucleoprotein 
which was not identified during Sanger sequencing of the unpassaged JL-CK virus, was 
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detected at low frequency (9.1 %) by deep sequencing.  This mutation whilst present at low 
levels in unpassaged JL-CK vaccine increased 5 fold after passage in Vero cells.  The C244R 
and E569K mutations that are present in all JL-CK variants occurred as frequently in the 
unpassaged JL-CK vaccine and in the plaques produced in Vero cells, as did the non-coding 
leader g/a
nt92
 and the N56T, P93S and D311G mutations, which are unique to the JL-CK4 
variant.  
 
Table 15:  Comparison of mutation frequencies detected in JL-CK plaques and by deep 
sequencing of unpassaged JL-CK and RIT 4385 viruses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
#
81 plaques were sequenced except 
a 
49 plaques and 
b
 79 plaques due to lack of material.         
c
 Mutation in non-coding region. n.d. not detected 
 
 
 
Nucleotide Protein Amino acid Mutation Frequency (%) 
Position  substitution JL-CK 
Plaques
# 
JL-CK 
Unpassaged 
RIT 4385 
Unpassaged 
92 - Leader 98
a 
96.70 n.d. 
252 N K36R 46
b 
9.10 n.d. 
469 N E108D 51 86.60 n.d. 
1731 N V529A 4 27.00 6.20 
1769 N L542L 4 26.20 16.60 
1793 N Ter550Q 44 74.20 n.d. 
1815 N L557P 4 26.50 21.30
c 
2145 V/P/I N56T 38 40.50 n.d. 
3993 M C244R 96 97.50 n.d. 
4822 F P93S 38 45.30 n.d. 
5429/30 F F295S 4 27.3 n.d. 
8318 HN E569K 96 96.90 n.d. 
9369 L D311G 38 43.40 n.d. 
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The results demonstrated that the growth of JL-CK in Vero cells alters the virus population 
dynamics, preferentially selecting the JL-CK1 and JL-CK4 variants. 
The results of deep sequencing the unpassaged RIT 4385 virus are also shown in Table 15.  
Three of the mutations identified in JL-CK are also present in RIT 4385; V529A at 6.2 % 
frequency, L542L at 16.6 %, and L557P at 21.3 %.  The Ter550Q mutation was not detected 
in RIT 4385, indicating the L557P mutation is not expressed in this virus.  This confirms the 
earlier Sanger sequencing and MAPREC data.  These mutations have not previously been 
reported for this vaccine. 
 
5.3  Deep sequencing of JL-CK and RIT 4385 after growth in Vero and MDCK cells 
The difference in progeny virus titres described in Chapter 3 showed that the JL-CK virus 
produced a higher yield of progeny virus in both Vero and MDCK cells compared to RIT 
4385.  To investigate how the population dynamics change during growth in these cell lines, 
deep sequencing was performed on RNA extracted from cell lysates after Vero or MDCK 
cells were infected at a MOI of 0.0001 and incubated until CPE was observed (3 days post-
infection).  Table 16 shows the frequencies of mutations identified in unpassaged JL-CK, 
compared to those detected in cell lysates after 3 days incubation in Vero or MDCK cells or 
from plaques formed on Vero cells after 10 days incubation. 
After 3 days incubation in Vero cells the frequencies for mutations V529A, L542L, L557P 
and F295S, which are unique to the JL-CK5 variant, decreased by 2.6, 2.8, 2.7 and 2.5 fold 
respectively.  The frequency of the K36R mutation, which is unique to JL-CK1 increased 3 
fold and the frequencies of mutations N56T, P93S and D311G which are unique to the JL-
CK4 variant remained at similar levels.  This suggests that Vero cells do not support the 
growth of the JL-CK5 variant.  The JL-CK1 and JL-CK4 variants appeared to be 
preferentially selected in Vero cells over the other variants, even after 3 days post-infection.  
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This was in agreement with the results shown in Table 15 and demonstrated that by the time 
CPE was observed in Vero cells, there was already a change in the JL-CK virus population. 
In MDCK cells on the other hand, all mutation frequencies remained consistent with those of 
the unpassaged JL-CK virus, the exception being the K36R mutation, which increased 2 fold.  
This confirmed that different cell substrates have different effects on MuV and suggested that 
MDCK cells support the growth of all JL-CK variants, in particular the JL-CK1 variant. 
The frequencies of mutations identified in RIT 4385 after 3 days incubation in Vero or 
MDCK cells are shown in Table 17. 
In the case of the RIT 4385 virus, the three mutations that are common to both vaccine 
viruses (V529A, L542L and L557P) were found at similar frequencies after incubation in 
Vero and MDCK cells.  This suggested that the RIT 4385 virus is more stable in these cell 
lines than the JL-CK virus. 
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Table 16:  Mutation frequencies identified by deep sequencing of JL-CK. 
Mutation frequencies of unpassaged virus and Vero and MDCK cell lysates 3 days post-infection (in duplicate), in comparison to the frequency 
observed by Sanger sequencing of plaques formed in Vero cells 10 days post-infection. 
 
p.i. post-infection  
Nucleotide Protein Amino acid Mutation frequency (%) 
position  substitution Unpassaged Vero MDCK Vero 
    3 days p.i. 3 days p.i. 10 days p.i. 
92 - Leader 96.70 94.7 94.3 72.5 95.6 98
 
252 N K36R 9.10 23.7 30.3 24.3 13.3 46
 
469 N E108D 86.60 77.0 63.9 51.8 84.7 51 
1731 N V529A 27.00 11.3 9.5 14.3 32.3 4 
1769 N L542L 26.20 9.9 9.0 14.1 31.8 4 
1793 N Ter550Q 74.20 50.1 45.8 43.6 62.6 44 
1815 N L557P 26.50 10.3 9.1 14.8 31.5 4 
2145 V/P/I N56T 40.50 44.2 40.1 31.8 31.5 38 
3993 M C244R 97.50 95.2 95.9 79.3 99.6 96 
4822 F P93S 45.30 41.4 38.4 30.8 31.1 38 
5429/30 F F295S 27.3 11.6 10.3 17.6 34.9 4 
8318 HN E569K 96.90 95.5 96.1 79.8 99.5 96 
9369 L D311G 43.40 33.4 36.8 29.1 29.9 38 
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Table 17:  Mutation frequencies identified by deep sequencing of RIT 4385. 
Mutation frequencies of unpassaged virus and Vero and MDCK cell lysates 3 days post-infection (in duplicate). 
 
 
 
 
 
 
 
 
 
 
 
 
 
             n.d. not detected, p.i. post-infection 
Nucleotide Protein Amino acid Mutation frequency (%) 
position  substitution Unpassaged Vero  MDCK  
92 - Leader n.d. n.d. n.d. n.d. n.d. 
252 N K36R n.d. n.d. n.d. n.d. n.d. 
469 N E108D n.d. n.d. n.d. n.d. n.d. 
1731 N V529A 6.20 14.3 8.8 2.9 2.8 
1769 N L542L 16.60 19.9 23.1 28.7 34.4 
1793 N Ter550Q n.d. n.d. n.d. n.d. n.d. 
1815 N L557P 21.30
 
31.5 30.0 30.4 35.7 
2145 V/P/I N56T n.d. n.d. n.d. n.d. n.d. 
3993 M C244R n.d. n.d. n.d. n.d. n.d. 
4822 F P93S n.d. n.d. n.d. n.d. n.d. 
5429/30 F F295S n.d. n.d. n.d. n.d. n.d. 
8318 HN E569K n.d. n.d. n.d. n.d. n.d. 
9369 L D311G n.d. n.d. n.d. n.d. n.d. 
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5.4  Deep sequencing of JL-CK after growth in the neonatal rat brain 
To investigate the population dynamics in vivo, amplicon-based deep sequencing was 
performed on RNA extracted from three rat brains, 4 days post-inoculation with JL-CK virus.  
Brains from rats inoculated with the RIT 4385 virus did not contain enough progeny virus to 
enable sufficient amplification for deep sequencing. 
The frequencies of mutations in each brain compared to unpassaged JL-CK virus are shown 
in Table 18.  The results obtained from each animal were largely consistent, although the 
difference in one animal (Brain 1) was less prominent, compared to the other two animals.  
Compared with the inoculate (JL-CK) or the JL-CK plaques (Table 15), the frequencies of 
the majority of the mutations decreased (E108D, V529A, L542L, Ter550Q, L557P, N56T, 
P93S, F295S and D311G).  
The frequencies of the non-coding leader (g/a
nt92
), C244R and E569K, which are present in 
all JL-CK variants, remained mostly unchanged.  However, the K36R mutation in the 
nucleoprotein again was significantly more prominent after growth of the JL-CK virus in the 
rat brains.  An observed 9.6 fold increase suggested that only the JL-CK1 virus had grown in 
the rat brain.  All other mutations decreased in frequency, with the mutations unique to the 
JL-CK4 variant still present but at lower frequencies than observed after growth in Vero cells 
(3.5 fold decrease) or in unpassaged JL-CK virus (3.7 fold decrease).  The other mutations 
were reduced in frequency to undetectable in some instances.   
 
These results highlighted that the growth of the JL-CK virus in an in vivo system also alters 
the virus population dynamics of the vaccine, preferentially selecting the JL-CK1 variant.   
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Table 18:  Comparison of mutation frequencies identified by deep sequencing of 
neonatal rat brains after inoculation with JL-CK virus. 
 
n.d. not detected 
 
 
The JL-CK vaccine population was not stable when passaged in vivo or in Vero cells with 
preferential selection of the JL-CK1 variant in both cases.  The JL-CK4 variant only appeared 
to be selected for in Vero cells, but not in the rat brains.  The growth of all other JL-CK 
variants was not supported in either model.  By contrast, the JL-CK virus population 
remained stable in MDCK cells.  These findings also highlighted the ability of MuV to adapt 
to cell lines and the speed at which MuVs can adapt. 
 
  
Nucleotide Protein Amino acid Mutation frequency (%) 
position  substitution Unpassaged Brain 1 Brain 2 Brain 3 
92 - Leader 96.70 100 100 100 
252 N K36R 9.10 69.60 93.90 94.30 
469 N E108D 86.60 33.40 5.40 6.60 
1731 N V529A 27.00 1.30 n.d. n.d. 
1769 N L542L 26.20 1.30 n.d. n.d. 
1793 N Ter550Q 74.20 26.60 18.40 3.10 
1815 N L557P 26.50 1.20 n.d. n.d. 
2145 V/P/I N56T 40.50 25.70 5.10 3.00 
3993 M C244R 97.50 99.90 100 100 
4822 F P93S 45.30 27.20 5.80 3.80 
5429/30 F F295S 27.3 1.2 n.d. 0.3 
8318 HN E569K 96.90 99.90 100 99.90 
9369 L D311G 43.40 26.00 5.50 3.50 
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CHAPTER 6 – DISCUSSION 
 
Since the 1960’s, live attenuated mumps vaccines have been produced in cell culture systems 
worldwide, yet the effects of the cell substrates on the genetics and biology of the resulting 
virus populations are poorly understood.  MuV is a RNA virus and therefore has an intrinsic 
genetic instability due to the high error rate and lack of proof-reading of the RNA-dependant 
polymerase (Holland et al., 1982; Kenney et al., 2011).  This leads to a diverse population of 
mutants, which are referred to as a quasispecies (Domingo et al., 1996).  The ability of MuV 
to adapt to different cell substrates, including CEFs (Beck et al., 1989), canine kidney cells 
(Fedova et al., 1987), guinea pig kidney primary cells (Odisseev and Gacheva, 1994) and 
human diploid cells (Sassani et al., 1991), is a consequence of its quasispecies nature.  It is 
this adaptation to cell substrates that forms the basis for the attenuation of MuV for vaccine 
production.  However, the exact mechanism of attenuation of MuV is unknown, to date there 
are also no known genetic marker for attenuation (Boriskin Yu et al., 1988; Santak et al., 
2014; Sauder et al., 2011; Shah et al., 2009).  
 
It is recognised that different growth conditions and growth substrates can alter the ratio of 
Jeryl Lynn mumps subpopulations (Amexis et al., 2001; Amexis et al., 2002).  It has also 
been documented that Vero cells can introduce mutations throughout the genome of MuV 
(Parker, 2013) and that serial passage of MuV through Vero cells accumulates defective 
interfering particles, that have been shown to attenuate a neurovirulence phenotype (Santak et 
al., 2014).   The initial indication of a difference between the two vaccine viruses JL-CK and 
RIT 4385, described in this thesis, was based on the observation that they displayed different 
plaque morphologies in Vero cells, with JL-CK presenting a smaller plaque phenotype.  
However, the growth profile of both JL-CK and RIT 4385 in Vero cells was similar despite 
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JL-CK yielding a significantly higher progeny virus titre compared to RIT 4385 at similar 
timepoints.  A difference in progeny virus yield was also observed after growth of JL-CK and 
RIT 4385 in MDCK cells, with JL-CK again producing significantly more progeny virus at 
both three and seven days post-infection.  This result was not unexpected as the production of 
JL-CK on primary canine kidney cells is likely to have led to the virus adapting to canine 
kidney cells (Starke and Hlinak, 1974).  It would have been interesting to compare progeny 
virus titres and plaque morphologies of JL-CK and RIT 4385 in primary canine kidney cells, 
had they been available and also to passage RIT 4385 through the primary cells to see if RIT 
4385 could display a JL-CK-like phenotype.  Similarly, it would have been interesting to 
perform passage through CEFs and examine progeny virus titres and plaque morphologies 
had they also been more freely available.  
 
Neurovirulence testing of attenuated mumps seed viruses for use in vaccine manufacture is 
routinely performed in order to distinguish suitable attenuation of the MuV, using non-human 
primates.  However, the neonatal rat model has been proposed as a more sensitive 
replacement (Rubin et al., 1998; Rubin et al., 2000).  This model has been shown to 
distinguish between neurovirulent and non-neurovirulent MuVs (Rubin and Afzal, 2011; 
Rubin et al., 2005), with an increase in hydrocephalus which results in an enlarged ventricle 
correlating to an increase in neurovirulence potential.  The neonatal rat model, however is 
complicated by the large amount of variability observed between animals, with large groups 
(30 - 60 animals) routinely used in order to obtain statistically significant results (Rubin et al., 
1998; Rubin et al., 2000; Santak et al., 2014; Sauder et al., 2011). 
In this study, the initial in vivo data suggested that JL-CK was more virulent than RIT 4385 in 
the neonatal rat model, causing a higher degree of hydrocephalus and producing higher titres 
of progeny virus in the brain.  However, the degree of hydrocephalus observed for JL-CK 
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was not as severe as that seen in the neurovirulent wild-type Mu90.  Despite these findings in 
the rats, there have been no reports of neurotropic adverse events occurring in patients who 
have received the JL-CK-containing vaccine, unlike patients who received the Urabe Am9 or 
Leningrad-3 vaccine strains (Cizman et al., 1989; Miller et al., 1993).  The differences 
observed between JL-CK and RIT 4385 in the rat neurovirulence model here are however 
significant, as the differences between closely related strains described, have been hard to 
detect in previous studies (Rubin et al., 2005; Rubin et al., 2000).  Viruses previously 
compared included the parent Jeryl Lynn vaccine consisting of two virus strains (JL-2 and 
JL-5), which was indistinguishable from RIT 4385 and the Urabe vaccine virus which was 
indistinguishable from a clinical isolate obtained from a Urabe vaccine-associated case of 
aseptic meningitis (Rubin et al., 2005).  The differences observed between RIT 4385 and 
Mu90 in this thesis have been previously reported (Malik et al., 2009; Rubin et al., 2005). 
 
The ferrets that were inoculated with JL-CK or RIT 4385 did not exhibit any clinical signs of 
MuV infection, which was in agreement with previously described studies of experimental 
infection of ferrets with MuV (Parker et al., 2013).  However, there was a difference 
observed in the serum antibody responses of the ferrets inoculated with each virus, although 
the data must be interpreted with some caution due to the small number of animals used in 
this study.  The ferrets inoculated with the JL-CK virus produced low levels of neutralising 
antibody, with neutralisation titres comparable to the pre-bleed samples.  In contrast, 
neutralising antibodies were produced by ferrets in response to inoculation with RIT 4385, 
which had previously been shown to be mumps-specific (Parker et al., 2013).  The 
neutralising antibody response from one ferret in particular showed a cross-protective effect 
by neutralising the Mu90 MuV.  The human reference serum notably gave a low level of 
neutralising antibody (ND50 = 12), when challenged with the RIT 4385 virus.  A neutralising 
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antibody level of 4 in human serum, when assessed by PRN, is generally considered to 
provide protection against mumps infection, (Mauldin et al., 2005).  The low levels of 
neutralising antibody observed in ferrets inoculated with JL-CK may reflect the lower 
serological response previously observed in vaccinees receiving the JL-CK vaccine (Boxall et 
al., 2008; Lexova et al., 2013; Limberkova and Lexova, 2014; Mrazova et al., 2003; Plesnik 
et al., 1984).  It would have been of interest to test the serum from patients who had been 
vaccinated with the JL-CK or RIT 4385 vaccines, however this material was unavailable for 
this study.  Ferrets are not an established model for MuV infection (Parker et al., 2013) and 
the absence of a more suitable animal model for mumps limits the scope for testing 
neutralising antibody responses to infection.  
 
The genomes of both JL-CK and RIT 4385 were compared by Sanger sequencing and aligned 
against the parental JL-5 database sequence to identify whether the differences observed 
could be attributed to changes at the genomic level.  JL-CK displayed heterogeneity at 
thirteen positions throughout the genome compared to the parental JL-5 sequence and eleven 
positions compared to the RIT 4385 genome.  Variations at these positions have not been 
reported before.  This indicated that the JL-CK vaccine contained a higher level of 
heterogeneity than RIT 4385, when compared to the JL-5 sequence.  The data obtained from 
MAPREC analysis of the N and P genes of JL-CK and RIT 4385, confirmed these 
polymorphic regions.  Each of the genes throughout the JL-CK genome contained at least one 
polymorphic site, corresponding to predicted substitutions of encoded amino acids, and the 
non-coding leader sequence contained one mutation, g/a
nt92
.  The SH gene, which is the most 
variable (Cui et al., 2009; Takeuchi et al., 1991) and used to determine MuV genotype 
because of its variability (Afzal et al., 1997; Cui et al., 2009; Kunkel et al., 1995; Yeo et al., 
1993), showed no genomic changes in JL-CK and had identical sequence to JL-5.  The 
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majority of the variation observed was in the N gene with five polymorphic sites identified, 
one of which was a silent mutation (L542L).  However the other mutations resulted in 
predicted amino acid changes (E108D, V529A, Ter550Q and L557P), with one in particular 
(Ter550Q) eliminating the Stop codon and extending the nucleoprotein by 21 amino acids.  
The extended nucleoprotein was shown to be expressed in JL-CK and mass spectrometry 
identified the presence of both the parent peptide (LTPIATIPGQSSHS) and the mutant 
peptide (PTPIATIPGQSSHS).   
 
Isolation of viruses from individual plaques produced from JL-CK identified five JL-5 virus-
variants within the JL-CK vaccine, plus a “Parental” virus which did not contain any of the 
polymorphic regions and was identical to the parent JL-5 strain.  The five variants, which 
differed from the parent JL-5 virus, each contained the three mutations observed in the 
population; g/a
nt92
 in the non-coding leader sequence, C244R in the M protein and E569K in 
the HN protein, plus one or more of the other mutations that had been observed.  Each of the 
JL-CK variants isolated from plaques were found at different frequencies as described in 
Table 14, with JL-CK1 and JL-CK4 identified at the highest frequencies of 46 % and 38 %, 
respectively.  The remaining isolated variants were present at much lower frequencies; JL-
CK2 at 7 %, JL-CK5 at 4 % and JL-CK3 at 2 % of the population, and the virus isolated 
which was identical to the JL-5 parent virus represented only 4 % of the population of the JL-
CK vaccine.  The frequencies of the JL-CK variants identified from plaques confirmed the 
earlier MAPREC data (Figure 19), with E108D, V529A, L542L and L557P each displaying 
band intensities in line with the frequencies of those mutations derived from the plaque data.  
The MAPREC signal intensities for mutations Ter550Q and N56T were lower than expected, 
considering that the variants containing those mutations are present in around 44 % 
(Ter550Q) and 38 % (N56T) of the JL-CK vaccine population (Table 14).  This may be as a 
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consequence of the many variables associated with the MAPREC method.  In addition, two 
of the polymorphisms in the N gene corresponding to L542L and L557P, were found in both 
JL-CK and RIT 4385 to a similar level by both MAPREC (Figure 19) and amplicon-based 
deep sequencing of the unpassaged virus (Table 15).  Amplicon-based deep sequencing of 
JL-CK confirmed the presence of all of the mutations identified by Sanger sequencing of the 
isolated JL-CK plaques.  In addition, the K36R mutation was identified in the JL-CK vaccine 
at low frequency (9.1 %), compared to the others, which may explain why it was not found 
initially by Sanger sequencing.  Three of the heterogeneities (V529A, L542L and L557P) 
were also found in RIT 4385 at lower levels (6.2 %, 16.6 % and 21.3 % respectively), when 
RIT 4385 was analysed by deep sequencing.  The V529A mutation had not been identified in 
RIT 4385 by Sanger sequencing or by MAPREC, this again is likely due to the low frequency 
of the mutation.  Mutations, L542L and L557P were found to be present in RIT 4385 by 
MAPREC analysis, L542L is silent and L557P mutation is non-coding in this case.   
Analysis of cell lysates three days post-infection with JL-CK showed that growth in Vero 
cells altered the frequencies of the mutations.  The K36R mutation in the nucleoprotein of JL-
CK1, increased three-fold during growth in Vero cells, even after only three days incubation, 
confirming previous findings that there is selective pressure from Vero cells on MuV (Afzal 
et al., 2005; Parker, 2013; Santak et al., 2014).  Linkage between mutations cannot be 
confirmed by deep sequencing, due to the fragmentation step in the method.  However, those 
mutations which were unique to a particular variant all behaved in a similar manner.  The 
frequency of mutations associated with the JL-CK4 variant appeared to remain consistent, 
with N56T, P93S and D311G occurring at frequencies of 42.2 %, 39.9 % and 35 % in Vero 
lysates.  This suggests that Vero cells preferentially select both JL-CK1 and JL-CK4.  All 
other mutations reduced in frequency from unpassaged virus and were comparable to the 
plaque frequencies.  The JL-CK variant population was less affected by passage on MDCK 
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cells, with the frequencies of mutations remaining comparable to the unpassaged JL-CK 
virus, suggesting a key effect from the species of cell used.   
RIT 4385 was more genetically stable during growth in both Vero and MDCK cells.  This 
may be because RIT 4385 appears to contain fewer virus variants compared to JL-CK.  
Plaque purification of RIT 4385 was not performed in order to isolate additional RIT 4385 
variants, during this study.  It is also possible that there are other regions of the RIT 4385 
genome which are less stable after passage in cell lines, and have not been investigated in this 
study.  These would have been identified if the whole genome of RIT 4385 had been 
analysed by shotgun sequencing however, this method was unable to be optimised for use 
during this study. 
 
All of the JL-CK variants were capable of independent growth in Vero cells and all variants 
produced higher progeny virus titres than RIT 4385.  In particular JL-CK1 produced the 
highest progeny virus titre in the shortest time (1.35 x 10
7
 pfu/ml, 3 days p.i.) suggesting it 
may contain mutations that permit faster replication in Vero cells, which is in agreement with 
the deep sequencing data.  In each of the JL-CK variants the nucleoprotein was the most 
variable, containing between one (JL-CK1) and four (JL-CK5) mutations.  The K36R 
mutation was not identified in the JL-CK vaccine vial by Sanger sequencing, but was found 
to be present at low frequency (9.1 %) by amplicon-based deep sequencing and was shown to 
be present in the JL-CK1 variant, after Sanger sequencing of the isolated plaques.  Variants 
JL-CK3, JL-CK4 and JL-CK5 all contain the Ter550Q mutation.  The presence of the 
Ter550Q mutation in plaque isolates correlated with the small plaque phenotype.  The 
nucleoprotein is required for transcription, replication and virus assembly (Ivancic-Jelecki et 
al., 2008).  The first 375 amino acids of the nucleoprotein are required to form the 
nucleocapsid and modifications to the C terminal tail can affect assembly (Kingston et al., 
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2004).  During virus assembly, M proteins are thought to interact directly with the 
cytoplasmic tails of the F and HN glycoproteins and also with the nucleoprotein (Pei et al., 
2010).  Elongation of the nucleoprotein with or without the combination of the C244R 
mutation in the M protein, which is involved in virus assembly and budding from the cell 
membrane (Li et al., 2009), may affect the ability of progeny viruses to bud effectively from 
infected cells limiting the infection of neighbouring cells.  The small plaque phenotype 
however was not the result of a growth defect, as the variants were all capable of growing in 
Vero cells to maximum comparable titres at day 4 post-infection, JL-CK3 1.6 x 10
6
 pfu per 
ml, JL-CK4 2.3 x 10
6
 pfu per ml and JL-CK5 1.4 x 10
6
 pfu per ml.  This result contradicts the 
deep sequencing results for the analysis of the cell lysates, 3 days post-infection, where JL-
CK3 and JL-CK5 did not appear to grow well in Vero cells.  This might be as a result of the 
further growth of the progeny viruses in Vero cells (over 10 days), to obtain the viral titre for 
each variant.  Deep sequencing of cell lysates and Vero cell titres are therefore not a directly 
comparable method to identify whether specific viruses can grow in a cell line.  It would be 
of interest to sequence the progeny virus plaques from the JL-CK3, JL-CK4 and JL-CK5 
variants, to identify any change in the mutation frequency in comparison to the 3 day post-
infection cell lysates. 
 
None of the ferrets inoculated with the JL-CK variants showed any clinical signs of disease, 
which was also the case during the initial study where JL-CK and RIT 4385 were inoculated.  
There was considerable variation in neutralising antibody titre between each group of ferrets 
and also between each ferret in some cases.  However, overall the sera from ferrets inoculated 
with RIT 4385, JL-CK1 and JL-CK3 produced an increase in serum antibody response by 
day 28, when challenged with the RIT 4385 virus.  The serum antibody response to RIT 4385 
in the two ferret studies was variable.  This is most likely due to a difference in the stock 
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virus concentration used to prepare the inoculum, which was found to be lower than expected 
in the second study. 
The sera from ferrets inoculated with JL-CK5 and from two of the ferrets inoculated with JL-
CK4 demonstrated a maximum serum antibody response to the RIT 4385 challenge virus at 
day 7, which was similar to the response of the “Parental” virus isolated from JL-CK.  In 
these cases, the neutralising antibody level began to reduce at day 14 and declined to the level 
of the pre-bleed sample by day 28.  In these cases it is unlikely that the increase in ND50 
value at day 7 is due to neutralising antibody, this is more likely a response to cellular debris 
in the inocula which was remaining after isolation and growth of the variants in Vero cells, 
both the “Parental” and JL-CK5 viruses had undergone one additional passage in Vero cells, 
compared to the other variants.  The Vero cell lysates had been centrifuged to remove cellular 
debris but the preparation is unlikely to be as pure as the vaccine preparation for RIT 4385 or 
JL-CK.  It also is possible that any neutralisation response observed would be lower due to 
the challenge virus (RIT 4385) used.  The sera from the ferrets inoculated with JL-CK4 and 
JL-CK5 may not have been able to cross neutralise the RIT 4385 virus.  A cross-protective 
effect was suggested in the initial ferret study when the RIT 4385 vaccine was inoculated, 
however the sera from JL-CK inoculated ferrets did not appear to show cross-protection 
against the other challenge MuVs.  Ideally, the challenge virus would have been the same as 
the virus used to inoculate each group, as in the initial study.  However, there were limited 
stocks of each of the JL-CK variants and therefore to use these as the challenge virus in the 
PRN assays would have required a further passage in Vero cells, which may have introduced 
additional mutations.  The observation that the ferrets inoculated with the “Parental” virus 
isolated from the JL-CK vaccine displayed a different neutralising antibody profile to RIT 
4385 was unexpected.  The “Parental” virus had undergone one additional passage in Vero 
cells, prior to inoculation into the ferrets (as had the JL-CK5 variant), to enable a virus stock 
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with a suitable titre to be used in the assay.  In each case the virus had been sequenced over 
the known variable regions to ensure the mutations were still present (or not in the case of the 
“Parental” virus).  However, it is not inconceivable that as the entire genomes of the 
“Parental” and JL-CK5 viruses were not sequenced there may have been the introduction of 
additional mutations at other sites which were undetected, with unknown effect(s) on the 
viruses.   
The outcome of the ferret studies are further complicated in that there is no definitive 
correlate of protection in terms of neutralisation antibody for MuV.  This makes it difficult to 
determine the level at which an ND50 value has a biological meaning with regards to 
protective levels of antibody.  The human reference serum control gave a neutralising 
antibody level of 12 which was lower than the day 28 values for the sera from RIT 4385, JL-
CK1 and JL-CK3 inoculated ferrets (Figures 27 and 28).  It has been reported that serum 
antibody levels as low as 2 and 4 can be considered protective in human serum (Ennis, 1969; 
Mauldin et al., 2005). 
There have also been some concerns over the use of the PRN assay to determine neutralising 
ability and its correlation to protection.  It has been shown that different virus strains and 
even the cell type used during the assay can affect the ND50 value (Mukherjee et al., 2014; 
Pipkin et al., 1999).  That, coupled with the lack of a suitable animal model for MuV 
infection and the findings that the ferret may not be the most suitable model for assessing 
neutralising antibodies against MuV (Parker et al., 2013) limits the biological conclusions 
from the ferret study. 
 
There was a range of hydrocephalus severity observed in the rat brains after infection with 
the JL-CK variants and there was also variation between animals in each group.  The 
hydrocephalus associated with JL-CK2 was significantly lower than RIT 4385 and the 
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hydrocephalus associated with JL-CK1 and JL-CK5 was significantly higher than RIT 4385 
and comparable to JL-CK.  Interestingly, the two variants which caused similar levels of 
hydrocephalus in the neonatal rat compared to JL-CK contained either the fewest mutations 
(JL-CK1) or the most mutations (JL-CK5).  This suggests that the neurovirulence phenotype 
observed is not specific to one mutation.  Therefore, there must be a requirement for a 
combination of mutations for a neurovirulence phenotype to be displayed.  The neurovirulent 
Urabe MuV vaccine contains a mixture of two viruses which contain either a glutamic acid 
(E) or lysine (K) at position 335 of the HN protein.  The virus containing K335 has been 
shown to be responsible for an increase in development of meningitis post-vaccination 
(Brown et al., 1996) and it has been shown that K335 changes the receptor binding and 
neuraminidase activity of the virus (Reyes-Leyva et al., 2007).  However, studies involving 
recombinant Urabe MuV have identified that K335 is not responsible for a neurovirulence 
phenotype (Sauder et al., 2009).  It has been demonstrated using recombinant MuV that 
combinations of genes can alter the neurovirulence phenotype observed in neonatal rats 
(Lemon et al., 2007; Sauder et al., 2011).  Sauder et al. investigated gene-specific 
neurovirulence phenotypes showing that the Jeryl Lynn N and M genes in combination, could 
neuroattenuate a recombinant wild-type MuV.  However, no combination of wild-type MuV 
genes could transfer a neurovirulent phenotype to a recombinant Jeryl Lynn MuV (Sauder et 
al., 2011).  In contrast, a study by Lemon et al. showed the induction of a neurovirulence 
phenotype in a recombinant Jeryl Lynn MuV by insertion of the F and HN genes of a 
neurovirulent rodent-brain-adapted MuV, either individually or in combination (Lemon et al., 
2007).  
A correlation between neurovirulence potential and viral titre in the rat brain has been 
previously suggested (Sauder et al., 2011).  However, comparison of the titres of the JL-CK 
variants in the brains of inoculated rats provided conflicting results when taken together with 
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the neurovirulence data,  The JL-CK1 variant produced the highest progeny virus titres in the 
rat brain (3.5 x 10
4
 pfu per ml, 4 days p.i.), which is in agreement with the neurovirulence 
data and amplicon-based deep sequencing of the neonatal rat brains which had been 
inoculated with JL-CK confirmed that the JL-CK1 variant was preferentially selected for in 
the rat brain.  However, the maximum titres of the JL-CK5 variant (6.6 x 10
3
 pfu per ml, 7 
days p.i.) and JL-CK virus (2.5 x 10
3
 pfu per ml, 10 days p.i.), were lower than that of the JL-
CK1 variant despite displaying a similar neurovirulence potential.  This could be due in part 
to the highly variable nature of the neonatal rat model and the fact that in these studies 
comparatively small numbers of animal were used in each group.  Further studies would be 
useful to confirm these findings, which could not be initiated during the course of this study.   
The identification of a neurovirulence marker for MuV is lacking and appears to be a more 
complex issue than the identification of mutation(s).  It has been described that changes in 
viral genetic heterogeneity may have an impact on MuV neurovirulence potential (Sauder et 
al., 2006).  Amplicon-based deep sequencing of neonatal rat brains which had been 
inoculated with JL-CK also identified a dramatic change in the population of the JL-CK 
variants.  The K36R mutation increased ten-fold and along with the non-coding leader, 
C244R and E569K mutations which are all found in the JL-CK1 variant were present at 
almost 100 % frequency, suggesting preferential selection of the JL-CK1 variant, which is in 
agreement with the high titre of the JL-CK1 variant observed.  This may imply a role for 
these mutations in the neurovirulence phenotype.  The other mutations all reduced in 
frequency, in particular mutations V529A, L542L, L557P and F295S, which are all unique to 
JL-CK5 were detected at only 1 % frequency or less.  
The results for the neurovirulence studies and the deep sequencing of the rat brains provide 
conflicting data, with the JL-CK5 virus giving a high neurovirulence score but the deep 
sequencing suggesting that this virus does not replicate as well as the other JL-CK variants in 
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the rat brain.  This could be due to the small number animal used in the neurovirulence 
studies and also in the analysis by deep sequencing, which was due to time constraints.  A 
follow up study could provide valuable information on the growth of the JL-CK1 and JL-
CK5 variants in the rat brain and the resulting neurovirulence phenotype could provide useful 
information on the role of the K36R, C244R and E569K mutations as a possible marker for 
neurovirulence.  
 
The deep sequencing analysis also highlighted the variation found between animals infected 
with the same virus, with mutation frequencies displaying the same trend between animals 
but to varying degrees.  In particular, the Ter550Q mutation (common to JL-CK3, JL-CK4 
and JL-CK5) was found to decrease in frequency compared to the JL-CK virus (74.2 %).  In 
each of the animals the frequencies were substantially different, RNV1 26.6 %, RNV2 18.4 
% and RNV3 3.1 %.  This may reflect a degree of preferential replication of JL-CK4 over JL-
CK3 and JL-CK5 within the rat brain, which would be similar to the observation in Vero 
cells. This may explain the variation seen within groups of animals in the neurovirulence 
study.  It would be of interest to confirm this finding in future studies with a larger group of 
animals and in combination with a neurovirulence study.  This would provide valuable 
information linking an increase in ventricle size to a particular variant. 
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CONCLUSIONS 
 
The two mumps viruses that were studied are closely related, originating from the same Jeryl 
Lynn parent strain.  They differ only in their passage history, with JL-CK produced by 
passage in primary canine kidney cells and RIT 4385 produced by passage in CEFs.  The aim 
of this project was to compare the biological characteristics of the JL-CK and RIT 4385 
vaccine viruses in vitro and in vivo, identify any differences at the genomic level and examine 
how these genomic differences affect the biological properties of the JL-CK vaccine virus. 
 
The data presented in this thesis confirmed the vaccine manufacturers’ statements that both 
JL-CK and RIT 4385 comprise only the JL-5 virus strain.  However, both viruses differ at the 
genomic level and in their biological phenotypes and suggested the JL-CK vaccine virus 
contained a more mixed population of MuVs compared to the RIT 4385 virus, which was 
previously unknown.  The genetic differences between JL-CK and RIT 4385 are presumably 
a reflection of the passage history of the viruses in primary canine kidney cells and chick 
embryo fibroblasts respectively, although due to the lack of availability of primary canine 
kidney cells and CEF cells this was not assessed directly in this study.  Further investigation 
revealed that the JL-CK vaccine virus contained a mixture of five JL-5 virus variants, plus the 
parent virus which has an identical sequence to the database sequence of the JL-5 virus. 
 
The passage of the JL-CK virus, whether in vitro or in vivo, affects the genotype of the virus-
variants and dramatically alters the composition of the virus population, within a short time, 
preferentially selecting some virus populations over others, JL-CK1 and JL-CK4 in Vero 
cells and JL-CK1 in vivo.  The selection effects of the human host on the virus are unknown.  
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However, genomic variations identified in clinical MuV isolates following immunisation 
with the L-Zagreb vaccine strain have previously been reported (Gilliland et al., 2013).  
The work covered in this thesis confirms the genetic instability of MuV in cell substrates and 
suggests that propagation of MuV on a cell substrate which is related to the passage history of 
the virus is likely to produce progeny virus which are more stable e.g. JL-CK growth in 
MDCK cells.  It would be interesting to see if the same were true for RIT 4385 after growth 
in CEFs and clinical MuV isolates in a human cell line, for example ex vivo human airway 
epithelial cells as reported previously (Parker, 2013).  At present the preferred cell line for 
plaque formation and titration of MuV is the Vero cell line.  This study has shown that there 
is a selection pressure on the MuV in Vero cells and there may be some virus variants which 
do not produce plaques, which is of importance when determining MuV titres and potencies 
of vaccines for example.  During the production of mumps vaccines, different batches are not 
routinely checked for mutations that may be introduced during growth.  The findings from 
this thesis emphasise the importance of choosing suitable cell substrates for mumps vaccine 
manufacture. 
 
The functions of the mutations identified were not assessed in this project and the use of a 
reverse genetics system to study the effects of particular mutations would be of interest.  
However, careful consideration of the cell lines used to produce recombinant MuVs would be 
required, to minimise the risk of introducing unwanted mutations.  The use of a human 
derived cell line would be advantageous, in particular Hep2C (human cervical carcinoma), 
MCF-7 (human breast carcinoma) or HGT-1 (human stomach carcinoma), which have been 
shown to produce high titre, genetically stable progeny virus (Parker, 2013).  Any 
recombinant viruses generated would need to be thoroughly characterised by deep 
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sequencing to ensure that no other genetic changes have occurred and that a single population 
of MuV was recovered. 
 
The data from the neonatal rats provided conflicting data and there was considerable 
variation within experimental groups.  This may in part be due to the small numbers of 
animal used for the studies.  By combining the neurovirulence testing with deep sequencing, 
larger groups of animals could be used in future.  Half of the brain could be fixed for 
neurovirulence scoring and the other half could be used for deep sequencing.  This could 
provide a link to increased hydrocephalus and growth of a single population of MuV. 
 
This study has generated valuable data which will be of interest to researchers in the 
paramyxovirus field.  It has enabled the identification of mutations in the MuV genome 
which have not previously been described.  These mutations are not known to be within any 
known antigenic or structurally relevant areas (inferred from related viruses).  This study has 
also confirmed the previous findings that growth of MuV in vitro and in vivo alter the virus 
population dynamics and highlights that the changes to the viral population occur within 
three to four days of infection.  The project has however also highlighted that there is still a 
lack of fundamental knowledge surrounding MuV.  Much of what is known about MuV 
protein structure and function is inferred from related paramyxoviruses.  The fact that still 
very little is known about MuV pathogenesis and the lack of a suitable animal model are 
limiting factors for future mumps pathogenesis research. 
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APPENDICES 
 
Appendix 1:  Alignments of JL-CK and JL-5 protein sequences 
 
JL-CK and JL-5 nucleoprotein amino acid sequence. 
 
 
JL-CK      MSSVLKAFERFTIEQELQDRGEEGSIPPETLKSAVRVFVINTPNPTTRYQMLNFCLRIIC 60 
JL-5       MSSVLKAFERFTIEQELQDRGEEGSIPPETLKSAVKVFVINTPNPTTRYQMLNFCLRIIC 60 
           *********************************** ************************ 
 
JL-CK      SQNARASHRVGALITLFSLPSAGMQNHIRLADRSPEAQIERCEIDGFDPGTYRLIPNARA 120 
JL-5       SQNARASHRVGALITLFSLPSAGMQNHIRLADRSPEAQIERCEIDGFEPGTYRLIPNARA 120 
           *********************************************** ************ 
 
JL-CK      NLTANEIAAYALLADDLPPTINNGTPYVHADVEGQPCDEIEQFLDRCYSVLIQAWVMVCK 180 
JL-5       NLTANEIAAYALLADDLPPTINNGTPYVHADVEGQPCDEIEQFLDRCYSVLIQAWVMVCK 180 
           ************************************************************ 
 
JL-CK      CMTAYDQPAGSADRRFAKYQQQGRLEARYMLQPEAQRLIQTAIRKSLVVRQYLTFELQLA 240 
JL-5       CMTAYDQPAGSADRRFAKYQQQGRLEARYMLQPEAQRLIQTAIRKSLVVRQYLTFELQLA 240 
           ************************************************************ 
 
JL-CK      RRQGLLSNRYYAMVGDIGKYIENSGLTAFFLTLKYALGTKWSPLSLAAFTGELTKLRSLM 300 
JL-5       RRQGLLSNRYYAMVGDIGKYIENSGLTAFFLTLKYALGTKWSPLSLAAFTGELTKLRSLM 300 
           ************************************************************ 
 
JL-CK      MLYRGLGEQARYLALLEAPQIMDFAPGGYPLIFSYAMGVGTVLDVQMRNYTYARPFLNGY 360 
JL-5       MLYRGLGEQARYLALLEAPQIMDFAPGGYPLIFSYAMGVGTVLDVQMRNYTYARPFLNGY 360 
           ************************************************************ 
 
JL-CK      YFQIGVETARRQQGTVDNRVADDLGLTPEQRTEVTQLVDRLARGRGAGIPGGPVNPFVPP 420 
JL-5       YFQIGVETARRQQGTVDNRVADDLGLTPEQRTEVTQLVDRLARGRGAGIPGGPVNPFVPP 420 
           ************************************************************ 
 
JL-CK      VQQQQPAAVYEDIPALEESDDDGDEDGGAGFQNGVQLPAVRQGGQTDFRAQPLQDPIQAQ 480 
JL-5       VQQQQPAAVYEDIPALEESDDDGDEDGGAGFQNGVQLPAVRQGGQTDFRAQPLQDPIQAQ 480 
           ************************************************************ 
 
JL-CK      LFMPLYPQVSNMPNNQNHQINRIGGLEHQDLLRYNENGDSQQDARGEHANTFPNNPNQNA 540 
JL-5       LFMPLYPQVSNMPNNQNHQINRIGGLEHQDLLRYNENGDSQQDARGEHVNTFPNNPNQNA 540 
           ************************************************ *********** 
 
JL-CK      QLQVGDWDEQITDMIKPTPIATIPGQSSHS 570 
JL-5       QLQVGDWDE--------------------- 549 
           *********                      
 
Comparison of JL-CK and JL-5 (accession AF201473).  Amino acid substitutions; K36R, 
E108D, V529A, Ter550Q) are highlighted in RED, silent mutation (L542L) in BOLD font 
and the extension to the nucleoprotein is highlighted. 
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JL-CK and JL-5 phosphoprotein amino acid sequence. 
 
 
JL-CK      MDQFIKQDETGDLIETGMNVANHFLSTPIQGTNSLSKASILPGVAPVLIGNPEQKTIQHP 60 
JL-5       MDQFIKQDETGDLIETGMNVANHFLSTPIQGTNSLSKASILPGVAPVLIGNPEQKNIQHP 60 
           *********************************************************** 
 
JL-CK      TASHQGSKTKGRGSGVRSIIVSPSEAGNGGTQIPEPLFAQTGQGGIVTTVYQDPTIQPTG 120 
JL-5       TASHQGSKTKGRGSGVRSIIVSPSEAGNGGTQIPEPLFAQTGQGGIVTTVYQDPTIQPTG 120 
           ************************************************************ 
 
JL-CK      SYRSVELAKIGKERMINRFVEKPRTSTPVTEFKRGAGSGCSRPDNPRGGHRREWSLSWVQ 180 
JL-5       SYRSVELAKIGKERMINRFVEKPRTSTPVTEFKRGAGSGCSRPDNPRGGHRREWSLSWVQ 180 
           ************************************************************ 
 
JL-CK      GEVRVFEWCNPICSPITAAARFHSCKCGNCPAKCDQCERDYGPP 224 
JL-5       GEVRVFEWCNPICSPITAAARFHSCKCGNCPAKCDQCERDYGPP 224 
           ******************************************** 
 
Comparison of JL-CK and JL-5 (accession AF201473).  Amino acid substitution N56T 
highlighted in RED 
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JL-CK and JL-5 matrix protein amino acid sequence. 
 
 
JL-CK      MAGSQIKIPLPKPPDSDSQRLNAFPVIMAQEGKGRLLRQIRLRKILSGDPSDQQITFVNT 60 
JL-5       MAGSQIKIPLPKPPDSDSQRLNAFPVIMAQEGKGRLLRQIRLRKILSGDPSDQQITFVNT 60 
           ************************************************************ 
 
JL-CK      YGFIRATPETSEFISESSQQKVTPVVTACMLSFGAGPVLEDPQHMLKALDQTDIRVRKTA 120 
JL-5       YGFIRATPETSEFISESSQQKVTPVVTACMLSFGAGPVLEDPQHMLKALDQTDIRVRKTA 120 
           ************************************************************ 
 
JL-CK      SDKEQILFEINRIPNLFRHYQISADHLIQASSDKYVKSPAKLIAGVNYIYCVTFLSVTVC 180 
JL-5       SDKEQILFEINRIPNLFRHYQISADHLIQASSDKYVKSPAKLIAGVNYIYCVTFLSVTVC 180 
           ************************************************************ 
 
JL-CK      SASLKFRVARPLLAARSRLVRAVQMEILLRVTCKKDSQMAKSMLNDPDGEGCIASVWFHL 240 
JL-5       SASLKFRVARPLLAARSRLVRAVQMEILLRVTCKKDSQMAKSMLNDPDGEGCIASVWFHL 240 
           *********************************************************** 
 
JL-CK      CNLRKGRNKLRSYDENYFASKCRKMNLTVSIGDMWGPTILVHAGGHIPTTAKPFFNSRGW 300 
JL-5       CNLCKGRNKLRSYDENYFASKCRKMNLTVSIGDMWGPTILVHAGGHIPTTAKPFFNSRGW 300 
           *** ******************************************************** 
 
JL-CK      VCHPIHQSSPSLAKTLWSSGCEIKAASAILQGSDYASLAKTDDIIYSKIKVDKDAANYKG 360 
JL-5       VCHPIHQSSPSLAKTLWSSGCEIKAASAILQGSDYASLAKTDDIIYSKIKVDKDAANYKG 360 
           ************************************************************ 
 
JL-CK      VSWSPFRKSASMRNL 375 
JL-5       VSWSPFRKSASMRNL 375 
           *************** 
 
Comparison of JL-CK and JL-5 (accession AF201473).  Amino acid substitution (C244R) 
highlighted in RED 
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JL-CK and JL-5 fusion protein amino acid sequence. 
 
 
JL-CK      MNAFPVICLGYAIFSSSICVNINTLQQIGYIKQQVRQLSYYSQSSSSYVVVKLLPNIQPT 60 
JL-5       MNAFPVICLGYAIFSSSICVNINTLQQIGYIKQQVRQLSYYSQSSSSYVVVKLLPNIQPT 60 
           ************************************************************ 
 
JL-CK      DNSCEFKSVTQYNKTLSNLLLPIAENINNIASSSLGSRRHKRFAGIAIGIAALGVATAAQ 120 
JL-5       DNSCEFKSVTQYNKTLSNLLLPIAENINNIASPSLGSRRHKRFAGIAIGIAALGVATAAQ 120 
           ******************************** *************************** 
 
JL-CK      VTAAVSLVQAQTNARAIAAMKNSIQATNRAVFEVKEGTQQLAIAVQAIQDHINTIMSTQL 180 
JL-5       VTAAVSLVQAQTNARAIAAMKNSIQATNRAVFEVKEGTQQLAIAVQAIQDHINTIMSTQL 180 
           ************************************************************ 
 
JL-CK      NNMSCQILDNQLATSLGLYLTELTTVFQPQLINPALSPISIQALRSLLGSMTPAVVQATL 240 
JL-5       NNMSCQILDNQLATSLGLYLTELTTVFQPQLINPALSPISIQALRSLLGSMTPAVVQATL 240 
           ************************************************************ 
 
JL-CK      STSISAAEILSAGLMEGQIVSVLLDEMQMIVKINIPTIVTQSNALVIDFYSISSSINNQE 300 
JL-5       STSISAAEILSAGLMEGQIVSVLLDEMQMIVKINIPTIVTQSNALVIDFYSISSFINNQE 300 
           ****************************************************** ***** 
 
JL-CK      SIIQLPDRILEIGNEQWRYPAKNCKLTRHHMFCQYNEAERLSLETKLCLAGNISACVFSP 360 
JL-5       SIIQLPDRILEIGNEQWRYPAKNCKLTRHHMFCQYNEAERLSLETKLCLAGNISACVFSP 360 
           ************************************************************ 
 
JL-CK      IAGSYMRRFVALDGTIVANCRSLTCLCKSPSYPIYQPDHHAVTTIDLTSCQTLSLDGLDF 420 
JL-5       IAGSYMRRFVALDGTIVANCRSLTCLCKSPSYPIYQPDHHAVTTIDLTSCQTLSLDGLDF 420 
           ************************************************************ 
 
JL-CK      SIVSLSNITYTENLTISLSQTINTQPIDISTELSKVNASLQNAVKYIKESNHQLQSFSVG 480 
JL-5       SIVSLSNITYTENLTISLSQTINTQPIDISTELSKVNASLQNAVKYIKESNHQLQSFSVG 480 
           ************************************************************ 
 
JL-CK      SKIGAIIVSALVLSILSIIISLLFCCWAYIATKEIRRINFKTNHINTISSSVDDLIRY 538 
JL-5       SKIGAIIVSALVLSILSIIISLLFCCWAYIATKEIRRINFKTNHINTISSSVDDLIRY 538 
           ********************************************************** 
 
Comparison of JL-CK and JL-5 (accession AF201473).  Amino acid substitutions (P93S and 
F295S) are highlighted in RED 
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JL-CK and JL-5 haemagglutinin-neuraminidase protein amino acid sequence. 
 
 
JL-CK      MEPSKLFIMSDNATFAPGPVVNAAGKKTFRTCFRILVLSVQAVILILVIVTLGELIRMIN 60 
JL-5       MEPSKLFIMSDNATFAPGPVVNAAGKKTFRTCFRILVLSVQAVILILVIVTLGELIRMIN 60 
           ************************************************************ 
 
JL-CK      DQGLSNQLSSITDKIRESAAVIASAVGVMNQVIHGVTVSLPLQIEGNQNQLLSTLATICT 120 
JL-5       DQGLSNQLSSITDKIRESAAVIASAVGVMNQVIHGVTVSLPLQIEGNQNQLLSTLATICT 120 
           ************************************************************ 
 
JL-CK      NRNQVSNCSTNIPLINDLRFINGINKFIIEDYATHDFSIGHPLNMPSFIPTATSPNGCTR 180 
JL-5       NRNQVSNCSTNIPLINDLRFINGINKFIIEDYATHDFSIGHPLNMPSFIPTATSPNGCTR 180 
           ************************************************************ 
 
JL-CK      IPSFSLGKTHWCYTHNVINANCKDHTSSNQYVSMGILAQTASGYPMFKTLKIQYLSDGLN 240 
JL-5       IPSFSLGKTHWCYTHNVINANCKDHTSSNQYVSMGILAQTASGYPMFKTLKIQYLSDGLN 240 
           ************************************************************ 
 
JL-CK      RKSCSIATVPDGCAMYCYVSTQLETDDYAGSSPPTQKLILLFYNDTITERTISPSGLEGN 300 
JL-5       RKSCSIATVPDGCAMYCYVSTQLETDDYAGSSPPTQKLILLFYNDTITERTISPSGLEGN 300 
           ************************************************************ 
 
JL-CK      WATLVPGVGSGIYFENKLIFPAYGGVLPNSTLGVKLAREFFRPVNPYNPCSGPQQELDQR 360 
JL-5       WATLVPGVGSGIYFENKLIFPAYGGVLPNSTLGVKLAREFFRPVNPYNPCSGPQQELDQR 360 
           ************************************************************ 
 
JL-CK      ALRSYFPSYFSSRRVQSAFLVCAWNQILVTNCELVVPSNNQTLMGAEGRVLLINNRLLYY 420 
JL-5       ALRSYFPSYFSSRRVQSAFLVCAWNQILVTNCELVVPSNNQTLMGAEGRVLLINNRLLYY 420 
           ************************************************************ 
 
JL-CK      QRSTSWWPYELLYEISFTFTNYGQSSVNMSWIPIYSFTRPGSGHCSGENVCPIVCVSGVY 480 
JL-5       QRSTSWWPYELLYEISFTFTNYGQSSVNMSWIPIYSFTRPGSGHCSGENVCPIVCVSGVY 480 
           ************************************************************ 
 
JL-CK      LDPWPLTPYRHQSGINRNFYFTGALLNSSTTRVNPTLYVSALNNLKVLAPYGTQGLFASY 540 
JL-5       LDPWPLTPYRHQSGINRNFYFTGALLNSSTTRVNPTLYVSALNNLKVLAPYGTQGLFASY 540 
           ************************************************************ 
 
JL-CK      TTTTCFQDTGDASVYCVYIMELASNIVGKFQILPVLARLTIT 582 
JL-5       TTTTCFQDTGDASVYCVYIMELASNIVGEFQILPVLARLTIT 582 
           **************************** ************* 
 
Comparison of JL-CK and JL-5 (accession AF201473).  Amino acid substitution (E569K) 
highlighted in RED 
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JL-CK and JL-5 large protein amino acid sequence. 
 
 
JL-CK     MAGLNEILLPEVHLNSPIVRYKLFYYILHGQLPNDLEPDDLGPLANQNWKAIRAEESQVH 60 
JL-5      MAGLNEILLPEVHLNSPIVRYKLFYYILHGQLPNDLEPDDLGPLANQNWKAIRAEESQVH 60 
          ************************************************************ 
 
JL-CK     ARLKQIRVELIARIPSLRWTRSQREIAILIWPRILPILQAYDLRQSMQLPTVWEKLTQST 120 
JL-5      ARLKQIRVELIARIPSLRWTRSQREIAILIWPRILPILQAYDLRQSMQLPTVWEKLTQST 120 
          ************************************************************ 
 
JL-CK     VNLISDGLERVVLHISNQLTGKPNLFTRSRAGQDTKDYSIPSTRELSQIWFNNEWSGSVK 180 
JL-5      VNLISDGLERVVLHISNQLTGKPNLFTRSRAGQDTKDYSIPSTRELSQIWFNNEWSGSVK 180 
          ************************************************************ 
 
JL-CK     TWLMIKYRMRQLITNQKTGELTDLVTIVDTRSTLCIITPELVALYSSEHKALTYLTFEMV 240 
JL-5      TWLMIKYRMRQLITNQKTGELTDLVTIVDTRSTLCIITPELVALYSSEHKALTYLTFEMV 240 
          ************************************************************ 
 
JL-CK     LMVTDMLEGRLNVSSLCTASHYLSPLKKRIEVLLTLVDDLALLMGDKVYGIVSSLESFVY 300 
JL-5      LMVTDMLEGRLNVSSLCTASHYLSPLKKRIEVLLTLVDDLALLMGDKVYGIVSSLESFVY 300 
          ************************************************************ 
 
JL-CK     AQLQYGDPVIGIKGTFYGFICNEILDLLTEDNIFTEEEANKVLLDLTSQFDNLSPDLTAE 360 
JL-5      AQLQYGDPVIDIKGTFYGFICNEILDLLTEDNIFTEEEANKVLLDLTSQFDNLSPDLTAE 360 
          ********** ************************************************* 
 
JL-CK     LLCIMRLWGHPTLTASQAASKVRESMCAPKVLDFQTIMKTLAFFHAILINGYRRSHNGIW 420 
JL-5      LLCIMRLWGHPTLTASQAASKVRESMCAPKVLDFQTIMKTLAFFHAILINGYRRSHNGIW 420 
          ************************************************************ 
 
JL-CK     PPTTLHGNAPKSLIEMRHDNSELKYEYVLKNWKSISMLRIHKCFDASPDEDLSIFMKDKA 480 
JL-5      PPTTLHGNAPKSLIEMRHDNSELKYEYVLKNWKSISMLRIHKCFDASPDEDLSIFMKDKA 480 
          ************************************************************ 
 
JL-CK     ISCPRQDWMGVFRRSLIKQRYRDANRPLPQPFNRRLLLNFLEDDRFDPIKELEYVTSGEY 540 
JL-5      ISCPRQDWMGVFRRSLIKQRYRDANRPLPQPFNRRLLLNFLEDDRFDPIKELEYVTSGEY 540 
          ************************************************************ 
 
JL-CK     LRDPEFCASYSLKEKEIKATGRIFAKMTKRMRSCQVIAESLLANHAGKLMRENGVVLDQL 600 
JL-5      LRDPEFCASYSLKEKEIKATGRIFAKMTKRMRSCQVIAESLLANHAGKLMRENGVVLDQL 600 
          ************************************************************ 
 
JL-CK     KLTKSLLTMNQIGIISEHSRRSTADNMTLAHSGSNKHRINNSQFKKNKDNKHEMPDDGFE 660 
JL-5      KLTKSLLTMNQIGIISEHSRRSTADNMTLAHSGSNKHRINNSQFKKNKDNKHEMPDDGFE 660 
          ************************************************************ 
 
JL-CK     IAACFLTTDLTKYCLNWRYQVIIPFARTLNSMYGIPHLFEWIHLRLMRSTLYVGDPFNPP 720 
JL-5      IAACFLTTDLTKYCLNWRYQVIIPFARTLNSMYGIPHLFEWIHLRLMRSTLYVGDPFNPP 720 
          ************************************************************ 
 
JL-CK     SDPTQLDLDTALNDDIFIVSPRGGIEGLCQKLWTMISISTIILSATEANTRVMSMVQGDN 780 
JL-5      SDPTQLDLDTALNDDIFIVSPRGGIEGLCQKLWTMISISTIILSATEANTRVMSMVQGDN 780 
          ************************************************************ 
 
JL-CK     QAIAITTRVVRSLSHSEKKEQAYKASKLFFERLRANNHGIGHHLKEQETILSSDFFIYSK 840 
JL-5      QAIAITTRVVRSLSHSEKKEQAYKASKLFFERLRANNHGIGHHLKEQETILSSDFFIYSK 840 
          ************************************************************ 
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JL-CK     RVFYKGRILTQALKNVSKMCLTADILGDCSQASCSNLATTVMRLTENGVEKDLCYFLNAF 900 
JL-5      RVFYKGRILTQALKNVSKMCLTADILGDCSQASCSNLATTVMRLTENGVEKDLCYFLNAF 900 
          ************************************************************ 
 
JL-CK     MTIRQLCYDLVFPQTKSLSQDITNAYLNHPILISRLCLLPSQLGGLNFLSCSRLFNRNIG 960 
JL-5      MTIRQLCYDLVFPQTKSLSQDITNAYLNHPILISRLCLLPSQLGGLNFLSCSRLFNRNIG 960 
          ************************************************************ 
 
JL-CK     DPLVSAIADVKRLIKAGCLDIWVLYNILGRRPGKGKWSTLAADPYTLNIDYLVPSTTFLK 1020 
JL-5      DPLVSAIADVKRLIKAGCLDIWVLYNILGRRPGKGKWSTLAADPYTLNIDYLVPSTTFLK 1020 
          ************************************************************ 
 
JL-CK     KHAQYTLMERSVNPMLRGVFSENAAEEEEELAQYLLDREVVMPRVAHVILAQSSCGRRKQ 1080 
JL-5      KHAQYTLMERSVNPMLRGVFSENAAEEEEELAQYLLDREVVMPRVAHVILAQSSCGRRKQ 1080 
          ************************************************************ 
 
JL-CK     IQGYLDSTRTIIRYSLEVRPLSAKKLNTVIEYNLLYLSYNLEIIEKPNIVQPFLNAINVD 1140 
JL-5      IQGYLDSTRTIIRYSLEVRPLSAKKLNTVIEYNLLYLSYNLEIIEKPNIVQPFLNAINVD 1140 
          ************************************************************ 
 
JL-CK     TCSIDIARSLRKLSWATLLNGRPIEGLETPDPIELVHGCLIIGSDECEHCSSGDDKFTWF 1200 
JL-5      TCSIDIARSLRKLSWATLLNGRPIEGLETPDPIELVHGCLIIGSDECEHCSSGDDKFTWF 1200 
          ************************************************************ 
 
JL-CK     FLPKGIRLDDDPASNPPIRVPYIGSKTDERRVASMAYIKGASVSLKSALRLAGVYIWAFG 1260 
JL-5      FLPKGIRLDDDPASNPPIRVPYIGSKTDERRVASMAYIKGASVSLKSALRLAGVYIWAFG 1260 
          ************************************************************ 
 
JL-CK     DTEESWQDAYELASTRVNLTLEQLQSLTPLPTSANLVHRLDDGTTQLKFTPASSYAFSSF 1320 
JL-5      DTEESWQDAYELASTRVNLTLEQLQSLTPLPTSANLVHRLDDGTTQLKFTPASSYAFSSF 1320 
          ************************************************************ 
 
JL-CK     VHISNDCQILEIDDQVTDSNLIYQQVMITGLALIETWNNPPINFSVYETTLHLHTGSSCC 1380 
JL-5      VHISNDCQILEIDDQVTDSNLIYQQVMITGLALIETWNNPPINFSVYETTLHLHTGSSCC 1380 
          ************************************************************ 
 
JL-CK     IRPVESCVVNPPLLPVPLINVPQMNKFVYDPEPLSLLEMEKIEDIAYQTRIGGLDQIPLL 1440 
JL-5      IRPVESCVVNPPLLPVPLINVPQMNKFVYDPEPLSLLEMEKIEDIAYQTRIGGLDQIPLL 1440 
          ************************************************************ 
 
JL-CK     EKIPLLAHLTAKQMVNSITGLDEATSIMNDAVVQADYTSNWISECCYTYIDSVFVYSGWA 1480 
JL-5      EKIPLLAHLTAKQMVNSITGLDEATSIMNDAVVQADYTSNWISECCYTYIDSVFVYSGWA 1480 
          ************************************************************ 
 
JL-CK     LLLELSYQMYYLRIQGIQGILDYVYMTLRRIPGMAITGISSTISHPRILRRCINLDVIAP 1500 
JL-5      LLLELSYQMYYLRIQGIQGILDYVYMTLRRIPGMAITGISSTISHPRILRRCINLDVIAP 1500 
          ************************************************************ 
 
JL-CK     INSPHIASLDYTKLSIDAVMWGTKQVLTNISQGIDYEIVVPSESQLTLSDRVLNLVARKL 1560 
JL-5      INSPHIASLDYTKLSIDAVMWGTKQVLTNISQGIDYEIVVPSESQLTLSDRVLNLVARKL 1560 
          ************************************************************ 
 
JL-CK     SLLAIIWANYNYPPKVKGMSPEDKCQALTTHLLQTVEYVEYIQIEKTNIRRMIIEPKLTA 1620 
JL-5      SLLAIIWANYNYPPKVKGMSPEDKCQALTTHLLQTVEYVEYIQIEKTNIRRMIIEPKLTA 1620 
          ************************************************************ 
 
JL-CK     YPSNLFYLSRKLLNAIRDSEEGQFLIASYYNSFGYLEPILMESKIFNLSSSESASLTEFD 1680 
JL-5      YPSNLFYLSRKLLNAIRDSEEGQFLIASYYNSFGYLEPILMESKIFNLSSSESASLTEFD 1680 
          ************************************************************ 
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JL-CK     FILNLELSDASLEKYSLPSLLMTAENMDNPFPQPPLHHVLRPLGLSSTSWYKTISVLNYI 1740 
JL-5      FILNLELSDASLEKYSLPSLLMTAENMDNPFPQPPLHHVLRPLGLSSTSWYKTISVLNYI 1740 
          ************************************************************ 
 
JL-CK     SHMKISDGAHLYLAEGSGASMSLIETFLPGETIWYNSLFNSGENPPQRNFAPLPTQFIES 1800 
JL-5      SHMKISDGAHLYLAEGSGASMSLIETFLPGETIWYNSLFNSGENPPQRNFAPLPTQFIES 1800 
          ************************************************************ 
 
JL-CK     VPYRLIQAGIAAGNGIVQSFYPLWNGNSDITDLSTKTSVEYIIHKVGADTCALVHVDLEG 1860 
JL-5      VPYRLIQAGIAAGNGIVQSFYPLWNGNSDITDLSTKTSVEYIIHKVGADTCALVHVDLEG 1860 
          ************************************************************ 
 
JL-CK     VPGSMNSMLERAQVHALLITVTVLKPGGLLILKASWEPFNRFSFLLTVLWQFFSTIRILR 1920 
JL-5      VPGSMNSMLERAQVHALLITVTVLKPGGLLILKASWEPFNRFSFLLTVLWQFFSTIRILR 1920 
          ************************************************************ 
 
JL-CK     SSYSDPNNHEVYIIATLAVDPTTSSFTTALNRARTLNEQGFSLIPPELVSEYWRKRVEQG 1980 
JL-5      SSYSDPNNHEVYIIATLAVDPTTSSFTTALNRARTLNEQGFSLIPPELVSEYWRKRVEQG 1980 
          ************************************************************ 
 
JL-CK     QIIQDCIDKVISECVRDQYLADNNIILQAGGTPSTRKWLDLPDYSSFNELQSEMARLITI 2040 
JL-5      QIIQDCIDKVISECVRDQYLADNNIILQAGGTPSTRKWLDLPDYSSFNELQSEMARLITI 2040 
          ************************************************************ 
 
JL-CK     HLKEVIEILKGQASDHDTLLFTSYNVGPLGKINTILRLIVERILMYTVRNWCILPTQTRL 2100 
JL-5      HLKEVIEILKGQASDHDTLLFTSYNVGPLGKINTILRLIVERILMYTVRNWCILPTQTRL 2100 
          ************************************************************ 
 
JL-CK     TLRQSIELGEFRLRDVITPMEILKLSPNRKYLKSALNQSTFNHLMGETSDILLNRAYQKR 2160 
JL-5      TLRQSIELGEFRLRDVITPMEILKLSPNRKYLKSALNQSTFNHLMGETSDILLNRAYQKR 2160 
          ************************************************************ 
 
JL-CK     IWKAIGCVIYCFGLLTPDVEGSERIDVDNDIPDYDIHGDII 2201 
JL-5      IWKAIGCVIYCFGLLTPDVEGSERIDVDNDIPDYDIHGDII 2201 
          ***************************************** 
 
Comparison of JL-CK and JL-5 (accession AF201473).  Amino acid substitution (D311G) 
highlighted in RED 
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Appendix 2a:  RIT 4385 nucleoprotein identification by LC-MS/MS 
 
Native Jeryl Lynn nucleoprotein (UniProt Q77158) 
 
MSSVLKAFER FTIEQELQDR GEEGSIPPET LKSAVKVFVI NTPNPTTRYQ MLNFCLRIIC 
SQNARASHRV GALITLFSLP SAGMQNHIRL ADRSPEAQIE RCEIDGFEPG TYRLIPNARA 
NLTANEIAAY ALLADDLPPT INNGTPYVHA DVEGQPCDEI EQFLDRCYSV LIQAWVMVCK 
CMTAYDQPAG SADRRFAKYQ QQGRLEARYM LQPEAQRLIQ TAIRKSLVVR QYLTFELQLA 
RRQGLLSNRY YAMVGDIGKY IENSGLTAFF LTLKYALGTK WSPLSLAAFT GELTKLRSLM 
MLYRGLGEQA RYLALLEAPQ IMDFAPGGYP LIFSYAMGVG TVLDVQMRNY TYARPFLNGY 
YFQIGVETAR RQQGTVDNRV ADDLGLTPEQ RTEVTQLVDR LARGRGAGIP GGPVNPFVPP 
VQQQQPAAVY EDIPALEESD DDGDEDGGAG FQNGVQLPAV RQGGQTDFRA QPLQDPIQAQ 
LFMPLYPQVS NMPNNQNHQI NRIGGLEHQD LLRYNENGDS QQDARGEHVN TFPNNPNQNA  
QLQVGDWDE 
 
10 peptides (highlighted) were matched, corresponding to 214 / 549 residues (39 %) sequence 
coverage, which was identical to the MuV (Jeryl Lynn) nucleoprotein (UniProt Q77158).  
The carboxy-terminal peptide was identified (bold/underlined). 
 
 
Modified Jeryl Lynn nucleoprotein containing the carboxy-terminal putative additional 
amino acids QITDMIKPTPIATIPGQSSHS 
 
MSSVLKAFER FTIEQELQDR GEEGSIPPET LKSAVKVFVI NTPNPTTRYQ MLNFCLRIIC 
SQNARASHRV GALITLFSLP SAGMQNHIRL ADRSPEAQIE RCEIDGFEPG TYRLIPNARA 
NLTANEIAAY ALLADDLPPT INNGTPYVHA DVEGQPCDEI EQFLDRCYSV LIQAWVMVCK 
CMTAYDQPAG SADRRFAKYQ QQGRLEARYM LQPEAQRLIQ TAIRKSLVVR QYLTFELQLA 
RRQGLLSNRY YAMVGDIGKY IENSGLTAFF LTLKYALGTK WSPLSLAAFT GELTKLRSLM 
MLYRGLGEQA RYLALLEAPQ IMDFAPGGYP LIFSYAMGVG TVLDVQMRNY TYARPFLNGY 
YFQIGVETAR RQQGTVDNRV ADDLGLTPEQ RTEVTQLVDR LARGRGAGIP GGPVNPFVPP 
VQQQQPAAVY EDIPALEESD DDGDEDGGAG FQNGVQLPAV RQGGQTDFRA QPLQDPIQAQ 
LFMPLYPQVS NMPNNQNHQI NRIGGLEHQD LLRYNENGDS QQDARGEHVN TFPNNPNQNA 
QLQVGDWDEQ ITDMIKPTPI ATIPGQSSHS 
 
9 peptides (highlighted) were matched, corresponding to 214 / 570 (37.5 %) sequence 
coverage, against the modified MuV (Jeryl Lynn) nucleoprotein.  Italic indicates the 
additional putative amino acids at the carboxy-terminal, including P557.  No matching 
carboxy-terminal peptide (underlined) was identified. 
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Modified Jeryl Lynn nucleoprotein containing the carboxy-terminal putative additional 
amino acids QITDMIKLTPIATIPGQSSH 
 
MSSVLKAFER FTIEQELQDR GEEGSIPPET LKSAVKVFVI NTPNPTTRYQ MLNFCLRIIC 
SQNARASHRV GALITLFSLP SAGMQNHIRL ADRSPEAQIE RCEIDGFEPG TYRLIPNARA 
NLTANEIAAY ALLADDLPPT INNGTPYVHA DVEGQPCDEI EQFLDRCYSV LIQAWVMVCK 
CMTAYDQPAG SADRRFAKYQ QQGRLEARYM LQPEAQRLIQ TAIRKSLVVR QYLTFELQLA 
RRQGLLSNRY YAMVGDIGKY IENSGLTAFF LTLKYALGTK WSPLSLAAFT GELTKLRSLM 
MLYRGLGEQA RYLALLEAPQ IMDFAPGGYP LIFSYAMGVG TVLDVQMRNY TYARPFLNGY 
YFQIGVETAR RQQGTVDNRV ADDLGLTPEQ RTEVTQLVDR LARGRGAGIP GGPVNPFVPP 
VQQQQPAAVY EDIPALEESD DDGDEDGGAG FQNGVQLPAV RQGGQTDFRA QPLQDPIQAQ 
LFMPLYPQVS NMPNNQNHQI NRIGGLEHQD LLRYNENGDS QQDARGEHVN TFPNNPNQNA 
QLQVGDWDEQ ITDMIKLTPI ATIPGQSSH 
 
9 peptides (highlighted) were matched, corresponding to 214 / 570 (37.5 %) sequence 
coverage, against the modified MuV (Jeryl Lynn) nucleoprotein.  Italic indicates the 
additional putative amino acids at the carboxy-terminal, including L557.  No matching 
carboxy-terminal peptide (underlined) was identified. 
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Appendix 2b:  JL-CK nucleoprotein identification by LC-MS/MS  
 
Native Jeryl Lynn nucleoprotein (UniProt Q77158) 
 
MSSVLKAFER FTIEQELQDR GEEGSIPPET LKSAVKVFVI NTPNPTTRYQ MLNFCLRIIC 
SQNARASHRV GALITLFSLP SAGMQNHIRL ADRSPEAQIE RCEIDGFEPG TYRLIPNARA 
NLTANEIAAY ALLADDLPPT INNGTPYVHA DVEGQPCDEI EQFLDRCYSV LIQAWVMVCK 
CMTAYDQPAG SADRRFAKYQ QQGRLEARYM LQPEAQRLIQ TAIRKSLVVR QYLTFELQLA 
RRQGLLSNRY YAMVGDIGKY IENSGLTAFF LTLKYALGTK WSPLSLAAFT GELTKLRSLM 
MLYRGLGEQA RYLALLEAPQ IMDFAPGGYP LIFSYAMGVG TVLDVQMRNY TYARPFLNGY 
YFQIGVETAR RQQGTVDNRV ADDLGLTPEQ RTEVTQLVDR LARGRGAGIP GGPVNPFVPP 
VQQQQPAAVY EDIPALEESD DDGDEDGGAG FQNGVQLPAV RQGGQTDFRA QPLQDPIQAQ 
LFMPLYPQVS NMPNNQNHQI NRIGGLEHQD LLRYNENGDS QQDARGEHVN TFPNNPNQNA  
QLQVGDWDE 
 
9 peptides (highlighted) were matched, corresponding to 190 / 549 residues (34.6 %) 
sequence coverage, which was identical to the MuV (Jeryl Lynn) nucleoprotein (UniProt 
Q77158).  The carboxy-terminal peptide was not identified (underlined). 
 
 
Modified Jeryl Lynn nucleoprotein containing the carboxy-terminal putative additional 
amino acids QITDMIKPTPIATIPGQSSHS 
 
MSSVLKAFER FTIEQELQDR GEEGSIPPET LKSAVKVFVI NTPNPTTRYQ MLNFCLRIIC 
SQNARASHRV GALITLFSLP SAGMQNHIRL ADRSPEAQIE RCEIDGFEPG TYRLIPNARA 
NLTANEIAAY ALLADDLPPT INNGTPYVHA DVEGQPCDEI EQFLDRCYSV LIQAWVMVCK 
CMTAYDQPAG SADRRFAKYQ QQGRLEARYM LQPEAQRLIQ TAIRKSLVVR QYLTFELQLA 
RRQGLLSNRY YAMVGDIGKY IENSGLTAFF LTLKYALGTK WSPLSLAAFT GELTKLRSLM 
MLYRGLGEQA RYLALLEAPQ IMDFAPGGYP LIFSYAMGVG TVLDVQMRNY TYARPFLNGY 
YFQIGVETAR RQQGTVDNRV ADDLGLTPEQ RTEVTQLVDR LARGRGAGIP GGPVNPFVPP 
VQQQQPAAVY EDIPALEESD DDGDEDGGAG FQNGVQLPAV RQGGQTDFRA QPLQDPIQAQ 
LFMPLYPQVS NMPNNQNHQI NRIGGLEHQD LLRYNENGDS QQDARGEHVN TFPNNPNQNA 
QLQVGDWDEQ ITDMIKPTPI ATIPGQSSHS 
 
9 peptides (highlighted) were matched, corresponding to 190 / 570 residues (33.3 %) 
sequence coverage, against the modified MuV (Jeryl Lynn) nucleoprotein.  Italic indicates 
the additional putative amino acids at the carboxy-terminal, including P557.  No matching 
carboxy-terminal peptide (underlined) was identified. 
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Modified Jeryl Lynn nucleoprotein containing the carboxy-terminal putative additional 
amino acids QITDMIKLTPIATIPGQSSH 
 
MSSVLKAFER FTIEQELQDR GEEGSIPPET LKSAVKVFVI NTPNPTTRYQ MLNFCLRIIC 
SQNARASHRV GALITLFSLP SAGMQNHIRL ADRSPEAQIE RCEIDGFEPG TYRLIPNARA 
NLTANEIAAY ALLADDLPPT INNGTPYVHA DVEGQPCDEI EQFLDRCYSV LIQAWVMVCK 
CMTAYDQPAG SADRRFAKYQ QQGRLEARYM LQPEAQRLIQ TAIRKSLVVR QYLTFELQLA 
RRQGLLSNRY YAMVGDIGKY IENSGLTAFF LTLKYALGTK WSPLSLAAFT GELTKLRSLM 
MLYRGLGEQA RYLALLEAPQ IMDFAPGGYP LIFSYAMGVG TVLDVQMRNY TYARPFLNGY 
YFQIGVETAR RQQGTVDNRV ADDLGLTPEQ RTEVTQLVDR LARGRGAGIP GGPVNPFVPP 
VQQQQPAAVY EDIPALEESD DDGDEDGGAG FQNGVQLPAV RQGGQTDFRA QPLQDPIQAQ 
LFMPLYPQVS NMPNNQNHQI NRIGGLEHQD LLRYNENGDS QQDARGEHVN TFPNNPNQNA 
QLQVGDWDEQ ITDMIKLTPI ATIPGQSSH 
 
10 peptides (highlighted) were matched, corresponding to 203 / 570 residues (35.6 %) 
sequence coverage, against the modified MuV (Jeryl Lynn) nucleoprotein.  Italic indicates 
the additional putative amino acids at the carboxy-terminal, including L557.  The carboxy-
terminal peptide (bold, highlighted and underlined) was identified. 
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